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Microtubule-Stabilizing Anticancer Agents 
 
 
 
1.1 Introduction1 
 
Cancer is a generic term for a group of more than 100 diseases that can affect any part of the 
body; other terms used are malignant tumors and neoplasms. One defining feature of cancer is the 
rapid creation of abnormal cells which grow beyond their usual boundaries, and which can invade 
adjoining parts of the body and spread to other organs, a process referred to as metastasis, which 
are the major cause of death.  
Early detection of cancer is very important since treatment is more effective when cancer is 
localized. The principal methods of treatment are surgery, radiotherapy and chemotherapy. 
Fundamental for adequate treatment is an accurate diagnosis by means of investigations involving 
imaging technology (ultrasound, endoscopy, radiography) and laboratory (pathology).  
A wide variety of anticancer drugs are employed nowadays for the treatment of a number of 
different cancers. These can be classified according to their chemical nature and mode of action. A 
general property which divides the anticancer drugs into two major classes, is the dependence of 
their action upon the specific phase in which the cancer cell is found at the point of subministration 
of the drug. Thus, substances which are active only if the cell is in a specific phase of the cell cycle 
are named Cellular Cycle Specific (CCS), while the others are termed Cellular Cycle Nonspecific 
(CCNS). This characteristic has a tremendous impact on the mode of subministration of a given 
drug, since, in contrast to antibacterial and antiviral drugs, substances that are able to eliminate 
only a fraction of the affected cells (i.e. the fraction of cells which are found in a specific phase of 
the cell cycle) are not very effective in the treatment of cancer. For example, a drug capable of 
eliminating 99.9% of a tumor mass consisting of approximately 1012 cells would leave 109 cells in 
the organism, a number still too large for the immune system to cope with. For this reason, a 
number of anticancer drugs are administered in combination with other drugs that are CCNS or 
specific for a different phase of the cell cycle. The effectiveness of polichemotherapy is thus at 
least additive and in some cases even higher than it could be expected based on the simple sum of 
the two actions. Another effect of the CCS chemotherapy is a decrease in the effectiveness of the 
treatment, as a tumor gets older, due to a decrease in the rate of reproduction and differentiation of 
the cells. 
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1.2 Microtubules as a Target for Anticancer Drugs2 
1.2.1 Microtubules and Their Polymerization Dynamics 
 
Microtubules are fibrillar structures structures involved in many aspects of cellular biology 
(transport, signaling, and mitosis). They are used by the cell to form a static structure, called the 
cytoskeleton, which helps to shape the cell. Microtubules are fundamental for cell division, where 
they play a central role through their characteristic polymerization dynamics. Microtubules are 
composed of -tubulin and -tubulin heterodimers arranged in the form of slender filamentous 
tubes which can be many micrometres long (Figure 1.1). Approximately 20% of the mass of a 
microtubule is made up of heterogeneous Microtubule-Associated Proteins (MAPs).  
The biological functions of microtubules in all cells are determined and regulated in large part 
by their polymerization dynamics. The polymerization of microtubules occurs by a nucleation-
elongation mechanism. The initial event in the polymerization of a microtubule is the relatively 
slow formation of heterodimers of α- and β-tubulin that assemble to form a short microtubule 
nucleus. Nucleation is followed by rapid elongation of the microtubule at both ends (by reversible 
non-covalent addition) to form a cylinder that is composed of tubulin heterodimers arranged head-
to-tail in 13 protofilaments. Each microtubule is a left-handed helix having a so-called plus end 
(+), with β-tubulin facing outward, and a minus end (–), with α-tubulin facing outward. The 
filamentous structure of the microtubule is overlaid with MAPs, some of which appear to have a 
stimulatory effect on the polymerization. Microtubules are not simple equilibrium polymers: they 
show complex polymerization dynamics that use energy provided by the hydrolysis of GTP at that 
time that tubulin with bound GTP adds to the microtubule ends; these dynamics are crucial to their 
cellular functions.  
 
 
 
Figure 1.1 Polymerization of microtubules 
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1.2.2 Why Target Microtubules? 
 
Microtubules and their uniquely rapid dynamics are extremely important in the process of 
mitosis, during which the duplicated chromosomes of a cell are separated into two identical sets 
before cleavage the cell into two daughter cells. Their importance in mitosis and cell division 
makes microtubules an important target for anticancer drugs. Microtubules and their dynamics are 
the targets of a chemically diverse group of antimitotic drugs (with various tubulin-binding sites) 
that have been used with great success in the treatment of cancer. In view of the success of this 
class of drugs, it has been argued that microtubules represent the best cancer target to be identified 
so far, and it seems likely that drugs of this class will continue to be important chemotherapeutic 
agents, even as more selective approaches are developed.3 
Microtubule-targeted antimitotic drugs are usually classified into two main groups. One group, 
known as the microtubule-destabilizing agents, inhibits microtubule polymerization at high 
concentrations and includes several compounds, such as the Vinca alkaloids that are used clinically 
or are under clinical investigation for treatment of cancer. The second main group is known as the 
Microtubule-Stabilizing Agents (MSAs). These agents stimulate microtubule polymerization and 
include, among others, paclitaxel (Taxol®, the first agent to be identified in this class), docetaxel 
(Taxotere®), the epothilones, discodermolide, dictyostatin, eleutherobins, laulimalide, and 
pelurosides. The classification of drugs as microtubule ‘stabilizers’ or ‘destabilizers’ is overly 
simplistic and can lead to confusion. The reason, is that drugs that increase or decrease 
microtubule polymerization at high concentrations powerfully suppress microtubule dynamics at 
10–100-fold lower concentrations and, therefore, kinetically stabilize the microtubules. 
 
 
1.2.3 The Mechanism of Action of Paclitaxel and Related Microtubule-Stabilizing Agents 
 
Paclitaxel and its semi-synthetic analogue docetaxel were among the most important new 
additions to the chemotherapeutic arsenal in the late twentieth century. Paclitaxel, a complex 
molecule that was isolated from the bark of the yew tree in 1967 by Monroe Wall and Wani,4 
underwent slow development until, in 1979, Schiff and Horwitz made the surprising discovery 
that, unlike the Vinca alkaloids, paclitaxel stimulated microtubule polymerization. The taxanes 
bind poorly to soluble tubulin itself, but instead bind directly with high affinity to tubulin along the 
length of the microtubule. The binding site for paclitaxel is in the β-subunit, and its location, which 
is on the inside surface of the microtubule, is known with precision because determination of the 
crystal structure of tubulin was carried out with the latter complexed with paclitaxel.5 
Binding of paclitaxel to its site on the inside microtubule surface stabilizes the microtubule and 
increases microtubule polymerization, presumably by inducing a conformational change in the 
tubulin which, by an unknown mechanism, increases its affinity for neighbouring tubulin 
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molecules.6 Suppression of microtubule dynamics by paclitaxel leads to mitotic block and the cells 
eventually die by apoptosis.  
Although other cells are also affected adversely, the main reason for cancer cells to be 
extremely sensitive to MSAs is that they divide more frequently than normal cells and therefore 
more frequently pass through a stage of vulnerability to mitotic poisons.  
The clinical success of the taxanes has led to a search for other drugs that enhance microtubule 
polymerization. This search yielded several promising compounds. Some of these compounds 
compete with paclitaxel for binding to microtubules and are thought to bind at or near the taxane 
site (epothilones, discodermolide, eleutherobins and sarcodictyins), but others, such as laulimalide, 
seem to bind to unique sites on microtubules.7 
 
 
1.3 The Use of Taxol® : Scope and Limitations2a 
 
1.3.1 Isolation and Syntheses of Taxol® 
 
Paclitaxel (1.1, Figure 1.2) is a mitotic inhibitor used in cancer chemotherapy. It was 
discovered in a U.S. National Cancer Institute program in 1967 when Wall and Wani isolated it 
from the bark of the Pacific yew tree (Taxus brevifolia) and named it taxol (which was to become 
the trademark). From 1967 to 1993, almost all paclitaxel was derived from natural source. 
Consequently, early research on paclitaxel was limited by a restricted supply, due to several 
difficulties in obtaining the drug. The concentration of the compound in yew bark is low, and 
paclitaxel extraction is complex and expensive. In addition, bark collection was restricted because 
the Pacific yew is a limited resource located in old-growth forests which are the habitat of the 
endangered spotted owl.  
As for total synthesis, several efforts have been devoted by the chemical community to this 
challenging structure, since its structural elucidation in the early 1970’s. The total synthesis of 
paclitaxel is called one of the most hotly contested of the 1990s,8 with around 30 competing 
research groups by 1992. The number of research groups actually having reported a total synthesis 
stands currently at seven, with the Holton group9 (1994, article first accepted for publication) and 
the Nicolaou group10 (1994, article first published) first and second in what is called a “photo-
finish”. Since then, other syntheses of paclitaxel have been reported by Danishefsky11 (1996), 
Wender12 (1997), Kuwajiama13 (1998), Mukaiyama14 (1998) and Takahashi15 (2006). 
The commercial semisynthesis of paclitaxel, and its slightly modified version docetaxel (1.2), 
starts from 10-deacetylbaccatin III (1.3), isolated from the European yew (Taxus baccata), and is 
based on the addition of synthetic side chains. Currently, paclitaxel production, involves a plant 
cell fermentation technology. 
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Figure 1.2 Paclitaxel (from Taxus brevifolia), baccatin III (from Taxus baccata) and synthetic docetaxel 
 
 
1.3.2 Clinical Application of Taxol® 
 
Clinical trials on Paclitaxel began in 1983. In 1989, investigators at The Johns Hopkins 
Oncology Center reported that the drug produced partial or complete responses (shrinking or 
disappearance of the tumor) in 30% of previously treated patients with advanced ovarian cancer. In 
1992, the Food and Drug Administration (FDA) approved the use of paclitaxel for refractory 
(treatment-resistant) ovarian cancer. 
Subsequently, clinical trials using paclitaxel for the treatment of advanced breast cancer 
demonstrated that the drug is effective against this disease. In 1994, the FDA approved the use of 
paclitaxel for breast cancer that has recurred within six months after the completion of initial 
chemotherapy and for metastatic breast cancer that is not responding to combination 
chemotherapy. Trials to test the effectiveness of paclitaxel against other types of cancer, including 
leukemia, lymphoma, cancers of the lung, colon, head and neck were also made. In the cases of 
ovarian cancer, paclitaxel gives a response with manageable side effects in 30-35% of cases. These 
results, which represent the highest reported salvage rate for ovarian cancer, are particularly 
significant as these patients show resistance to other therapies. 
Since 1992, paclitaxel (with the registered trade name Taxol®), has developed into a 1,5 billion 
dollar drug, representing over 10% of the pharmaceutical sales of Bristol-Myers Squibb.16 Today, 
Taxol® is the drug of choice for many solid tumors, including ovarian, breast, non-small cell lung, 
bladder, esophagus, head and neck; and it has proven to be particularly effective at treating 
recurrent tumors as well as those unresponsive to previous first line therapies. 
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1.3.3 The Side Effects of Taxol® 
 
Like most cancer drugs, paclitaxel has certain side effects, some of which can be serious. When 
Taxol® molecules bind to microtubules, they render them extremely stable and static, making cell 
division impossible and killing the cells as it begin to divide. Taxol® damages all rapidly dividing 
cells: cancer cells, but also white blood cells and hair cells. Consequently, severe side effects are 
experienced by people taking the drug. 
The most serious and dose limiting side effect of Taxol® is depression of the bone marrow 
(neutropenia) which in turn diminishes the body’s ability to produce the blood cells that fight 
infection. Reversible hair loss is a common consequence of paclitaxel treatment, as well as 
gastrointestinal problems, nerve damage (peripheral neuropathy), haematic and cardiac problems 
and other adverse effects.17 
Administration of taxanes can also be hampered by hypersensitivity reactions.18 This 
phenomenon results from their poor solubility (Taxol® in particular) and the consequent need to 
dissolve in solvents such as polyoxyethylated castor oil (Cremophor EL®) or polysorbate, which 
are known to cause histamine release. This risk has been substantially reduced by the use of 
premedications, but nonetheless remains a clinical problem. 
 
 
1.3.4 The Insurgence of Multiple Drug Resistance 
 
The most severe limitation to the clinical application of Taxol® is the emergence of tumor 
phenotypes resistant to taxanes, as well as to other chemoterapeutic agents. This phenomenon, 
known as Multiple Drug Resistance (MDR), results from two mechanisms: (i) over-expression of 
membrane transporter proteins, on the surface of neoplastic cells, which lower the intracellular 
concentration of cytotoxic products; (ii) over-expression of tubulin isotypes which  are less 
susceptible to induced polymerization and stabilization. 
The first mechanism consists in the over-expression of a class of membrane transporter proteins 
known as ABC-transporters (ATP-dependent drug efflux pumps or ATP-binding cassettes).2b 
These membrane pumps produce decreased intracellular drug levels and lead to cross-resistance to 
drugs of different chemical structures, such as paclitaxel. The first ABC-transporters to be 
identified was P-glycoprotein (PgP), the product of the human MDR1 gene. Considerable efforts 
are underway to understand these mechanisms of resistance, to develop PgP inhibitors and 
microtubule-targeted drugs that are not removed by these pumps.19 
The second mechanism is related to the expression of different β-tubulin isotypes,20 which 
confer resistance or determine intrinsic insensitivity to antimitotic drugs. In particular aberrant 
expression of βIII-tubulin can affect the response of tumour cells to MSAs. The mechanisms 
underlying this behavior are currently unclear. Understanding the role of the other β-tubulin 
isotypes in cancer development is also at an early stage.  
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In sum, there is a need to develop novel taxane derivatives and newer agents to target 
microtubules in order to overcome this set of problems. 
 
 
1.4 Natural Products with Paclitaxel-like Activity 
 
The need for a general solution to the limitations of Taxol® has elicited large scale screening 
efforts to identify other natural product leads, which have the same mechanism of action and 
cytotoxicity profile. It is thought that, by acting through a common mechanism, these new leads 
might share Taxol®’s clinical benefits, but their distinct structures will endow them with unique 
and perhaps improved pharmacological profiles in terms of toxicity and susceptibility to resistance.  
These efforts have resulted in the identification of several novel structural types (Figure 1.3) 
including the epothilones (1.4a, 1.4b, 1.4c, 1.4d), discodermolide (1.5), eleutherobin (1.6) 
sarcodictyins (1.7a, 1.7b), dictyostatin (1.8 see Chapter 2), laulimalide (1.9), pelorusides (1.10a, 
1.10b) and few others. 
 
 
 
Figure 1.3 Microtubule-stabilizing anticancer agents 
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As is often the case for natural products extracted from marine organisms, as most of the above 
mentioned compounds are, natural supply is insufficient for extensive in vitro studies, 
determination of Structure-Activity Relationship (SAR), in vivo studies and in general for 
advancement to clinical trials. The need for a partially or fully synthetic approach is therefore 
motivated both by the scarcity as well as the fascination of their challenging molecular 
architecture. 
 
 
1.4.1 Epothilones21 
 
The epothilones (1.4a-d) are 16-membered macrolides named for their molecular structure, 
which includes an epoxide, methyl thiazole, and ketone moieties. Epothilones A, B, C and D were 
extracted by Höfle and Reichenbach in the 1986 from myxobacterium Sorangium cellulosum 
(Figure 1.4), collected on the banks of the Zambesi River.22,23  
Initially investigated as anti-fungal agents, epothilones A and B were proven capable of 
inducing tubulin polymerization and stabilizing microtubules as Taxol®. Both compounds compete 
with paclitaxel for binding to tubulin and are able to displace paclitaxel from microtubules, 
suggesting that they occupy the same binding site as taxanes.24 Despite these similarities, analysis 
using electron crystallography has shown that epothilones interact with the β-subunit of tubulin 
through unique and independent molecular interactions.25 In vitro studies in tumor cell lines 
showed that epothilone B is more active than epothilone A. Both epothilones have greater potency 
than paclitaxel or docetaxel in vitro, with mean inhibitory concentration (IC50) values in the low 
nanomolar range. The epothilones are also active against cells that over-express Pgp,26 a 
mechanism implicated in development of resistance to taxanes.27 In addition, mutations in β-
tubulin, that confer resistance to taxanes,28 did not significantly alter the cytotoxicity of 
epothilones A and B. 
 
 
 
 
Figure 1.4 Myxobacterium Sorangium cellulosum 
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Epothilone B has been evaluated in clinical trials against a variety of solid tumors. It crosses the 
blood-brain barrier and has shown activity in patients with recurrent or progressive brain 
metastases from non small-cell lung cancer.29 Epothilone D, which lacks the epoxide moiety, has 
shown superior in vivo anticancer activity relative to epothilone B. However, its clinical 
development has been discontinued. 
Due to the high potency and clinical need for cancer treatments, epothilones have been the 
target of many total syntheses. The first group to publish the total synthesis of epothilones A and B 
was that of Danishefsky, in 1996.30 Other syntheses of epothilones were published by Nicolaou,31 
Schinzer,32 Mulzer,33 and Carreira.34 Moreover, the promising anticancer activity of epothilones 
and their ability to overcome resistance resulted in the synthesis of several epothilone analogs.  
 
1.4.2 Discodermolide35 
 
Discodermolide (1.5) was first reported in 1990 by Gunasekera and co-workers.36 Isolated from 
the marine sponge Discodermia dissolute (Figure 1.5), collected at a depth of 33 m off Grand 
Bahama Island, in the Caribbean, a combination of exhaustive extraction and chromatography 
afforded discodermolide in 0.002% wet weight from the frozen sponge. 
 
 
 
 
Figure 1.5 Marine sponge Discodermia dissolute 
 
 
The planar structure of this novel polyketide was elucidated through detailed NMR studies, and 
the relative configuration defined by single-crystal X-ray diffraction analysis. Following its initial 
isolation, preliminary biological evaluation revealed discodermolide to possess both potent cell 
growth inhibitory and immunosuppressive activity. Both the cyotoxicity exhibited against certain 
human cancer cell lines and binding affinity of discodermolide for tubulin are superior those of 
Taxol®. Importantly, the antiproliferative activity of discodermolide is retained in cell lines 
exhibiting resistance to Taxol®. The discodermolide binding site on tubulin was first probed 
through a series of competition studies with Taxol®;37 the ability of discodermolide to displace 
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Taxol® suggested it occupied an identical or similar binding site on -tubulin. However, the 
identification of a synergistic potentiation of the cytotoxicity of discodermolide, when used in 
combination with Taxol®, provided stronger evidence that the binding sites, in fact, overlap and are 
not the same.38 
The remarkable biological profile of discodermolide was recognized by Novartis Pharma AG 
and, following a huge synthetic effort to obtain sufficient drug amounts, discodermolide was 
progressed into phase I clinical trials in patients with advanced solid malignancies. In 2004, these 
trials were halted due to problems associated with severe toxicity.39 
A number of interesting syntheses of 1.5 have appeared in the literature,40 namely by the groups 
of Smith III (the first gram-scale synthesis),41 Marshall,42 Schreiber,43 Myles,44 and Paterson,45 
along with several synthetic studies46 and synthesis of analogues.47 
 
1.4.3 Eleutherobin and Sarcodyctins48 
 
Eleutherobin (1.6) and sarcodictyins, (1.7a, 1.7b) all belong to the eleuthesides category.49 
Sarcodictyins were the funding members of this category, having been isolated in 1987 by Pietra 
and co-workers from the Mediterranean coral Sarcodictyin roseum.50 Nine years later, Fenical and 
co-workers reported the isolation of eleutherobin from an Eleutherobia soft coral (Figure 1.6) 
found in Western Australia.51  
 
 
 
Figure 1.6 Soft coral Eleutherobia 
 
Eleutherobin has been shown to be a Pgp substrate, which does not offer any advantages over 
paclitaxel in the growth inhibition of MDR cell lines.52 In addition, the compound also exhibits 
reduced activity against paclitaxel-sensitive cell lines compared with paclitaxel itself. 
Contradictory data exist in the literature with regard to eleutherobin activity against paclitaxel-
resistant cell lines that are characterized either by tubulin mutations or changes in -tubulin isotype 
expression. Even in the most favorable case, however, the absolute cytotoxicity (IC50) of 
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eleutherobin in the paclitaxel-resistant cell lines was found to be no more than twofold higher than 
that of paclitaxel. Sarcodictyins A and B are reported to exhibit very low resistance factors against 
Pgp-over-expressing human cancer cell lines,53 but, at the same time, their intrinsic 
antiproliferative activity against drug-sensitive cells is significantly lower than that of all other 
MSAs.52c In summary, eleutherobin and sarcodictyins as such are much less attractive 
antiproliferative agents than epthilones or discodermolide. However, they could still be interesting 
starting points for chemical derivatization or analog programs, and efforts along these lines have 
been reported.52c, 52d 
Sarcodictyins A and B have been synthesized successfully by Nicolaou and co-workers54 who 
have also exploited a similar route for accessing eleutherobin.55 A second report by Danishefsky 
and co-workers details an alternative access to the latter compound.56 A formal total synthesis of 
eleutherobin was reported also by Gennari’s group in 2005.57 A number of other partial syntheses 
and alternative strategies have also been described.58 
 
1.4.4 Laulimalide 
 
Although first isolated in 1988 from several different species of sponge,59 laulimalide (1.9) was 
only recently identified as a microtubule depolymerization, inhibitor in a mechanism-based 
screening program.60 
Laulimalide is a potent microtubule-stabilizing agent, with IC50 values against numerous drug 
sensitive cell lines in the low nanomolar range.61 The compound is also active against PgP 
expressing MDR cell lines. While epothilones, discodermolide and eleutherobin inhibit the binding 
of Taxol® to tubulin polymer in a competitive manner, it has been shown that laulimalide binds to a 
different site.62  
After its discovery, the syntheses of several fragments of 1.9 were reported.63 In the following 
years, total syntheses of laulimalide itself were published by Ghosh,64 Mulzer,65 Williams,66 
Paterson,67 Nelson68 and Wender,69 along with synthesis of analogs.70 
 
 
1.4.5 Pelorusides71 
 
Pelorusides (1.10a, 1.10b) are a secondary metabolite isolated in 1999 from the marine sponge 
Mycale hentscheli (Figure 1.7),72 collected from Pelorus Sound in New Zealand.  
They have potent paclitaxel-like microtubule-stabilizing activity and are cytotoxic at nanomolar 
concentrations.73 Peloruside A (1.10a) was also shown to have a different binding site on the 
tubulin dimer to paclitaxel, but was seen to bind to the same or overlapping site with laulimalide.74 
Peloruside A has some promising advantages over paclitaxel, being more soluble and therefore not 
requiring the use of Cremophore EL® to deliver the drug to the body. This should correlate with 
fewer vehicle-associated side effects than paclitaxel.75 Peloruside A is also more likely to be 
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effective against cells that acquire the MDR phenotype, since it remains active in cells with high 
PgP expression.  
Tests of peloruside in animals have been very promising, with peloruside A showing no overt 
toxicity in mice and being more efficacious in inhibiting tumor growth than paclitaxel and 
docetaxel. At the present time, preclinical studies and the advancement of peloruside A into phase 
I clinical trials for cancer therapy are being held back due to the short supply of natural and 
synthetic peloruside A. 
The De Brabander’s group was the first to carry out a total synthesis of peloruside A.76  This 
first synthesis produced the inactive enantiomer of peloruside A, but the group subsequently re-
synthesized the correct, bioactive enantiomer. Since then, three other laboratories have synthesized 
the compound in milligram amounts77 and several syntheses of fragments have appeared in the 
literature. 78 The synthetic strategies for peloruside A have been reviewed by Williams and co-
workers.79 Peloruside B (1.10b), has recently been synthesized by the Ghosh laboratory.80 The 
relatively simple structure of pelorusides makes them suitable for the design and synthesis of 
analogues with improved tumor targeting and reduced tumor cross-resistance. 
 
 
 
Figure 1.7 Marine sponge Mycale hentscheli 
 
 
1.4.6 Other Microtubule-Stabilizing Agents 
 
In addition to the above mentioned classes of MSAs other interesting compounds were recently 
reported (Figure 1.8).  
Cyclostreptin (1.11 originally named FR182877) was isolated by a group of Japanese scientists 
from Streptomyces sp 9885.81 Interesting, it is the only known MSA which covalently binds to 
tubulin.82 The preparation of this compound by fermentation and its activity were patented.83 Total 
syntheses of cyclostreptin were reported by Sorensen84 and Evans.85  
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Figure 1.8 Other microtubule-stabilizing anticancer agents. 
 
 
Zampanolide (1.12) and dactylolide (1.13) are structurally related polyketide-based macrolides, 
characterized by a highly unsaturated 20-membered macrolactone ring. Zampanolide was first 
isolated in 1996 by Tanaka and co-workers from the marine sponge Fasciospongia rimosa at Cape 
Zampa in Okinawa.86 More recently, 1.12 was also isolated from the Togan sponge Cacospongia 
mycofijiensis (Figure 1.9) by Northcote and co-workers, who demonstrated the compound to be an 
efficient promotor of tubulin assembly.87 
Dactylolide was isolated in 2001 by Cutignano and co-workers from the sponge Dactylospongia 
at the Vanuatu Islands.88 In contrast to zampanolide, dactylolide is only a moderately potent 
inhibitor of human cancer cell growth, with IC50 in the low micromolar range. 
While a number of stereoselective syntheses of this two related compound have appeared in the 
literature,89,90 little work has been reported on analogue structures and their biological activity.89d 
 
 
 
 
Figure 1.9 Marine sponge Cacospongia mycofijiensis 
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Chapter 2 
 
 
 
(-)-Dictyostatin 
 
 
 
2.1 Isolation and Structure Determination 
 
In 1994, Pettit and co-workers reported the isolation of (-)-dictyostatin (1.8) from a marine 
sponge of the genus Spongia sp. (family Spongiidae), collected in the Republic of Maldives, in 3.7 
10-7 % yield (1.35 mg was obtained from 400 kg wet mass of sponges).1 The planar gross structure, 
comprising an unsaturated 22-membered macrolactone ring, 11 stereogenic centers, a (2Z,4E)-
dienoate moiety, a disubstituted (Z)-olefin and a terminal (Z)-diene, was determined based on the 
basis of the analysis of 2D NMR spectroscopic data,1 and a partial stereostructure (2.1) was 
proposed (Figure 2.1).2 
More recently, (-)-dictyostatin was isolated by Wright and co-workers from a Lithistida sponge 
of the family Corallistidae collected off the north Jamaican coast, in much higher yield (5.7 mg, 
2.8 10-3 % of wet weight).3 Paterson and Wright subsequently proposed a full stereochemical 
assignment for (-)-dictyostatin, as indicated in Figure 2.1, based on extensive high-field NMR 
experiments, including application of the Murata J-based configuration analysis, in combination 
with molecular modeling.4 This stereochemical assignment was also based on (-)-dictyostatin 
being biogenetically related to (+)-discodermolide 1.5. This stereochemical assignment was 
confirmed unequivocally by Paterson’s total synthesis of (-)-dictyostatin5 and validated 
independently by the total synthesis of Curran,6 as described in §2.3.1 and §2.3.2. 
 
 
 
Figure 2.1 Initial and reassigned structure of (-)-dictyostatin and structure of (+)-discodermolide 
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2.2 The Biological Profile of (-)-Dictyostatin7 
 
Upon its initial isolation, (-)-dictyostatin displayed growth inhibitory activity against a single 
murine P388 cell line.1 This antiproliferative activity was not further investigated until the 2003 re-
isolation, for the simple reason that natural supply was very low.3 Now, with the development of 
various synthetic routes to dictyostatin, a complete evaluation of the in vitro biological profile of  
(-)-dictyostatin has been possible.8,9 
(-)- Dictyostatin demonstrates a low nanomolar cytotoxicity, lower than that of Taxol®, towards 
a range of human cell lines. Additionally, like discodermolide, retains this activity in human cell 
lines displaying both P-glycoprotein and -tubulin mutation-mediated paclitaxel-resistance (Table 
2.1).3,8 All three compounds bind to the same site on tubulin (Figure 2.2), with dictyostatin 
displaying the strongest assembly-inducing abilities.10 
 
Compound 
IC50 (nM) 
AsPC-1 
(pancreatic) 
DLD-1  
(colon) 
PANC-1  
(pancreatic) 
NCI/ADR  
(Taxol®- resistant) 
(-)-Dictyostatin 6.2 2.2 4.2 6.6 
Taxol® 89 22 9.9 1300 
(+)-Discodermolide 98 29 59 160 
 
Table 2.1  Cytotoxicity of dictyostatin, Taxol® and discodermolide in cultured human cancer cells11 
 
 
 
 
Figure 2.2  Dictyostatin docked into the taxanes binding site on β-tubulin 
 
 
2.3 Total Syntheses of (-)-Dictyostatin 
 
Four different total syntheses of (-)-dictyostatin (1.8) have been reported: in 2004, by the 
Paterson’s group5,12 and the Curran’s group concurrently;6,13,14 in 2006, by the Phillips’s group;15 in 
2007 by the Ramachandran’s group.16 
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2.3.1 Paterson’s Total Synthesis5,12 
 
With confidence in their stereochemical assignment, Paterson designed a highly convergent 
synthetic strategy for (−)-dictyostatin (shown in Scheme 2.1), which relied largely on substrate-
directed stereoinduction. The modular synthetic approach employed by Paterson is flexible, highly 
convergent, and stereocontrolled, and thus offers the potential to provide useful quantities of 
dictyostatin as well a range of structural derivatives for SAR studies. 
Two Horner-Wadsworth-Emmons (HWE) reactions were instrumental in joining the key 
subunits as well as providing enone substrates for stereoselective ketone reduction. The 
macrocyclic conformation of the 22-membered ring 2.2, as predicted by molecular modeling 
studies, suggested a preference for hydride attack from the less hindered Re-face of the carbonyl 
group to create the requisite C9 stereocenter. This macrocycle was assembled by a complex Still-
Gennari-type HWE coupling reaction between β-keto phosphonate 2.3 and aldehyde 2.4, in 
conjunction with a Stille cross-coupling reaction with the three-carbon linking unit 2.5 to install 
the (Z)-enoate.  
 
 
 
Scheme 2.1 Paterson’s retrosynthetic approach 
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Aldehyde 2.4 was accessible by a HWE reaction between aldehyde 2.6 and phosphonate 2.7, 
which has the terminal diene moiety already incorporated. Recognizing that these two subunits 
share an identical stereotriad, they were prepared from the common intermediate 2.8, which was 
readily available in multigram quantities from ketone 2.9, through the boron aldol methodology 
developed by the Paterson’s group.17 
 
 
2.3.2 Curran’s Total Synthesis6,13,14 
 
Interestingly, the Curran’s group synthesis was initiated prior to the stereochemical 
reassignment of dictyostatin and therefore the adopted strategy shows stereochemical flexibility in 
most key coupling steps. This flexibility is expected to facilitate the synthesis of a diverse range of 
dictyostatin analogues. Their general synthetic strategy relied upon the use of synthetic studies 
from earlier work towards the synthesis of discodermolide analogs. 
The Curran group’s approach to dictyostatin is shown in Scheme 2.2 Strategic bond 
disconnections as indicated provided three key fragments: Weinreb amide 2.10, alkyne 2.11, and 
-keto phosphonate 2.12.  
 
 
 
Scheme 2.2 Curran’s retrosynthetic approach 
 
While addition of an acetylenic anion to Weinreb amide 2.10 was used to couple 2.10 and 2.11, 
a HWE reaction with phosphonate 2.12 was employed to form the C17-C18 bond during 
construction of the macrolactone. The diene unit was introduced in the final stages of the synthesis, 
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based on the Paterson protocol of Nozaki-Hiyama-Kishi/Peterson olefination, as was the HWE 
coupling using the Still-Gennari-type phosphonate 2.13 to introduce the (Z)-enoate. 
 
 
2.3.3 Phillips’s Total Synthesis15 
 
In contrast, the Phillips’s group used the total synthesis as a showcase for their work on 
titanium (II)-mediated cyclization of (silyloxy)enynes as a means of constructing polypropionate 
stereotriads. The general utility of this methodology in the construction of polyketide natural 
product synthesis was evident, establishing these related stereocentres without resorting to chiral 
auxiliary control. 
To maximize convergence, Phillips’s strategy called for the union of three subunits of similar 
complexity (compounds 2.14, 2.15 and 2.16) by olefin metathesis at C10-C11, olefination at C17-
C18, and a late stage macrocyclization by an intramolecular Still-Gennari HWE (Scheme 2.3). 
 
 
 
 
 
Scheme 2.3 Phillips’s retrosynthetic approach 
 
 
2.3.4 Ramachandran’s Total Synthesis16 
 
The most recent total synthesis from the Ramachandran’s group, demonstrated their in-house 
developed crotylation methodology. Pinene-based chiral reagents showed the general utility of this 
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widely used procedure (notably used by Curran and Paterson in their total syntheses) in the 
synthesis of poliketide natural products. 
Ramachandran’s retrosynthetic analysis is illustrated in Scheme 2.4. Height of the eleven 
stereocenters were created via four pinene-mediated crotylborations; the Roche ester and Myers’ 
alkylation provided two more stereocenters. The three subunits (2.17, 2.18 and 2.19) were 
assembled via Julia olefination and a substrate-controlled (Z)-vinylzincate addition, which 
provided the remaining stereocenter. 
 
 
 
 
Scheme 2.4 Ramachandran’s retrosynthetic approach. 
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Chapter 3 
 
 
 
Analogs and Hybrids 
 
 
 
3.1 Introduction 
 
Along with the numerous efforts towards the total synthesis of dictyostatin already discussed, 
some groups have reported the synthesis of novel structural analogs (e.g. desmethyldictyostatins, 
epi-dictyostatins, hydrodictyostatins, dehydrodictyostatins, methoxy-dictyostatins)1 and hybrids 
(discodermolide/dictyostatin and discodermolide/paclitaxel/dictyostatin)2 that maintain the 
impressive microtubule-stabilizing activity of the parent compound. These modified structures 
have provided invaluable information in structure–activity relationship (SAR) studies. From a 
pragmatic standpoint, the identification of analogs and hybrids of reduced molecular complexity, 
yet retaining the biological function and potency of the parent natural products, offers a more 
realistic starting point for drug development by the pharmaceutical industry.3 
 
 
3.2 Analogs of (-)-Dictyostatin 
 
3.2.1 Design and Synthesis of Analogs 
 
(-)-Dictyostatin (1.8) is one of the most potent microtubule-stabilizing agents discovered to 
date. Consequently, an increased understanding of the structure-activity relationship of (-)-
dictyostatin is an important goal. Known features of the SAR of discodermolide4 (1.5) provide a 
starting point for addressing the SAR of dictyostatin, and the activities of synthetic analogs born 
during structure-assignment studies offer additional information.1d 
With this backdrop, there are two key portions of the dictyostatin molecule that differ 
significantly from discodermolide (Figure 3.1): (i) the bottom chain (C1-C9 region); (ii) the 
isolated, methyl-bearing stereocenter at C16. 
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Figure 3.1 Compared structures of (-)-dictyostatin and (+)-discodermolide 
 
The bottom chain is an interesting region for addressing structural modifications; indeed, there 
are many active analogs of discodermolide with modifications in this part of the molecule.5 It was 
observed that discodermolide analogues with modification of the C7 hydroxyl group 
(removal/methylation/acylation) displayed antiproliferative activities similar to discodermolide.6 
Interestingly, methylation or acylation resulted in comparable and occasionally increased 
cytotoxicities relative to discodermolide, including in Taxol®-resistant cell lines. 
The isolated stereocenter at C16 of dictyostatin is of special interest, because discodermolide 
does not have a corresponding stereocenter; instead, discodermolide posses a C13-C14 (Z)-alkene 
(note that the carbon backbone of dictyostatin is two atoms longer than that of discodermolide, so 
C13 and C14 of discodermolide correspond to C15 and C16 of dictyostatin). The methyl group on 
C14 of discodermolide is not essential for biological activity; 14-desmethyldiscodermolide is a 
highly potent compound, as are a number of other 14-desmethyl analogues.7 If the C16 methyl 
group of dictyostatin were unnecessary, then the synthesis of such molecules would be much 
simpler than the parent compound, as the installation of this isolated stereocenter requires 
considerable effort.  
On the basis of this rational, a wide variety of dictyostatin analogs were synthesized 
independently by Paterson’s and Curran’s laboratories. A schematic overview is offered in Figure 
3.2. Structures 3.1 to 3.19 originate from appropriate diversifications in the synthetic pathways to 
(-)-dictyostatin. On the contrary, compounds 3.20 to 3.24 were not deliberately devised, but are 
rather by-products of certain late-stage reactions (namely, HCl global deprotection affords the iso-
dictyostatin series, while Yamaguchi macrolactonization leads to partial E-isomerization). 
Nevertheless, biological screening of compounds 3.20 to 3.24 broadened the understanding of the 
SAR for (-)-dictyostatin. 
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Figure 3.2 Analogs of (-)-dictyostatin 
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3.2.2 Biological Evaluation 
 
In a series of cytotoxicity assays performed by Wright and co-workers (Table 3.1),3 the cell 
growth inhibitory activities (IC50) of the fully synthetic dictyostatin analogs from Paterson’s group 
were evaluated in vitro against four human cancer cell lines: AsPC-1 (pancreatic), DLD-1 (colon), 
PANC-1 (pancreatic) and NCI/ADR (ovarian, Taxol®-resistant). The latter cell line contains an 
over-expressed P-glycoprotein efflux pump within the cell membrane, which is responsible for its 
resistance to Taxol®. 
Notably, the most potent analogs were 9-methoxy- (3.10), 2,3-dihydro- (3.13) and 6-
desmethyldictyostatin (3.19), displaying low nanomolar cytotoxicity (intermediate between 
dictyostatin and discodermolide) in both paclitaxel-sensitive and paclitaxel-resistant cell lines. 
Furthermore 10, 11-dihydro- (3.11) and 2,3,4,5-tetrahydrodictyostatin (3.14) were also quite active 
and directly comparable to discodermolide. In contrast, low activity profiles were displayed by 9-
epi-16-desmethyl- (3.8), 9-epi-dictyostatin (3.9) and the iso-series (3.21, 3.22). 
 
 
Compound 
IC50 (nM) 
AsPC-1 
(pancreatic) 
DLD-1 
(colon) 
PANC-1 
(pancreatic) 
NCI/ADR 
(Taxol®-resistant) 
Taxol® 89 22 9.9 1300 
(+)-Discodermolide 98 29 59 160 
(-)-Dictyostatin 6.2 2.2 4.2 6.6 
3.1 170 85 130 1500 
3.8 2100 790 1500 2100 
3.9 410 150 240 1100 
3.10 31 2.4 9.7 8.2 
3.11 43 10 18 300 
3.13 94 22 42 66 
3.14 118 55 64 132 
3.19 56 8.1 17 43 
3.21 3100 930 1900 1600 
3.22 4900 1900 3200 3100 
 
Table 3.1 Cytotoxicity of listed compounds in cultured human cancer cells (Paterson’s data)3 
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Analogs from Curran’s laboratory were examined for their antiproliferative activities against 
cultures of human ovarian carcinoma 1A9 cells and their paclitaxel-resistant mutants, 1A9/Ptx10 
and 1A9/Ptx22 (Table 3.2).1d Each of these resistant lines contains single mutations in the major 
-tubulin gene that confer to the cells, which do not over-express drug efflux pumps, appreciable 
tolerance to paclitaxel.  
 
 
Compound 
IC50 (nM) 
1A9 
(ovarian) 
1A9/Ptx10 
(Taxol®-resistant ) 
1A9/Ptx22 
(Taxol®-resistant) 
Taxol® 0.71 64 51 
(+)-Discodermolide 1.7 6.2 7.0 
(-)-Dictyostatin 0.69 3.2 1.3 
3.1 0.41 4.70 5.6 
3.2  61 862 543 
3.3 20900 50000 11560 
3.4 8.3 942 62 
3.5 4260 19300 4600 
3.6 285 2817 445 
3.7 241 4090 193 
3.9  79 2160 160 
3.12 21 120 43 
3.15  28000 26000 30000 
3.16 0.85 4.5 0.81 
3.17 n.a. n.a. 4.7 
3.18  n.a. n.a. 123 
3.20 7800 44190 53760 
3.23  310 780 790 
3.24 25000 25000 30000 
 
 
Table 3.2 Cytotoxicity of listed compounds in cultured human cancer cells (Curran’s data)1a,1c,1d,1i 
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Interestingly, 16-desmethyldictyostatin (3.1) exhibited superior activity on ovarian cell lines 
than on pancreatic and colon cell lines (compare data on Table 3.1 and Table 3.2 for this common 
analog). Enhanced cytotoxicity was also shown by 6- and 7- dictyostatin epimers (3.16, 3.17), 
while low activity was recorded for 9-epi- (3.9, 3.5), iso- (3.20) and (2E)-series (3.23, 3.24). 
 
 
3.2.3 Structure-Activity Relationship1c,3 
 
From these citotoxicity assay results, it is possible to formulate SAR conclusions regarding the 
importance of the modified regions of dictyostatin structure, and hence speculate on ligand 
interactions with the -tubulin binding site. SAR analysis is summarized in Figure 3.3. 
The C16 methyl substituent, if present, must be in the (S) configuration. This substituent is 
disposable; indeed, C15-C16 (Z)-alkene (without the C16 methyl group) is well tolerated. 
As to the bottom fragment, cytotoxicity data show the importance of C2-C3 (Z)-geometry as 
and the C2-C5 dienoate moiety (analogs with saturated C2-C5 region possess diminished 
biological activity). The 22-membered lactone (C1-C21 ester linkage) is essential; a 20-membered 
lactone (C1- C19 ester linkage) abates the desired biological action.  
C6 and C7 isomers showed an intermediate activity between that of dictyostatin and 
discodermolide, confirming the prediction that the C6 methyl group is unlikely to contribute to a 
strong interaction with tubulin binding site and occupies a relatively open region. Another finding 
is that natural (19R) and (14S) configurations confer higher activity. 
 
 
 
 
 
Figure 3.3 Qualitative structure-activity relationship for dictyostatin 
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The obtained data also clearly show that C9 must be in the (S) configuration. In fact, inversion 
of C9 configuration resulted in a substantial drop in cytotoxicity The effect of “capping” the C9 
hydroxyl group with a methyl had an insignificant effect on the binding ability of the analog. From 
this finding, it was proposed that the C9 hydroxyl group of dictyostatin does not act as a significant 
intermolecular hydrogen bond donor with proximal tubulin residues, and does not form any 
intermolecular hydrogen bonds, which might stabilize the bioactive conformation.  
In conclusion, 9-methoxydictyostatin (3.10) represents the most active dictyostatin analog 
prepare so far, and, importantly, shows comparable cytotoxicity relative to dictyostatin against a 
Taxol®-resistant cell line. 
 
 
3.3 Hybrids of (-)-Dictyostatin 
 
3.3.1 Design and Synthesis of Hybrids 
 
Several hybrid structures of discodermolide/dictyostatin (double hybrids) were conceived and 
synthesized by the Curran’s and Paterson’s laboratories (Figure 3.4).2 
The first hybrid molecules (3.25, 3.26) were reported in 2002 by Curran and co-workers.2a They 
were intended to feature structural and stereochemical motifs from both discodermolide and 
dictyostatin. However, as a consequence of the work pre-dating the stereochemical reassignment 
of dictyostatin, these structures contain regions that bear little resemblance to the stereochemistry 
of either natural products. The acyclic hybrid-intermediates 3.27 to 3.29, which led to 3.25 were 
also screened. 
Recently, the bioactive conformations of dictyostatin and discodermolide were elucidated using 
a combination of NMR analysis, molecular modeling and docking studies.8 The overlay of these 
tubulin-bound structures revealed some striking conformational similarities. The overlap is most 
pronounced from the common terminal diene moiety through to C9 on dictyostatin and C7 on 
discodermolide, whereas there appears to be minimal spatial correlation between the -lactone of 
discodermolide and the dienoate of dictyostatin. In addition, the models for tubulin binding 
indicates that both discodermolide and dictyostatin occupy the taxane site and share similar 
interactions with the protein residues of the receptor (Figure 3.5). 
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Figure 3.4 Discodermolide, dictyostatin and the resulting double hybrids 
 
 
 
Figure 3.5 Overlay of the NMR-derived bioactive conformations of discodermolide (green) and dictyostatin (blue) 
at the taxane binding site on -tubulin 
 
 
With this information in hand two hybrid structures (3.30, 3.31) were synthesized by Paterson 
and co-workers in 2007 and 2008.2b,2c Furthermore, the encouraging biological results of the O-
methylated analog 3.10 recently prompted the design and synthesis of hybrids 3.32 and 3.33.2d  
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Inspection of the overlaid tubulin-bound conformations of the discodermolide, paclitaxel and 
dictyostatin indicated that the side chain of paclitaxel occupied a region of the binding pocket that 
was not exploited by dictyostatin or discodermolide (Figure 3.6).8 
 
 
 
Figure 3.6 Overlay of the NMR-derived bioactive conformations of discodermolide (green), dictyostatin (blue) 
and paclitaxel (red) at the taxane binding site on -tubulin 
 
However, the C7 and C9 hydroxyls on dictyostatin were orientated to point into this vacant 
region. It was hypothesized that the addition of the paclitaxel (1.1, Figure 3.7) or docetaxel (1.2) 
side chain onto either of these hydroxyls would insure additional binding interactions.9  
 
 
 
Figure 3.7. Discodermolide, taxanes, dictyostatin, and the resulting triple hybrids 
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Consequently Paterson and co-workers reported the synthesis of a small library of 
discodermolide/taxanes/dictyostatin (triple hybrids), shown in Figure 3.7.2d 
 
 
3.2.2 Biological Evaluation 
 
The collection of double and triple hybrids was evaluated in vitro against several human cancer 
cell lines. A selection of the resulting biological data is available in Table 3.3.2,3 
Macrolactone 3.25, non-cyclized alcohol 3.27 and ester 3.28 exhibited similar moderate 
activity, whereas carboxylic acid 3.29 was inactive, possibly due to poor cell membrane 
penetration.  
Compound 3.26, the most functionalized of Curran’s hybrids, proved to be the most potent in 
terms of antiproliferative activity against ovarian and breast carcinoma cells. 
The low citotoxicity determined for 3.30 indicated its reduced binding affinity relative to the 
parent compounds. Gratifyingly a much better result was obtained with 3.31, which displayed 
intermediate cytotoxicity between that of discodermolide and dictyostatin.  
A similar biological activity was also recorded on 3.31 O-methylated derivatives: 3.32 and 3.33.  
As to triple hybrids, those bearing paclitaxel side chain, (3.34, 3.36, 3.38, 3.40) were somewhat 
more active than those bearing docetaxel side chain (3.35, 3.37, 3.39, 3.41), and the O-methylated 
triple hybrids (3.38 to 3.41) were less active than the non-methylated ones (3.34 to 3.37).  
In summary, the biological data obtained on the triple hybrids library demonstrated that the 
polycyclic baccatin core of paclitaxel can be replaced by a macrolide template whilst maintaining 
pronounced cytotoxicity. 
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Compound 
IC50 (nM) 
PANC-1 
(pancreatic)  
2008 
(ovarian) 
HT29 
(colon) 
MDA-MB-231 
(breast) 
NCI/ADR 
(Taxol®-resistant) 
Taxol® 9.9 n.a. n.a. n.a. 1300 
(+)-Discodermolide 59 0.072 0.015 0.016 160 
(-)-Dictyostatin 4.2 n.a. n.a. n.a. 6.6 
3.25 n.a. 16 n.a. 27 n.a. 
3.26 n.a. 1.0 n.a. 1.4 n.a. 
3.27 n.a. 22 n.a. 18 n.a. 
3.28 n.a. 19 n.a. 26 n.a. 
3.29 n.a. >50 n.a. >50 n.a. 
3.30 1800 n.a. 0.170 0.208 8200 
3.31 12.9 n.a. n.a. n.a. 66.4 
3.32 14 n.a. n.a. n.a. n.a. 
3.33 70 n.a. n.a. n.a. n.a. 
3.34 100 n.a. n.a. n.a. n.a. 
3.35 86 n.a. n.a. n.a. n.a. 
3.36 100 n.a. n.a. n.a. n.a. 
3.37 181 n.a. n.a. n.a. n.a. 
3.38 150 n.a. n.a. n.a. n.a. 
3.39 250 n.a. n.a. n.a. n.a. 
3.40 330 n.a. n.a. n.a. n.a. 
3.41 520 n.a. n.a. n.a. n.a. 
 
Table 3.3 Cytotoxicity of listed compounds in cultured human cells2,3 
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Chapter 4 
 
 
 
Our Route to (-)-Dictyostatin 
 
 
 
4.1 Introduction 
 
The development of a practical and flexible synthesis of (-)-dictyostatin (Figure 4.1) is still an 
important goal, particularly as the natural supply is extremely scarce. With the recent withdrawal 
of discodermolide from clinical development,1 the importance of dictyostatin further increases. 
From a pharmaceutical perspective, also the development of (-)-dictyostatin analogs is an 
appealing goal, which would provide interesting opportunities for structural simplification whilst 
maintaining biological potency, and increase our understanding of the structure-activity 
relationships (SAR) of this class of antitumor agents. 
 
 
 
 
Figure 4.1 (-)-dictyostatin 
 
 
4.2 Project Objectives 
 
While extensive structure-activity relationship data have been established for paclitaxel and 
epothilones,2 only limited data are available for other microtubule-stabilizing agents (MSAs). A 
more complete understanding of the SAR for the various natural products, through the synthesis of 
a broad variety of analogues, will be instrumental in the development of structurally simplified 
MSAs, which might then be more amenable to large-scale chemical synthesis. Of course, the 
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synthesis of analogues of such complex natural products requires an intricate understanding of the 
chemistry of these systems. This is best established initially through the total synthesis of the 
parent compounds themselves. In the case of (-)-dictyostatin, total synthesis is the only option to 
provide sufficient material for the biological profiling of the natural product itself. Therefore, the 
central aims of the project, of which this thesis work is part, are: (i) the synthesis and biological 
evaluation (effects on tubulin polymerization and antiproliferative activity) of (-)-dictyostatin; (ii) 
design and synthesis of analogues to establish comprehensive structure-activity relationships. 
In summary, this research project could lead to a breakthrough in the design of improved MSAs 
and to the discovery of a new generation of anti-cancer drugs. Such an accomplishment will 
advance the state-of-the-art in the development of natural products as cancer therapeutic agents, 
and demonstrate the enabling power of modern drug design and organic synthesis to provide 
practical sources of such complex compounds. 
 
 
4.3 Our First Retrosynthetic Approach to (-)-Dictyostatin 
 
In our first retrosynthetic approach, the macrolide ring is disconnected in the open-chain 
compound C1-C23 (4.1), which is itself obtained from two key intermediates: aldehyde C1-C9 
(4.2) and alkyne C10-C23 (4.3). Eight of the total eleven stereocenters and each stereogenic 
double-bond results from a highly stereoselective reaction, as shown in Scheme 4.1. 
 
 
 
Scheme 4.1 Our first retrosynthetic approach to (-)-dictyostatin  
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4.4 Synthesis of Aldehyde C1-C9 
 
 
 
Figure 4.2 Fragment C1-C9 of (-)-dictyostatin: Aldehyde (4.2) 
 
The C1–C9 fragment (Figure 4.2) contains two of the total eleven stereocenters and the 
(2Z,4E)-2,4-dienoate unit. A stereoselective synthesis of the C1–C9 fragment of (-)-dictyostatin 
was achieved and published in 20083 using a TiCl4-mediated chelation-controlled Mukaiyama-
aldol reaction and two modified Horner-Wadsworth-Emmons olefinations (under Roush-
Masamune and Still-Gennari conditions respectively).  
The synthetic pathway (Scheme 4.2) started from commercially available methyl (R)-3-
hydroxy-2-methylpropionate [(R)-Roche ester, 4.4]. Conversion of 4.4 to its benzyl ether (4.6) 
with benzyl trichloroacetimidate4 (4.5) was followed by LiAlH4 reduction of the ester to give 
alcohol 4.7 in 89% overall yield.5 Oxidation of alcohol 4.7 with Dess-Martin periodinane (DMP)6 
afforded aldehyde 4.8 in quantitative yield. Aldehyde 4.8 was not purified and it was immediately 
subjected to a TiCl4-mediated chelation-controlled Mukaiyama aldol reaction with 1-(tert-
butylthio)-1-(tert-butyldimethylsilyloxy)ethylene7 (4.9). The aldol product (4.10) was isolated in 
94% yield, with a 97:3 diastereomeric ratio in favor of the desired stereoisomer. Although it was 
reported that the two diastereomers could be separated with two consecutive purifications by flash 
chromatography,7a we still observed the presence of some epimer (≤3%) in  the 13C-NMR 
spectrum of 4.10. However, we decided to continue our synthesis as planned, confident that the 
minor isomer would be removable at a later stage of the sequence. Reduction (LiAlH4) of 4.10 
gave compound 4.11 in 98% yield. Subsequent double silylation (98%) led to the fully protected 
triol 4.12. Benzyl removal was accomplished by hydrogenolysis with Raney-Ni in EtOH8 (80%), 
and the resulting primary alcohol 4.13 was oxidized (DMP) to furnish aldehyde 4.14 in 
quantitative yield. Aldehyde 4.14 was not purified and immediately subjected to a Horner-
Wadsworth-Emmons reaction with diethyl (N-methoxy-N-methylcarbamoylmethyl) phosphonate9 
under the Roush-Masamune conditions.10 The olefination reaction afforded the Weinreb amide 
4.15 in 90% yield as single isomer (E:Z > 100:1). DIBAL-H reduction gave aldehyde 4.16 (91%) 
which was subjected to a Still-Gennari olefination11 to afford the methyl (2Z,4E)-2,4-dienoate 4.17 
in 90% yield as a single isomer (Z:E > 100:1).12 The minor (7R) isomer (≤3%), originated during 
the Mukaiyama-aldol reaction, was removed at this stage by flash chromatography. 
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Scheme 4.2 Synthesis of aldehyde C1-C9 (4.2) 
 
 
As for the final removal of the primary TBS group, three different procedures were tested 
(Scheme 4.3). With p-TSA in MeOH,13 selective deprotection occurred in poor yield (60%). With 
acetic acid in water and THF,14 no deprotection was observed. Finally, the use of the complex 
HF·Py in THF-Py15 turned out to be the best alternative: the desired alcohol 4.18 was isolated in 
86% yield. 
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Scheme 4.3 Different procedures for the selective deprotection of the primary alcohol 
 
 
The oxidation of alcohol 4.18, was carried out with DMP (Scheme 4.4), furnishing the C1-C9 
fragment of (-)-dictyostatin (4.2) in quantitative yield. 
 
 
 
Scheme 4.4 Completion of the synthesis of aldehyde C1-C9 (4.2) 
 
 
4.5 Synthesis of Alkyne C10-C23 
 
 
 
 
Figure 4.3 Fragment C10-C23 of (-)-dictyostatin: Alkyne (4.3) 
 
The synthesis of alkyne C10-C23 (4.3), published by our group in 2007,16 is based on the 
disconnection of our target macrolide into three key fragments: alkyne C13-C18 (4.19), aldehyde 
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C19-C23 (4.20) and (R)-3-butyn-2-ol mesylate (4.21). The latter compound was easily obtained 
from commercially available (R)-3-butyn-2-ol in one step. 
 
 
4.5.1 Synthesis of Alkyne C13-C18  
 
We started our synthesis of alkyne 4.19 (Scheme 4.5) with the protection17 of the hydroxyl 
group of (S)-3-hydroxy-2-methylpropionate [(S)-Roche ester, 4.22] with p-methoxybenzyl 
trichloroacetimidate (4.23), which gave compound 4.24 in 95% yield. Subsequent LiAlH4 
reduction of the ester group furnished the corresponding alcohol 4.25, which was converted (I2, 
PPh3, imidazole)18 into iodide 4.26 in high yield (95%). Myers alkylation19 with N-((1R,2R)-1-
hydroxy-1-phenylpropan-2-yl)-N-methylpropionamide (4.27) provided amide 4.28 in 92% yield 
and with a >98:2 diastereomeric ratio in favour of the desired diastereoisomer. Reduction with the 
borane-ammonia complex gave alcohol 4.29 in 95% yield. Benzyl protection (NaH, BnBr, n-
Bu4NI, 83%)20 led to 4.30, which, upon treatment with CAN, underwent selective removal of the 
PMB group over the benzyl group,21 to provide 4.31 in 93% yield. Dess Martin oxidation6 gave 
aldehyde 4.32, which was not isolated, and was directly homologated to alkyne 4.19. 
 
 
 
 
 
Scheme 4.5 Synthesis of fragment C10-C23: alkyne C13-C18 (4.33) 
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For this final alkynylation, different methods were tried with the twofold purpose of avoiding 
epimerization at the α stereocenter and obtaining a high yield (Scheme 4.6). The Seiferth-Gilbert 
procedure22 gave 10% epimerization along with a moderate yield. Corey-Fuchs 
dibromoolefination,23 followed by nBuLi promoted elimination, resulted in no epimerization but 
with a very low yield. The Shioiri’s lithiodiazomethane protocol24 (Colvin rearrangement) led to 
desired alkyne 4.19 in a higher yield as a single diastereomer, but the reaction suffered the scale up 
and could not be reproduced with the same yield. Finally, the Ohira-Bestmann protocol25 was 
explored. Under the original conditions, a good conversion was observed, but extensive 
epimerization of the  stereocenter occurred. After an in-depth investigation, it was found that the 
extent of epimerization could be limited by avoiding the use of a protic solvent and decreasing the 
amount of base. Optimal conditions26 were found which allowed to obtain alkyne 4.19 in excellent 
yield and a diastereomeric ratio. 
 
 
 
 
 
 
Scheme 4.6 Alkynylation: different methods 
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4.5.2 Synthesis of Aldehyde C19-C23 
 
The second key fragment was prepared according to Smith and co-workers,27 as shown in 
Scheme 4.7. 
 
 
 
Scheme 4.7 Synthesis of fragment C10-C23: aldehyde C19-C23 (4.20) 
 
 
Alcohol 4.25, previously obtained in the synthesis of alkyne 4.19, was used as starting material. 
The conversion of 4.25 into aldehyde 4.34 was accomplished through a Swern oxidation.28 
Subsequent Evans aldol condensation29 with (R)-4-benzyl-3-propionyloxazolidin-2-one (4.35) 
gave the aldol product 4.36 with a total control of stereochemistry.27 The conversion of adduct 4.36 
to the Weinreb amide30 4.37 was achieved by reaction with N,O-dimethylhydroxylamine 
hydrochloride in the presence of AlMe3. Weinreb amide 4.37 was then treated with DDQ to give 
the PMP acetal31 4.38, which was reduced32 (LiAlH4, THF, under controlled conditions) to the 
desired aldehyde C19-C23 (4.20). 
 
 
4.5.3 Completion of the Synthesis of Alkyne C10-C23 
 
With the two key fragments 4.19 and 4.20 in our hands, we proceeded to the coupling reaction 
(Scheme 4.8). Alkyne 4.19 was treated with nBuLi in THF at -78 °C and, then, with aldehyde 4.20 
to study the intrinsic preference of the two chiral coupling partners: a mixture of the two 
diastereomeric propargylic alcohols 4.39 and 4.40 in a 7:3 ratio (61% yield) was obtained.  
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Alternatively, a Carreira asymmetric alkynylation [Zn(OTf)2, Et3N, toluene, r.t.]33,34 was carried 
out with either of the two enantiomers of N-methyl-ephedrine (Scheme 4.8). The reaction with (-)-
(1R,2S)-N-methyl-ephedrine (matched pair) gave the desired (S)-alcohol 4.39 in 67% yield as a 
single diastereomer. In this reaction, slow addition of the aldehyde to the reaction mixture proved 
to be crucial to increase the yield, reducing the self-condensation of the aldehyde.35 On the 
contrary, the Carriera coupling with (+)-(1S,2R)-N-methyl-ephedrine (mismatched pair) afforded 
the addition product in 5% yield, with a 93:7 diastereomeric ratio in favor of the undesired (R)-
alcohol 4.40. 
 
 
 
Scheme 4.8 Carreira asymmetric alkynylation 
 
 
Although this step was initially carried out with satisfactory results on the small scale, the 
protocol resulted capricious and not reproducible on a larger scale; extensive degradation of the 
acetal was observed in the presence of Lewis-acidic Zn(OTf)2. As an alternative approach, we tried 
a modified Carreira alkynylation with a synthetic chiral aminoalcohol36 instead of N-
methylephedrine (Scheme 4.9), but no product was obtained. 
 
 
 
 
Scheme 4.9 Modified Carreira asymmetric alkynylation 
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At this point, we changed our synthetic strategy (Scheme 4.10). We ran the coupling reaction 
(nBuLi, THF, -78°C) between alkyne 4.19 and Weinreb amide 4.38 (instead of aldehyde 4.20),37 
which led to ynone 4.41 in 70 % yield. 
 
 
 
Scheme 4.10 Alternative approach for avoiding the Carreira alkynylation 
 
Afterwards, different methods for the stereoselective reduction of the ynone into the desired 
propargylic alcohol 4.39 were screened (Scheme 4.11). As a first attempt, we tried the reduction 
with the modified hydride Li(t-BuO)3AlH.15 Despite the excellent yield, the diasteromeric ratio 
resulted unsatisfactory (75:25). Corey’s borane-mediated enantioselective reduction (CBS 
reduction)38 with oxazaborolidines as chiral catalysts caused degradation of the ynone. The acidic 
environment involved in this method seems to be incompatible with our starting material. Finally, 
Noyori asymmetric transfer hydrogenation39 [(S,S)-Noyori catalyst, iPrOH] turned out to be the 
best choice, giving alcohol 4.39 in a >100:1 diastereomeric ratio, with an excellent yield (98%). 
 
 
 
Scheme 4.11 Screening of reduction methods for obtaining the propargylic alcohol 4.39 
 
With alcohol 4.39 in the hand we was able to complete the synthesis of key fragment C10-C23 
(4.3) as shown in Scheme 4.12. 
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Scheme 4.12 Completion of the synthesis of fragment C10-C23 (4.3) 
 
 
Acetal 4.39 was cleaved with DIBAL-H to generate the diol 4.42 in 75% yield. Hydrogenation 
of 4.42 (under 4 bar of hydrogen pressure) in the presence of a catalytic amount (10%) of 
Wilkinson’s catalyst40 afforded the desired saturated compound 4.43 (70%). Subsequent silylation 
(TBSOTf, 2,6-lutidine, DCM, 97%) provided the fully protected tetraol 4.44, which was subjected 
to selective removal of the benzyl group over the PMB group (H2, Raney-Ni, EtOH, 81%)41 to 
obtain the primary alcohol 4.45. TPAP/NMO oxidation42 of 4.45, which furnished aldehyde 4.46, 
was followed by a Marshall-Tamaru palladium-catalyzed allenylzinc addition43,44 with the 
mesylate of (R)-3-butyn-2-ol (4.21), leading to the desired alcohol 4.47 (82% over two steps) with 
a very high level of diastereoselectivity in favor of the desired anti,syn adduct (>98:2). Finally, 
TBS protection of alcohol 4.47 afforded quantitatively the desired key fragment C10-C23 (4.3) of 
(-)-dictyostatin (1.8). 
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4.6 Coupling Between Two Key Fragments C1-C9 and C10-C23 
 
Initially, we studied the coupling procedure between aldehyde C1-C9 (4.2) and the model 
alkyne 4.19 (Scheme 4.13). The formation of the alkynyl-lithium (nBuLi, THF, -78°C)15 and its 
addition to aldehyde 4.2 occurred in good yield (70%) and with an acceptable 65:35 
diastereoisomeric ratio in favor of the desired product 4.48 over the undesired propargylic alcohol 
4.49. 
 
 
Scheme 4.13 Coupling reaction of aldehyde 4.2 with the model alkyne 4.19 
 
 
The following reaction of hydrogenation of the triple bond to (Z)-double bond was tried on the 
mixture of model propargylic alcohol 4.48 and 4.49 (Scheme 4.14).  
 
 
 
Scheme 4.14 Reduction with Lindlar catalyst of mixture of model propargylic alcohol 4.49 
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We were fearing to be unable to perform the selective reduction of the triple bond in the 
presence of the conjugated double bond.45 Indeed, extensive investigation of reduction conditions 
failed to identify conditions that would selectively reduce the alkyne to the (Z)-alkene, while 
leaving the terminal diene intact. Hydrogenation over Lindlar catalyst46 gave only traces of the 
desired product 4.50, while the major products were over-hydrogenated compounds 4.51 and 4.52. 
We thus decided to adopt a different strategy (Scheme 4.15), and carry out the hydrogenation 
step on ynone 4.53 rather than on the propargyl alcohol. First, the mixture of propargylic alcohols 
4.48 and 4.49, derived from nBuLi coupling, was oxidized (DMP, Py, DCM, 90%) to give the 
ynone 4.53. This compound was then hydrogenated over Lindlar catalyst in the hope of observing 
better results. Unfortunately, we isolated either no product or decomposition products, depending 
on the amount of Lindlar catalyst. 
 
 
 
 
Scheme 4.15 Reduction with Lindlar catalyst of model ynone 4.53 
 
At this time it became evident that the reduction of the alkyne moiety in the presence of the 
competing terminal diene was a too high hurdle. As a consequence, we revised our retrosynthetic 
approach to (-)-dictyostatin (1.8).  
 
 
4.7 Our Second Retrosynthetic Approach to (-)-Dictyostatin 
 
Our alternative retrosynthetic approach to (-)-dictyostatin (Scheme 4.16) consisted in replacing 
the alkyne C10-C23 (4.3) with the vinyl iodide C10-C26 (4.54). In this new strategy, adopted by 
Ramachandran and co-workers in their total synthesis of (-)-dictyostatin, the troublesome alkynyl 
lithium coupling reaction is substituted by a lithium (Z)-vinylzincate addition13. 
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Scheme 4.16 Our second retrosynthetic approach to (-)-dictyostatin 
 
 
4.8 Synthesis of (Z)-Vinyl Iodide C10-C26 
 
The synthesis of new key fragment C10-C26 (4.54), published by our group in 201047, starts 
from fragment C10-C23 (4.3). The alkyne was lithiated with nBuLi and converted into the 
corresponding alkynyl iodide 4.55 in quantitative yield (Scheme 4.17). Reduction of compound 
4.55 with diimide15,48 (generated in situ from 2-nitrobenzenesulfonylhydrazide) provided (Z)-vinyl 
iodide 4.56 as a single diastereoisomer (Z:E > 100:1) in excellent yield (92%). The primary t-
butyldimethylsilyl ether of 4.56 was selectively cleaved (HF·Py, THF/Py, 80%) to give compound 
4.57, which was converted into aldehyde 4.58 by oxidation with Dess-Martin periodinane. The 
latter compound was reacted with (1-bromoallyl)trimethylsilane (4.59) under Nozaki-Hiyama-
Kishi coupling conditions (CrCl2),  followed by a Peterson elimination (KOH, MeOH)49 to give 
the C10-C26 fragment (4.54) in good yield (76%, 2 steps) and excellent diastereoselectivity (Z:E 
>100:1).50 
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Scheme 4.17 Synthesis of (Z)-vinyl iodide C10-C26 (4.54) 
 
 
4.9 Lithium (Z)-Vinylzincate Addition: The Surprise 
 
Once completed the synthesis of the fragment C10-C26 (4.54), we were ready to try its addition 
to the aldehyde C1-C9 (4.2). Following Ramachandran’s lead,13 lithiation of (Z)-vinyl iodide 4.54 
(tBuLi) and subsequent treatment with dimethylzinc provided the corresponding lithium (Z)-vinyl 
zincate,51 which was added to β-silyloxy aldehyde C1-C9 (4.2) to give the coupling product 4.60 
in moderate yield (40%) and excellent diastereomeric ratio (>95:5, Scheme 4.18). On the basis of 
the structural assignment of the final product [which will not be the desired (-)-dictyostatin (1.8), 
but (+)-9-epi-dictyostatin (4.65), as described in the next sections], the stereochemistry of the 
newly created stereogenic center C9 in compound 4.60 turned out to be (9R). We found this 
outcome quite surprising, as the addition of the same (Z)-vinylzincate to a very similar aldehyde 
(with the ethyl ester instead of the methyl ester) was reported to give an excellent ratio in favor of 
the (9S) stereoisomer.13 
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Scheme 4.18 Lithium (Z)-vinylzincate coupling reaction 
 
 
The preference for the 1,3-syn diastereomer observed in compound 4.60 can be rationalized on 
the basis of the 1,3-asymmetric induction models (Figure 4.4) thoroughly investigated by Evans.52 
Steric interactions in the aldehyde conformations are minimized when the β-alkyl substituent (Rβ) 
is oriented anti to the Cα-C=O bond as in structures A and B. Usually, β-OTBS substituted 
aldehydes afford preferentially the 1,3-anti diastereomer via the polar model A, where dipoles are 
opposed.52 When aluminum Lewis acids (Me2AlCl or MeAlCl2) are used, exceptional chelation 
control reinforces the 1,3-anti stereochemical outcome (model C, axial attack).53 Recently, Curran 
and co-workers studied the addition of a (Z)-vinyllithium compound to aldehyde 4.2, and reported 
a ca. 2:1 1,3-anti : 1,3-syn  diastereomeric ratio.54 Addition of other (Z)-vinyllithium compounds to 
similar aldehydes gave 1,3-anti : 1,3-syn ratios from 1.5:1 to 1:1.6.15,54 Apparently, models B 
and/or C (equatorial attack), leading to the 1,3-syn diastereomer, start making a substantial impact 
in these addition reactions. Surprisingly, when a dimethylalkenylzincate51,55 is used, the 
stereochemical outcome is determined only by models B and/or C (equatorial attack), leading to 
complete selectivity in favor of the 1,3-syn diastereomer. 
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Figure 4.4 Evans’s 1,3 asymmetric induction models 
 
 
4.10 Completion of the Synthesis of (+)-9-epi-dictyostatin 
 
As we were not yet aware of the stereochemical outcome of the (Z)-vinylzincate addition, we 
completed our synthesis as planned (Scheme 4.19). The secondary alcohol of compound 4.60 was 
silylated with TBSOTf to give the fully protected intermediate 4.61 (100%). Selective PMB 
removal with DDQ provided compound 4.62 (90%), which was then saponified under basic 
conditions (KOH) to provide seco-acid 4.63 (100%). Yamaguchi macrolactonization56 gave 
macrolide 4.64 in good yield (80%), together with a small amount (5-10%) of the (2E,4E)-dienoate 
(JH2-H3 = 15.2 Hz), probably formed via a reversible Michael addition of DMAP to the (2Z,4E)-
dienoate,57 and which could be separated by flash chromatography. The global deprotection of the 
TBS groups was initially attempted with 3N HCl/MeOH in THF (2.2:1 volume ratio).13 However, 
this method caused an extensive degradation of the product. Conversely, the use of HF·Py in 
THF58,59 cleanly converted 4.64 into (+)-9-epi-dictyostatin 4.65 in 70% yield.  
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Scheme 4.19 Completion of the total synthesis of (+)-9-epi-dictyostatin (4.65) 
 
 
Our synthetic compound 4.65 produced analytical data (1H-NMR in CD3OD, [α]D) in 
disagreement with those recorded from an authentic sample of (-)-dictyostatin (1.8) kindly 
provided by Prof. Ian Paterson (University of Cambridge, UK). On the contrary, our synthetic 
compound 4.65 was identical (1H-NMR and 13C-NMR in d6-benzene, [α]D, HRMS, IR, Rf) to those 
described by Paterson59 and Curran54 as (+)-9-epi-dictyostatin (see Chapter 6 for full analytical 
details). 
 
 
4.11 Conclusion 
 
A highly stereoselective synthesis of (+)-9-epi-dictyostatin (4.65) has been carried out in 1.53% 
overall yield over 29 steps (longest linear sequence from the Roche ester). Unfortunately, 
unnatural configuration at C9 is known to cause a substantial drop in cytotoxicity relative to (-)-
dictyostatin (1.8)54,59. Nevertheless, compound 4.60 should be easily conveyed into the total 
synthesis of (-)-dictyostatin (1.8) by oxidation of the (9R)-allylic alcohol to the corresponding 9-
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ketone 4.66, completion of the synthetic sequence (as outlined in Scheme 4.20) and reduction of 
the macrocyclized enone 4.67 to the (9S)-allylic alcohol 4.68 (NaBH4, CeCl3 7H2O, EtOH, -30 
°C)59,60 immediately before final deprotection. 
 
 
 
 
Scheme 4.20 Possible conveyance of 4.60 into the total synthesis of (-)-dictyostatin (1.8) 
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Chapter 5 
 
 
 
Our Route to 12,13-bis-epi-Dictyostatin 
 
 
 
5.1 Introduction 
 
The design and synthesis of non-natural dictyostatin analogs is an important goal for the 
evaluation of structure-activity relationships of this class of molecules. Although much work has 
been carried out in this field (as described in Chapter 3), syntheses of dictyostatin analogs 
modified at C12, C13 were never reported. Consequently, we decided to focus our efforts in the 
synthesis of dictyostatin epimers at C12 and C13. Biological screening of these new structures 
could be insightful to better understand the stereochemical requirements for antitumor activity. 
Our synthetic route to (+)-9-epi-dictyostatin (4.65) and (-)-dictyostatin (1.8) is flexible enough 
to allow the preparation of 12,13-bis-epi-dictyostatin (5.1, Figure 5.1). The following sections 
delineate our preliminary activity aimed to the synthesis of 5.1. 
 
 
 
 
Figure 5.1 12,13-bis-epi-dictyostatin 
 
 
5.2 Our Retrosynthetic Approach to 12,13-bis-epi-Dictyostatin 
 
As for the synthesis of (+)-9-epi-dictyostatin (4.65), our retrosynthetic approach identified two 
key fragments: aldehyde C1-C9 (4.2) and (Z)-vinyl iodide bis-epi-C10-C26 (5.2) as shown in 
Scheme 5.1. For the synthesis of the former compound, see Chapter 4. 
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Scheme 5.1 Our retrosynthetic approach to 12,13-bis-epi-dictyostatin 
 
5.3 Synthesis of (Z)-Vinyl Iodide 12,13-bis-epi-C10-C26 
 
Starting from primary alcohol 4.45 (Scheme 5.2), TPAP/NMO oxidation1 and subsequent 
Marshall-Tamaru palladium-catalyzed allenylzinc addition2,3 with the mesylate of (R)-3-butyn-2-ol 
(4.21), furnished alkyne 4.47 (anti, syn diastereomer).  
 
 
 
Scheme 5.2. Marshall-Tamaru allenylzinc addition with two enantiomers of 3-butyn-2-ol mesylate 
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This compound was conveyed in the synthesis of (+)-9-epi-dictyostatin (4.65), as described in 
Chapter 4. The same sequence was repeated employing the mesylate of (S)-3-butyn-2-ol (5.3). 
This second attempt led to alkyne 5.4 (anti, anti diastereomer, 84% over two steps) with an 
excellent control of diastereoselectivity. Therefore, the use of enantiomeric 3-butyn-2-ol mesylate 
in a Marshall-Tamaru reaction enabled us to modify the configuration at C12 and C13, thus 
opening the route to 12,13-bis-epi-dictyostatin (5.1). 
The synthesis of bis-epi-C10-C26 (5.2) was completed with an identical strategy (Scheme 5.3) 
to that devised for C10-C26 (4.54) TBS protection of Marshall-Tamaru adduct 5.4 provided alkyne 
5.5 (79%), which was then lithiated with nBuLi and converted into the corresponding alkynyl 
iodide 5.6 (100%). Reduction of the latter compound with diimide4,5,afforded (Z)-vinyl iodide 5.7 
quantitatively as a single diastereoisomer (Z:E > 100:1). The primary t-butyldimethylsilyl ether of 
5.7 was selectively removed (HF·Py, THF/Py, 80%)4 to give alcohol 5.8, which was oxidized to 
aldehyde 5.9 with Dess-Martin periodinane.6 Reaction with (1-bromoallyl)trimethylsilane (4.59) 
under Nozaki-Hiyama-Kishi coupling conditions (CrCl2),7 followed by Peterson elimination 
(KOH, MeOH), provided the bis-epi-C10-C26 fragment (5.2) in high yield (92% over 2 steps) and 
excellent diastereocontrol of the newly formed double bond (Z:E > 100:1).8 
 
 
 
Scheme 5.3 Synthesis of fragment 12,13-bis-epi-C10-C26 (5.2) 
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5.4 Lithium (Z)-Vinylzincate Addition and Completion of the Synthesis 
 
In our hands, the lithium (Z)-vinylzincate addition described in §4.9 resulted (9R)-
diastereoselective, despite what Ramachandran claimed in his total synthesis (-)-dictyostatin.9 
Bearing this stereochemical outcome in our minds, we attempted the same coupling reaction 
between aldehyde C1-C9 (4.2) and (Z)- vinyl iodide 12,13-bis-epi-C10-C26 (5.2) (Scheme 5.4). 
On the basis of an a posteriori assessment, the new stereocenter at C9 appeared to be (R) once 
again. 
 
 
 
 
 
Scheme 5.4 Lithium (Z)-vinylzincate coupling reaction 
 
 
The assignment of C9 configuration was accomplished through an empirical rule described by 
Curran in 2007.4 Such rule originates from an attentive analysis of 1H NMR spectra of some later-
stage precursors of dictyostatin analogs (shown in Figure 5.2). Curran observed that the signal for 
H9 in compound α (possessing 9S configuration) was a doublet-doublet at δ 4.5 (J values of 12.4 
and 7.6 Hz), whereas the same signal in compound β (possessing 9R configuration) was more 
closely resembling a triplet at δ 4.4 (J value of 8.1 Hz).  
 
 
 
Figure 5.2 Representative compounds from which Curran derived his rule 
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This trend was satisfactorily verified in other similar intermediates, thus providing a 
straightforward and reliable method for assigning C9 configuration. However, “Curran’s rule” 
cannot be applied directly to compound 5.10, because the PMB CH2 signals would cover the area 
of interest (4.4-4.6 ppm). In addition, no evidence is available for the rule to be valid when the 
hydroxyl group on C9 is unprotected. 
For these reasons, we resolved to bring a small amount of 5.10 some steps further in the 
synthesis (Scheme 5.5). 
 
 
 
 
Scheme 5.5 9,12,13-tris-epi series 
 
 
The hydroxyl moiety was silylated with TBSOTf to give the fully protected intermediate 5.11 
(100%). DDQ treatment cleaved PMB selectively, providing compound 5.12 (85%), which was 
then saponified (KOH, 100%) to provide seco-acid 5.13. 
With the spectral data of this set of compounds at our disposal, we were able to ascertain the 
configuration at C9 through the above-mentioned empirical rule. As shown in Figure 5.3, 
compounds 5.12 and 5.13 produced triplet signals in the spectral area of interest (right column). 
This pattern is consistent with the C9 configuration being (R). Further evidence is provided by the 
analysis of 1H NMR spectra of compounds 4.62 and 4.63 precursors of (+)-9-epi-dictyostatin (left 
column). Again, H9 signals are triplets, thus endorsing (9R) stereochemistry. Conversely, a similar 
intermediate, having (S) configuration at C9, gave rise to a characteristic doublet-doublet (bottom). 
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Figure 5.3 Application of “Curran’s rule” to our intermediates 
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5.5 Future Perspectives 
 
Although compound 5.13 is only two steps away from 9,12,13-tris-epi-dictyostatin (5.14, 
Figure 5.4), we are not interested in completing such synthesis. As a matter of fact, (R) 
configuration at C9 turned out to inhibit biological activity in other dictyostatin analogues.4,10 
Hence, macrolide 5.14 is likely to be worthless in a pharmaceutical scenario. 
 
 
 
Figure 5.4 9,12,13-tris-epi-dictyostatin (5.14) and “ox/red strategy” 
 
Nevertheless, our initial plan of synthesizing the potentially active 12,13-bis-epi-dictyostatin 
(5.1) is still attainable through an oxidation/reduction sequence (Figure 5.4). In contrast to the 
inversion strategy devised for compound 4.60 (see §4.11), reduction with Luche reagent (NaBH4, 
CeCl3·7H2O)11,12 might not be equally reliable in the bis-epi series. The stereoselectivity of Luche 
reduction of compound 4.67 stems from a macrocyclic control whose outcome is, by chance, the 
desired (9S)-epimer. As our bis-epi series exhibits opposed configuration at C12 and C13, a 
different preferred conformation of the macrocycle might reverse the stereochemical outcome. 
Consequently, conceived a modified strategy capable of delivering the desired (9S)-epimer 
unambiguously. The new approach, which we wish to put into pratice in the near future, is 
described in Scheme 5.6. Alcohol 5.10 will be oxidized4 to 9-ketone 5.15 through Dess-Martin 
periodinane. Subsequent reduction to the desired (9S)-allylic alcohol 5.16 will be carried out as a 
Corey’s borane-mediated enantioselective reduction (CBS reduction)13 with oxazaborolidines as 
chiral catalysts.14 The newly created 9-allylic alcohol 5.16 will be silylated with TBSOTf 
providing 5.17. Selective PMB removal with DDQ will give compound 5.18, which, after 
saponification (5.19), will undergo Yamaguchi macrolactonization (5.20).15 Final deprotection of 
5.20 with HF·Py 10a,11 will afford our desired macrolide 12,13-bis-epi-dictyostatin (5.1). 
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Figure 5.6 Proposed synthetic approach to 12,13-bis-epi-dictyostatin (5.1) 
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Chapter 6 
 
 
 
Experimental Detail 
 
 
 
6.1 General Comments 
 
1H (400.13 MHz) and 13C (100.58 MHz) NMR spectra were recorded on a Brüker Avance-400 
spectrometer. 1H NMR chemical shifts are reported relative to TMS, and the solvent resonance 
was employed as the internal standard (CDCl3,  = 7.26). The following abbreviations are used to 
describe spin multiplicity: s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet, dd = 
doublet-doublet, td = triplet-doublet, dt = doublet-triplet, br = broad signal. 13C NMR spectra were 
recorded with complete proton decoupling, and the chemical shifts are reported relative to TMS 
with the solvent resonance as the internal standard (CDCl3,  = 77.0). Infrared spectra were 
recorded on a standard FT/IR spectrophotometer. Optical rotation values were measured on an 
automatic polarimeter with a 1 dm cell at the sodium D line. High resolution mass spectra (HRMS) 
were performed on a Fourier Transform Ion Cyclotron Resonance (FT-ICR) Mass Spectrometer 
APEX II & Xmass software (Bruker Daltonics) – 4.7 T Magnet (Magnex) equipped with ESI 
source, available at C.I.G.A. (Centro Interdipartimentale Grandi Apparecchiature dell’Università 
degli Studi di Milano). All reactions were carried out in oven- or flame-dried glassware under 
nitrogen atmosphere, unless stated otherwise. All commercially available reagents were used as 
received. All solvents were dried by standard procedures before use. Organic extracts were dried 
over anhydrous Na2SO4. Reactions were magnetically stirred and monitored by TLC on silica gel 
(60 F254 pre-coated glass plates, 0.25 mm thickness). Visualization was accomplished by 
irradiation with a UV lamp and/or staining with a ceric ammonium molybdate or KMnO4 solution. 
Flash chromatography was performed on silica gel (60 Å, particle size 0.040–0.062 mm) according 
to the procedure of Still and co-workers.1 Yields refer to chromatographically and 
spectroscopically pure compounds, unless stated otherwise.  
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6.2 Preparation of Reagents 
 
 
 
 
Benzyl 2,2,2-trichloroacetimidate (4.5)2 
To a solution of freshly distilled benzyl alcohol (5.62 g, 52 mmol, 1 eq) in DCM (58 mL), a 
solution of KOH (50% in water, 58 mL) and tetrabutylammonium hydrogen sulfate (88.3 mg, 0.26 
mmol, 0.005 eq) were added. The mixture was cooled to -15 °C and after 10 min under vigorous 
stirring, trichloroacetonitrile (5.74 mL, 57.2 mmol, 1.1 equiv) was added. After 30 min the 
temperature was raised to R.T. and the yellow mixture was stirred for 30 min. Phases were 
separated and the aqueous phase was extracted with DCM (3 x 100 mL) The combined organic 
layers were dried over Na2SO4 and concentrated in under reduced pressure. The residue was 
filtered through a short plug of celite and concentration under reduced pressure gave the benzyl 
2,2,2-trichloroacetimidate 4.5 (13.2 g, 100% yield) as a yellow oil which was used without further 
purification. 
Rf 0.70 (80:20 hexane/EtOAc); 1H NMR (400 MHz, CDCl3): δ = 5.38 (s, 2H), 7.32-7.38 (m, 5H), 
8.43 (br s, 1H). 
 
 
 
 
4-methoxybenzyl 2,2,2-trichloroacetimidate (4.23)3 
p-Methoxybenzyl alcohol (5.53 g, 40 mmol, 1 eq) was added to a suspension of NaH (60% in 
mineral oil; 0.16 g, 4 mmol, 0.1 eq) in Et2O (39 mL) over 30 min at R.T. The mixture was stirred 
30 min further and cooled to 0 °C. Trichloroacetonitrile (4.41 mL, 44 mmol, 1.1 eq) was then 
introduced over 15 min. After 2 h the solution was concentrated with the water bath temperature 
maintained below 40 °C. The residue was treated with a mixture of pentane (41 mL) and MeOH 
(0.2 mL), stirred at room temperature for 30 min, and filtered through a short plug of celite. 
Concentration under reduced pressure gave the trichloroimidate 4.23 (11.3 g, 100% yield) as a 
yellow oil which was used without further purification. 
Rf 0.70 (80:20 hexane/EtOAc); 1H NMR (400 MHz, CDCl3): δ = 3.82 (s, 3H), 5.29 (s, 2H), 6.92 
(d, J = 8.6 Hz, 2H), 7.38 (d, J = 8.6 Hz, 2H), 8.37 (br s, 1H). 
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1-(tert-butylthio)-1-(tert-butyldimethylsilyloxy)ethylene (4.9)4 
A solution of DIPA (2.1 mL, 14.7 mmol, 1 eq) in THF (18.4 mL) was treated with nBuLi in 
hexane (1.6 M, 9.2 mL, 14.7 mmol, 1 eq) at 0 °C under stirring. After 30 min at 0 °C the mixture 
was cooled to -78 °C and a solution of commercially available t-butyl-thioacetate (2.0 mL, 14.7 
mmol, 1 eq) in THF (5.3 mL) was slowly added. After 30 min at -78 °C a solution of t-
butyldimethylsilyl chloride (2.2 g, 14.7 mmol, 1 eq) in DMPU (8.2 mL) was added. Then the 
mixture was warmed to R.T. during 30 min, diluted with ice-cold pentane and washed with water. 
The organic phase was dried over Na2SO4, filtered and concentrated under reduced pressure. The 
resulting crude product was purified by distillation (145 °C, 20 mmHg) to give the ketene acetal 
4.9 (2.7 g, 75% yield) as a colorless oil. 
Rf 0.80 (80:20 hexane/EtOAc); 1H NMR (400 MHz, CDCl3): δ = 0.19 (s, 6H), 0.91 (m, 9H), 1.38 
(m, 9H), 4.68 (d, J = 16 Hz, 2H). 
 
 
 
 
N-((1R,2R)-1-hydroxy-1-phenylpropan-2-yl)-N-methylpropionamide (4.27)5 
A 50 mL flask was charged with (1R,2R)-2-(methylamino)-1-phenylpropan-1-ol (1.0 g, 6.05 
mmol, 1 eq), TEA (1.0 mL, 7.26 mmol, 1.2 eq) and DCM (12 mL). The flask was placed in a 
water bath, at R.T., and propionic anhydride ( 0.85 mL, 6.65 mmol, 1.1 eq) was added. The 
reaction was stirred at R.T. for 1 h and quenched with water (2 mL). The organic phase was 
separated and extracted with half-saturated aq. NaHCO3 (2 x 2 mL) and 1N aq HCl (2 x 2mL), 
dried and concentrated under reduced pressure to afford a white solid. Re-crystallization from 
toluene yielded the pure product 4.27 (1,1 g, 80% yield) as a highly viscous, yellow oil containing 
mixture of rotamers (minor resonances are denoted by an asterisk). 
Rf 0.30 (10:20 hexane/EtOAc); 1H NMR (400 MHz, CDCl3): δ = 1.00* (d, J = 6.8 Hz, 0.7H), 1.08-
1.26* (m, 5.3H), 2.25-2.45 (m, 1.5H), 2.50-2.60* (m, 1H), 2.83 (s, 0.5H), 2.95 (s, 2.3H), 4.03* (m, 
0.7H), 4.46* (m, 0.3H), 4.60* (m, 1H). 
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Dimethyl (1-diazo-2-oxopropyl)phosphonate (4.33)6 
A solution of tosyl chloride (1.0 g, 5.25 mmol, 1 eq) and NaN3 (341.3 mg, 5.25 mmol, 1 eq) in 
acetone (15 mL) and water (15 mL) was stirred at 0 °C for 2 h. Acetone was evaporated and the 
reaction mixture was extracted with Et2O. The organic phase was dried and concentrated under 
reduced pressure to afford tosyl azide, which was used without further purification. 
A solution of dimethyl (2-oxopropyl)phosphonate (0.72 mL, 5.25 mmol, 1 eq) in CH3CN (5 mL) 
and solid K2CO3 (725 mg, 5.25 mmol, 1 eq) was added the crude tosyl azide (5.25 mmol, 1 eq) in 
CH3CN (4 mL). The mixture was stirred overnight, then Et2O (10 mL) was added and the solution 
was filtered through a short pad of celite. Purification by flash chromatography (20:80 
hexane/EtOAc) afforded Bestmann-Ohira phosponate 4.33 (453 mg, 45% yield) as a pale yellow 
oil. 
Rf 0.25 (20:80 hexane/EtOAc); 1H NMR (400 MHz, CDCl3): δ = 2.26 (s, 3H), 3.83 (d, J = 12.0 Hz, 
6H). 
 
 
 
 
(R)-4-benzyl-3-propionyloxazolidin-2-one (4.35)7 
A solution of (R)-4-benzyl-oxazolidin-2-one (3.91 mg, 22.1 mmol, 1 eq) in THF (98 mL) was 
cooled to -78 °C and nBuLi in hexane (1.6 M, 15.2 mL, 24.3 mmol, 1.1 eq) was added over 15 
min. After additional 30 min, a solution of propanoyl chloride (1.92 mL, 22.1 mmol, 1 eq) in THF 
(14 mL) was added dropwise over 10 min. The resultant mixture was stirred 2 h at -78 °C, then 
warmed to 0 °C and quenched by the addition of a sat. aq. NH4Cl solution (66 mL). The layers 
were separated, and the aqueous phase was extracted with Et2O. The combined organic layers were 
washed with water and brine, then dried over Na2SO4, filtered and concentrated under reduced 
pressure. Purification by flash chromatography (80:20 hexane/EtOAc) afforded the oxazolidinone 
4.35 (5.06 g, 98% yield) as a white solid. 
Rf 0.30 (80:20 hexane/EtOAc); 1H NMR (400 MHz, CDCl3): δ = 1.23 (t, J = 7.6 Hz, 3H), 2.82-
3.05 (m, 2H), 3.31-3.35 (dd, J = 3.4 Hz, 13.4 Hz, 1H), 4.18-4.25 (m, 2H), 4.67-4.73 (m, 1H), 7.24 
(d, J = 8.6 Hz, 2H), 7.36 (d, J = 8.6 Hz, 2H). 
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(1S,2S)-(-)-N-Tosyl-1,2-diphenylethane-1,2-diamine[(η6-1-isopropyl-4methylbenzene) 
ruthenium(II)] (Noyori Catalyst)8 
A mixture of di--chloro-bis[chloro(6-1-isopropyl-4-methylbenzene)ruthenium(II)] (0.306 g, 
0.500 mmol, 1 eq), N-((1S,2S)-2-amino-1,2-diphenylethyl)-4-methylbenzenesulfonamide (0.366 g, 
1.00 mmol, 2 eq) and KOH (0.411 g,7.33 mmol, 15 eq) in DCM (7 mL) was stirred at R.T. for 5 
min. On addition of water (7 ml), the color changed from orange to deep purple. The purple 
organic layer was washed with water (7 ml), dried over CaH2 and concentrated to dryness in vacuo 
to yield (S,S) Noyori Catalyst (0.564 g, 94%) as deep purple crystals. 
1H NMR (400 MHz, Toluene-d8): δ = 1.04 (d, J = 7.0 Hz, 3H), 1.09 (d, J = 7.0 Hz, 3H), 1.89 (s, 
3H), 2.05 (s, 3H), 2.37 (m, 1H), 3.91 (d, J = 4.0 Hz, 1H), 4.71 (s, 1H), 4.94 (d, J = 5.0 Hz, 1H), 
5.06 (d, J = 5.0 Hz, 1H), 5.11 (d, J = 5.0 Hz, 1H), 5.22 (d, J = 5.0 Hz, 1H), 6.42 (m, 1H), 6.70 (d, J 
= 8.0 Hz, 2H), 7.10 (m, 10H), 7.49 (d, J = 8.0 Hz, 2H). 
 
 
 
 
(R) and (S)-but-3-yn-2-yl methanesulfonate (4.21 and 5.3)9 
To a solution of (R) or (S)-but-3-yn-2-ol (0.2 mL, 2.5 mmol, 1 eq) in DCM (2 mL) at -78 °C TEA 
(1.40 mL, 10 mmol, 4 eq) and mesyl chloride (0.58 mL, 7.5 mmol, 3 eq) were added. The solution 
was stirred for 2 h at -78 °C (warning: starting material and final product co-spotted on TLC). 
After that, the mixture was quenched with sat. aq. NaHCO3 solution. The organic phase was 
separated, washed with sat. aq. NaHCO3 solution and brine, dried and concentrated under reduced 
pressure (>750 mbar). Purification by flash chromatography (30:10 pentane/Et2O) afforded 
mesylate 4.21/5.3 (963 mg, 98% yield) as a colorless oil. 
Rf 0.25 (30:10 pentane/ Et2O); 1H NMR (400 MHz, CDCl3): δ = 1.68 (d, J = 6.7 Hz, 3H), 2.73 (d, J 
= 2.1 Hz, 1H), 3.15 (d, J = 4.5 Hz, 3H), 5.31 (qd, J = 6.7, 2.1 Hz, 1H). 
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(1-bromoallyl)trimethylsilane (4.59)10 
To a stirred solution of DIPA (0.91 mL, 6.5 mmol, 1.3 eq) in THF (1.5 mL) at -78 °C was added 
nBuLi in hexane (1.6 M, 3.75 mL, 6.0 mmol, 1.2 eq) dropwise. After stirring at 0 °C for 30 min 
the solution was added to a flask containing allyl bromide (0.52 mL, 6.0 mmol, 1.2 eq) and 
ClSiMe3 (0.63 mL, 5.0 mmol, 1.0 eq) in THF (1.2 mL) at -78 °C. After 2 h the reaction was 
quenched by the addition of sat. aq. NH4Cl solution (3 mL) and the phases were separated. The 
aqueous phase was extracted with pentane and the combined organic extracts dried and 
concentrated under reduced pressure. Purification by flash chromatography (10:1 hexane/EtOAc) 
afforded compound 4.59 (590 mg, 61% yield) as a colorless oil. 
Rf 0.85 (10:1 hexane/EtOAc); 1H NMR (400 MHz, CDCl3): δ = 0.16 (s, 9H), 3.82 (d, J = 9.6 Hz, 
1H), 5.06 (d, J = 10.0 Hz, 1H), 5.19 (d, J = 16.8 Hz, 1H), 5.95 (m, 1H). 
 
 
 
 
o-Nitrobenzenesulfonohydrazide11 (NBSH) 
Hydrazine monohydrate (3.0 mL, 60 mmol, 2.5 eq) was added dropwise to a solution of o-
nitrobenzenesulfonyl chloride (5.6 g, 25 mmol, 1 eq) in THF (25 mL) at -30 °C. During the 
addition the reaction mixture became brown, and a white precipitate of hydrazine hydrochloride 
was deposited. After stirring at -30 °C for 30 min, thin-layer chromatographic  analysis (TLC) 
indicated that the sulfonyl chloride had been consumed (10:20 hexane/EtOAc). Ethyl acetate (50 
mL, 23°C) was added to the cold reaction solution and the mixture was washed repeatedly with 
ice-cold 10% aq. sodium chloride solution (5 x 35 mL). The organic layer was dried at 0 °C and 
then was added slowly to a stirring solution of hexane (250 mL) at 23 °C over 5 min. o-
Nitrobenzenesulfonohydrazide precipitated within 10 min as an off-white solid and was collected 
by filtration. The filter cake was washed with hexane (2 x 12 mL) and then was dried under 
vacuum to afford pure NBSH as an off-white powder (4.4 g, 81%). 
Rf 0.20 (1:2 hexane/EtOAc); 1H NMR (400 MHz, CD3CN): δ = 3.90 (br s, 2H), 5.97 (br s, 1H), 
7.84 (m, 3H), 8.10 (m, 1H). 
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6.3 Synthesis of Aldehyde C1-C9 
 
 
 
 
(R)-methyl-3-(benzyloxy)-2-methylpropanoate (4.6) 
Trifluoromethanesulfonic acid (15.8 mmol, 1.4 mL, 0.7 eq) was added to a solution of (R)-(-)-3-
hydroxy-2-methylpropionate (Roche ester) 4.4 (2.5 mL, 22.6 mmol, 1 eq) and benzyl 2,2,2-
trichloroacetimidate 4.5 (47.4 mmol, 11.97 g, 2.1 eq) in DCM/cyclohexane (1:2, 240 mL). The 
mixture was stirred overnight at R.T. After completion of the reaction the solution was 
concentrated under reduced pressure, diluted with DCM (10 mL) and washed with sat. aq. 
NaHCO3 solution (50 mL). The phases were separated and the aqueous phase was extracted with 
DCM (3 x 50 mL). The combined organic extracts were washed with brine (2 x 50 mL), dried 
(Na2SO4), and evaporated under reduced pressure. The crude product was filtered on short plug of 
celite and purified by flash chromatography (90:10 hexane/EtOAc) to give the the corresponding 
benzyl ether 4.6 (4.70 g, 100% yield) as a colorless oil. 
Rf 0.46 (90:10 hexane/EtOAc); 1H NMR (400 MHz,CDCl3): δ = 1.21 (d, J = 7.2 Hz, 3H,), 2.79-
2.84 (m, 1H), 3.50-3.54 (m, 1H), 3.65-3.70 (m, 1H), 3.71 (s, 3H), 4.55 (s, 2H), 7.28-7.32 (m, 5H). 
 
 
 
 
(S)-3-(benzyloxy)-2-methylpropan-1-ol (4.7) 
A solution of PMB ether 4.6 (2.02 g, 9.7 mmol, 1 eq) in THF (16 mL) was cooled to 0 °C and 
added to a solution of LiAlH4 (407 mg, 10.7  mmol, 1.1 eq) in THF (16 mL) over 30 min. The 
reaction mixture was gradually warmed to R.T., and stirred for 2 h. After cooling to 0 °C the 
mixture was quenched via dropwise addition of H2O (0.27 mL), 15% NaOH (0.27 mL), and H2O 
(0.82 mL). The solution was stirred for 30 min, treated with Na2SO4, filtered (3 mL Et2O rinse), 
and concentration under reduced pressure furnished an orange oil. Purification by flash 
chromatography (60:40 hexane/EtOAc) afforded the corresponding PMB ether 4.7 (1.55 g, 89% 
yield) as a pale yellow oil. 
Rf 0.54 (60:40 hexane/EtOAc); 1H NMR (400 MHz,CDCl3): δ = 0.91 (d, J = 7.2 Hz, 3H); 2.15-
2.51 (m, 1H), 2.06 (br s1H), 3.37-3.46 (m, 1H), 3.48-3.58 (m, 3H), 4.55 (s, 2H), 7.21-7.34 (m, 
5H). 
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(R)-3-(benzyloxy)-2-methylpropanal (4.8) 
A solution of alcohol 4.7 (0.4 g, 2.2 mmol, 1 eq) in DCM (12.3 mL) was treated at 0 °C with Py 
(0.45 mL, 5.5 mmol, 2.5 eq) and DMP (1.12 g, 2.64 mmol, 1.2 eq). The reaction mixture was 
warmed to R.T. and stirred for 1 h. After completion of the reaction, sat. aq. NaHCO3 solution 
(38.0 mL) and Na2S2O3 (3.99 g, 16.1 mmol, 7.3 eq) were added. After stirring for 30 min, the 
phases were separated and the aqueous phase was extracted with Et2O (3 x 40 mL). The combined 
organic extracts were washed with brine (2 x 50 mL), dried (Na2SO4), and evaporated under 
reduced pressure; this gave crude aldehyde 4.8 (392 mg, 100% yield) as a pale yellow oil, which 
was used without further purification. 
Rf 0.77 (60:40 hexane/EtOAc); 1H NMR (400 MHz, CDCl3): δ = 1.17 (d, J = 7.2 Hz, 3H), 2.65–
2.73 (m, 1H), 3.66 (dd, J = 4.8 Hz, 9.2 Hz, 1H), 3.72 (dd, J = 6.8 Hz, 9.2 Hz, 1H), 4.55 (s, 2H), 
7.10–7.36 (m, 5H), 9.75 (s, 1H). 
 
 
 
 
(3S,4R)-S-tert-butyl-5-(benzyloxy)-3-hydroxy-4-methylpentanethioate (4.10) 
A stirring solution of aldehyde 4.8 (392 mg, 2.2 mmol, 1 eq) in (5.0 mL) was treated at -80 °C 
with TiCl4 (0.49 mL, 2.2 mmol, 1 eq). After a few seconds, a solution of 1-(tert-butylthio)-1-(tert-
butyldimethylsilyloxy)ethylene 4.9 (814 mg, 3.3 mmol, 1.5 eq) in DCM (2.5 mL) was slowly 
added. After stirring for 2 h at -80 °C, the mixture was quenched with 1 M aq. KOH (18.0 mL). 
The organic phase was washed with brine (2 x 3 mL), dried (Na2SO4), filtered, and evaporated 
under reduced pressure. The crude product was purified by flash chromatography (85:15 
hexane/EtOAc,) to give 4.10 (642 mg, 94% yield, dr 97:3) as a colorless oil. Further purification 
by flash chromatography (95:5 benzene/Et2O) did not improve the dr. 
Rf 0.42 (85:15 hexane/EtOAc); [α]20D = –23.0 (c = 0.75, CH2Cl2); 1H NMR (400 MHz, CDCl3): δ 
= 0.96 (d, J = 7.2 Hz, 3H), 1.50 (s, 9H), 1.89–1.97 (m, 1H), 2.65 (dd, J = 8.0 Hz, 15.2 Hz, 1H), 
2.70 (dd,  J = 4.0 Hz, 15.2 Hz, 1H), 3.52 (dd, J = 6.4 Hz, 9.6 Hz, 1H), 3.58 (dd, J = 4.8 Hz, 9.6 Hz, 
1H), 4.04 (ddd, J = 4.0 Hz, 8.0 Hz, 6.4 Hz, 1H), 4.50 (s, 2H), 7.28–7.39 (m, 5H); 13C NMR (100 
MHz, CDCl3): δ = 11.8 (epimer at C-3, <3%), 14.5, 30.4, 38.3 (epimer at C-3, <3%), 38.6, 49.0, 
49.9, 70.8 (epimer at C-3, <3%), 73.0, 74.1, 74.4, 126.7, 127.2, 128.7, 138.6, 200.7; IR (neat): ν = 
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1101, 1253, 1364, 1455, 1681, 2860, 2926, 2962, 3470; HRMS (ESI): calcd. for C17H26O3SNa: 
333.4400 [M + Na]+; found: 333.4425. 
 
 
 
 
(3S,4R)-5-(benzyloxy)-4-methylpentane-1,3-diol (4.11) 
A solution of 4.10 (500 mg, 1.6 mmol, 1 eq) in THF (4.0 mL) was added to a suspension of 
LiAlH4 (122 mg, 3.2 mmol, 2 eq) in THF (4.0 mL) at 0 °C. The mixture was warmed to R.T. and 
stirred for 2 h. The solution was cooled to 0 °C and then quenched with H2O (0.7 mL), 2 M aq. 
NaOH (1.4 mL), and H2O (1.4 mL). After vigorously stirring for 1 h, the mixture was dried 
(Na2SO4), filtered, and evaporated under reduced pressure. The crude product was purified by 
flash chromatography (60:40 hexane/EtOAc), affording 4.11 (352 mg, 98% yield) as a colorless 
oil.  
Rf 0.50 (60:40 hexane/EtOAc); [α] 23D = –21.6 (c = 0.87, CH2Cl2); 1H NMR (400 MHz,CDCl3): δ = 
0.90 (d, J = 6.8 Hz, 3H), 1.73–1.82 (m, 2H), 1.90–2.00 (m, 1H), 2.98 (br s, 1 H), 3.50 (t, J = 9.2 
Hz, 1H), 3.66 (dd, J = 4.0 Hz, J = 9.2 Hz, 1H), 3.79–3.89 (m, 3H), 4.55 (s, 2H), 7.28–7.42 (m, 
5H); 13C NMR (100 MHz, CDCl3): δ = 12.1 (epimer at C-3, <3%), 14.3, 35.8 (epimer at C-3, 
<3%), 36.6, 39.1, 62.3, 74.2, 75.0 (epimer at C-3, <3%), 75.9, 77.5, 128.4, 128.6, 129.2, 138.3; IR 
(neat): ν = 1028, 1057, 1071, 1364, 1454, 2877, 2924, 2958, 3388; HRMS (ESI): calcd. for 
C13H20O3Na: 247.1347 [M + Na]+; found: 247.1301. 
 
 
 
 
(S)-5-((R)-1-(benzyloxy)propan-2-yl)-2,2,3,3,9,9,10,10-octamethyl-4,8-dioxa-3,9-
disilaundecane (4.12) 
A solution of diol 4.11 (350 mg, 1.56 mmol, 1 eq) in DCM (39 mL) was treated at -20 °C with 2,6-
lutidine (1.5 mL, 12.5 mmol, 8 eq), followed by TBSOTf (2.7 mL, 3.12 mmol, 3 eq). After stirring 
for 1 h, the mixture was quenched with sat. aq. NH4Cl solution (40 mL). The phases were 
separated, and the aqueous phase was extracted with DCM (2 x 40 mL). The combined organic 
extracts were washed with brine (2 x 50 mL), dried (Na2SO4), and evaporated under reduced 
pressure. The crude product was purified by flash chromatography (95:5 hexane/EtOAc) to give 
4.12 (692 mg, 98% yield) as a colorless oil.  
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Rf 0.60 (95:5 hexane/EtOAc); [α]16D = -7.1 (c = 0.86, CH2Cl2); 1H NMR (400 MHz, CDCl3): δ = 
0.07 (s, 9H), 0.89–0.91 (m, 21H), 0.95 (d, J = 6.8 Hz, 3H), 1.60–1.67 (m, 2H), 1.99–2.05 (m, 1H), 
3.31 (dd, J = 6.8 Hz, 9.2 Hz, 1H), 3.46 (dd, J = 6.4 Hz, 9.2 Hz, 1H), 3.63–3.76 (m, 2H), 3.89–3.92 
(m, 1H), 4.51 (s, 2H), 7.30–7.36 (m, 5H); 13C NMR (100 MHz, CDCl3): δ = –4.6, –3.9, –2.3, 12.2 
(epimer at C-3, <3%), 13.3, 18.8, 19.0, 26.5, 26.6, 36.4, 39.1 (epimer at C-3, <3%), 39.8, 60.9, 
70.3 (epimer at C-3, <3%), 71.1, 73.5, 73.7, 128.0, 128.1, 129.0, 139.4; IR (neat): ν = 774, 835, 
1092, 1254, 1471, 2856, 2928, 2955, 3113; HRMS (ESI): calcd. for C25H48O3Si2Na [M + Na]+: 
475.3034; found: 475.3049. 
 
 
 
 
(2R,3S)-3,5-bis((tert-butyldimethylsilyl)oxy)-2-methylpentan-1-ol (4.13) 
Raney-Ni was washed with H2O until the washings were pH neutral, and then rinsed with absolute 
EtOH (5 x 100 mL). A solution of 4.12 (690 mg, 1.52 mmol, 1 eq) in absolute EtOH (102 mL) was 
added, and the mixture was degassed and then purged with H2 (3x). After stirring for 72 h at R.T., 
the reaction mixture was filtered through a short pad of celite, washed with EtOAc (2 x 100 mL), 
and evaporated under reduced pressure. The crude product was purified by flash chromatography 
(10:1 hexane/EtOAc) to afford the desired product 4.13 (441 mg, 80% yield) as a colorless oil.  
Rf 0.16 (10:1 hexane/EtOAc); [α]20D = -4.0 (c = 1.11, CH2Cl2); 1H NMR (400 MHz, CDCl3): δ = 
0.07 (s, 6H), 0.12 (s, 6H), 0.91 (s, 9H), 0.92 (s, 9H), 1.04 (d, J = 7.2 Hz, 3H), 1.71–1.82 (m, 3H), 
2.61 (br s, 1H), 3.55 (dd, J = 5.6 Hz, 11.2 Hz, 1H), 3.68 (t, J = 6.4 Hz, 2H), 3.80 (dd, J = 4.0 Hz, 
11.2 Hz, 1 H), 3.90–3.94 (m, 1H); 13C NMR (100 MHz, CDCl3): δ = –4.7, –4.0, –3.8, 13.1 (epimer 
at C-3, <3%), 14.9, 18.6, 18.9, 26.5, 26.6, 38.2, 39.3, 40.5 (epimer at C-3, <3%), 60.4, 65.9, 73.4 
(epimer at C-3, <3%), 74.8; IR (neat): ν = 775, 836, 1094, 1255, 1472, 2858, 2885, 2929, 2956, 
3366; HRMS (ESI): calcd. for C18H42O3Si2Na [M + Na]+: 385.2565; found: 385.2564. 
 
 
 
 
(2S,3S)-3,5-bis((tert-butyldimethylsilyl)oxy)-2-methylpentanal (4.14) 
A solution of alcohol 4.13 (0.4 g, 1.1 mmol, 1 eq) in DCM (7.0 mL) was treated at 0 °C with 
pyridine (0.22 mL, 2.8 mmol, 2.5 eq) and DMP (0.56 g, 1.3 mmol, 1.2 eq). The reaction mixture 
was warmed to R.T. and stirred for 2 h. After completion of the reaction, sat. aq. NaHCO3 solution 
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(18 mL) and Na2S2O3 (2.0 g, 8.0 mmol, 7.3 eq) were added. After stirring for 30 min, the phases 
were separated and the aqueous phase was extracted with Et2O (3 x 20 mL). The combined organic 
extracts were washed with brine (2 x 25 mL), dried (Na2SO4), and evaporated under reduced 
pressure; this gave crude aldehyde 4.14 (397 mg, 100% yield) as a pale yellow oil, which was used 
without further purification.  
Rf 0.56 (90:10 hexane/EtOAc); 1H NMR (400 MHz, CDCl3): δ = 0.07 (s, 6H), 0.10 (s, 6H), 0.90 (s, 
9H), 0.91 (s, 9H), 1.10 (d, J = 7.2 Hz, 3H), 1.75–1.82 (m, 2H), 2.58–2.59 (m, 1H), 3.70–3.73 (m, 
2H), 4.17–4.19 (m, 1H), 9.76 (d, J =1.6 Hz, 1 H). 
 
 
 
 
(4R,5S,E)-5,7-bis((tert-butyldimethylsilyl)oxy)-N-methoxy-N,4-dimethylhept-2-enamide 
(4.15) 
Diethyl (N-methoxy-N-methylcarbamoylmethyl)phosphonate (0.25 mL, 1.2 mmol, 1.1 eq), DBU 
(0.2 mL, 1.3 mmol, 1.2 eq) and aldehyde 4.14 (397 mg, 1.1 mmol, 1 eq) were added to a stirred 
suspension of LiCl (flame-dried under vacuum before use; 112 mg, 2.6 mmol, 2.4 eq) in MeCN 
(8.7 mL) at R.T.. The mixture was stirred at R.T. for 1.5 h and then quenched with H2O (18 mL). 
After 15 min, EtOAc (18 mL) was added and the mixture was stirred for an additional 30 min. The 
two phases were separated, and the aqueous phase was extracted with EtOAc (3 × 30 mL). The 
combined organic extracts were dried and evaporated under reduced pressure. The crude product 
was purified by flash chromatography (90:10 hexane/EtOAc) to give 4.15 (441 mg, 90% yield) as 
a colorless oil. 
Rf 0.24 (90:10 hexane/EtOAc); [α]23D = +8.3 (c = 0.7, CH2Cl2); 1H NMR (400 MHz, CDCl3): δ = 
0.05 (s, 6H), 0.07 (s, 6H), 0.90 (s, 9H), 0.91 (s, 9H), 1.10 (d, J =7.2 Hz, 3H), 1.57–1.69 (m, 2H), 
2.50–2.59 (m, 1H), 3.26 (s, 3H), 3.60–3.70 (m, 2H), 3.71 (s, 3H), 3.83–3.88 (m, 1H), 6.40 (d, J = 
15.6 Hz, 1H), 6.97 (dd, J = 8.0 Hz, 15.6 Hz, 1H), 7.05 (dd, J = 7.2 Hz, 15.6 Hz, H-3, epimer at C-
5, <3%); 13C NMR (100 MHz, CDCl3): δ = –4.7, –3.8, 15.2 (epimer at C-5 <3%), 15.6, 18.7, 18.9, 
26.6, 26.7, 33.1, 37.5, 43.0, 45.1 (epimer at C-5,  <3%), 60.6, 62.3, 72.8, 73.1 (epimer at C-5,  
<3%), 119.4, 150.2, 167.6; IR (neat): ν = 775, 836, 1099, 1255, 1382, 1471, 1636, 1666, 2857, 
2886, 2895, 2929, 2955; HRMS (ESI): calcd. for C22H47O4NSi2Na: 468.2936 [M + Na]+; found: 
468.2328. 
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(4R,5S,E)-5,7-bis((tert-butyldimethylsilyl)oxy)-4-methylhept-2-enal (4.16) 
A stirred solution of Weinreb amide 4.15 (400 mg, 0.9 mmol, 1 eq) in THF (9.4 mL) was treated at 
-78 °C with 1M DIBAL-H in hexane (2.7 mL, 2.7 mmol, 3 eq). After being stirred for 90 min at -
78 °C, this solution was poured into a mixture of 1 M aq. tartaric acid (12.4 mL) and EtOAc (13.8 
mL). After stirring for 1 h, the layers were separated, the aqueous phase was extracted with Et2O 
(2 x 20 mL), and the combined organic extracts were washed with brine (2 x 25 mL), dried, and 
evaporated under reduced pressure; this gave crude aldehyde 4.16 (317 mg, 91% yield), which was 
used without further purification. 
Rf 0.81 (60:40 hexane/EtOAc); 1H NMR (400 MHz, CDCl3): δ = 0.06 (s, 6H), 0.09 (s, 6H), 0.90 (s, 
9H), 0.92 (s, 9H), 1.14 (d, J =7.2 Hz, 3H), 1.53–1.60 (m, 1H), 1.64–1.73 (m, 1H), 2.57–2.67 (m, 
1H), 3.64–3.67 (m, 2H), 3.90–3.91 (m, 1H), 6.13 (dd, J = 7.6 Hz, 15.6 Hz, 1H), 6.87 (dd, J = 7.6 
Hz, 15.6 Hz, 1H), 9.53 (d, J = 7.6 Hz, 1H). 
 
 
 
 
(2Z,4E,6R,7S)-methyl 7,9-bis((tert-butyldimethylsilyl)oxy)-6-methylnona-2,4-dienoate (4.17) 
A solution of (F3CCH2O)2P(O)CH2CO2Me (0.18 mL, 0.86 mmol, 1.2 eq) and 18-crown-6·MeCN 
(1.20 g, 3.9 mmol, 5 eq) in THF (15.6 mL) was cooled to -78 °C, and 0.5 M KHMDS in toluene 
(1.72 mL, 0.86 mmol, 1.2 eq) was added dropwise. After stirring a few minutes at -78 °C, a 
solution of aldehyde 4.16 (300 mg, 0.78 mmol, 1 eq) in THF (6.5 mL) was added dropwise. The 
mixture was stirred at -78 °C for 1 h and then treated with sat. aq. NH4Cl solution (20 mL) and 
Et2O (20 mL). The layers were separated, the aqueous phase was extracted with Et2O (2 x 30 mL), 
and the combined organic extracts were washed with H2O (2 x 40 mL), dried, and evaporated 
under reduced pressure. The crude product was purified by flash chromatography (100:5 
hexane/EtOAc) to give the desired product 4.17 (319 mg, 90% yield) as a colorless oil. 
Rf 0.35 (100:5 hexane/EtOAc); [α]24D = -6.4 (c = 0.35, CHCl3); 1H NMR (400 MHz, CDCl3): δ = 
0.05 (s, 6H), 0.08 (s, 6H), 0.90 (s, 9H), 0.92 (s, 9H), 1.09 (d, J = 6.9 Hz, 3H), 1.55–1.67 (m, 2H), 
2.47–2.57 (m, 1H), 3.63–3.68 (m, 2H), 3.75 (s, 3H), 3.82–3.85 (m, 1H), 5.61 (d, J = 11.3 Hz, 1H), 
6.06 (dd, J = 8.0 Hz, 15.2 Hz, 1H), 6.58 (t, J = 11.3 Hz, 1H), 7.37 (dd, J = 11.3 Hz, 15.2 Hz, 1H); 
13C NMR (100 MHz, CDCl3): δ = –4.7, –3.8, 16.1, 18.8, 18.9, 26.6, 37.8, 43.4, 51.7, 60.5, 73.0, 
116.0, 127.5, 146.3, 148.2, 167.6; IR (neat): ν = 775; 806, 835, 1030, 1098, 1176, 1194, 1258, 
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1438, 1471, 1602, 1639, 1722, 2341, 2360, 2710, 2738, 2856, 2927, 2957, 3408; HRMS (ESI): 
calcd. for C23H46O4Si2Na: 465.2827 [M + Na]+; found: 465.2823. 
 
 
 
(2Z,4E,6R,7S)-methyl 7-((tert-butyldimethylsilyl)oxy)-9-hydroxy-6-methylnona-2,4-dienoate  
(4.18) 
A solution of compound 4.17 (338 mg, 0.74 mmol, 1 eq) in THF (3.8 mL) at 0 °C was treated with 
a solution of HF-Py in THF/Py [16.5 mL, prepared by slow addition of HF-Py (1.3 mL) to a 
solution of pyridine (5.0 mL) and THF (10.2 mL)]. The reaction mixture was warmed to R.T. and 
stirred for 8 h. After quenching  the reaction by the addition of sat. aq. NaHCO3 solution (30 mL), 
the mixture was extracted with EtOAc (4 x 20 mL). The combined organic extracts were washed 
with sat. aq. CuSO4 (3 x 15 mL) and brine (2 x 40 mL), dried, and evaporated under reduced 
pressure. Purification by flash chromatography (80:20 hexane/EtOAc) afforded the alcohol 4.18 
(218 mg, 86% yield) as a colorless oil.  
Rf  0.20 (80:20 hexane/EtOAc); [α]24D = -14.0 (c = 0.2, CHCl3); 1H NMR (400 MHz, CDCl3): δ = 
0.09 (s, 3H), 0.10 (s, 3H), 0.91 (s, 9H), 1.09 (d, J = 6.8 Hz, 3H), 1.63–1.74 (m, 2H), 1.98 (br s, 
1H), 2.54–2.59 (m, 1H), 3.73 (s, 3H), 3.69–3.75 (m, 2H), 3.85–3.88 (m, 1H), 5.61 (d, J = 11.2 Hz, 
1H), 6.02 (dd, J = 8.0 Hz, 15.6 Hz, 1H), 6.56 (t, J = 11.2 Hz, 1H), 7.38 (dd, J = 11.2 Hz, 15.6 Hz, 
1H); 13C NMR (100 MHz, CDCl3): δ = –3.9, –3.7, 15.4, 18.7, 26.5, 36.3, 43.3, 51.8, 60.7, 74.4, 
116.4, 127.6, 146.0, 147.7, 167.6; IR (neat): ν = 775, 837, 1005, 1031, 1082, 1176, 1197, 1256, 
1439, 1601, 1637, 1719, 2857, 2885, 2929, 2954, 3418; HRMS (ESI): calcd. for C17H32O4SiNa: 
351.1962 [M + Na]+; found: 351.1957. 
 
 
 
 
(2Z,4E,6R,7S)-methyl 7-((tert-butyldimethylsilyl)oxy)-6-methyl-9-oxonona-2,4-dienoate (4.2) 
A solution of alcohol 4.18 (70 mg, 0.21 mmol, 1 eq) in DCM (1.3 mL) was treated at 0 °C with 
pyridine (43 μL, 0.52 mmol, 2.5 eq) and DMP (107 mg, 0.25 mmol, 1.2 eq). The reaction mixture 
was warmed to R.T. and stirred for 1 h. After completion of the reaction, sat. aq. NaHCO3 solution 
(3.5 mL) and Na2S2O3 (380 mg, 1.53 mmol, 7.3 eq) were added. The obtained mixture was stirred 
for 30 min, then the phases were separated and the aqueous phase was extracted with Et2O (3 x 4 
mL). The combined organic extracts were washed with brine (2 x 5 mL), dried over Na2SO4 and 
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evaporated under reduced pressure. The crude product was purified by flash chromatography 
(80:20 hexane/EtOAc) to give aldehyde 4.2 (67 mg, 100% yield) as a yellow oil.  
Rf 0.37 (80:20 hexane/EtOAc); 1H NMR (400 MHz, CDCl3): δ = 0.07 (s, 3H), 0.11 (s, 3H), 0.90 (s, 
9H), 1.12 (d, J = 6.8 Hz, 3H), 2.45-2.61 (m, 3H), 3.75 (s, 3H), 4.24 (m, 1H), 5.65 (d, J = 11.3 Hz, 
1H), 6.00 (dd, J = 7.9 Hz, 15.5 Hz, 1H), 6.58 (t, J = 11.3 Hz, 1H), 7.40 (dd, J = 11.2 Hz, 15.4 Hz, 
1H), 9.80 (dd, J = 1.9 Hz, 2.3 Hz, 1H). 
 
 
 
6.4 Synthesis of Alkyne C13-C18 
 
 
 
 
(S)-methyl 3-((4-methoxybenzyl)oxy)-2-methylpropanoate (4.24) 
A solution of methyl (S)-(+)-3-hydroxy-2-methylpropionate (Roche ester) 4.22 (2.67 mg, 22.6 
mmol, 1 eq) in DCM/cyclohexane (1:2, 45 mL) was cooled at 0 °C and treated with crude 
trichloroacetimidate 4.23 (11.3 g) and PPTS (0.29 g, 1.13 mmol, 0.05 eq) over 15 min. After 3 h, 
the mixture was warmed to R.T., stirred overnight, filtered through a short plug of silica and 
concentrated under reduced pressure. Purification of the crude product by flash chromatography 
(80:20 hexane/EtOAc) afforded the corresponding PMB ether 4.24 (4.95 g, 92% yield) as a pale 
yellow oil.  
Rf 0.40 (80:20 hexane/EtOAc); 1H NMR (400 MHz, CDCl3): δ = 1.19 (d, J = 7.1 Hz, 3H), 2.77-
2.82 (m, 1H), 3.46-3.50 (m, 1H), 3.63-3.67 (m, 1H), 3.71 (s, 3H), 3.82 (s, 3H), 4.48 (s, 2H), 6.90 
(d, J = 8.5 Hz, 2H), 7.27 (d, J = 8.5 Hz, 2H). 13C NMR (100 MHz, CDCl3): δ = 14.0, 40.2, 51.7, 
55.2, 71.5, 71.7, 72.8, 113.8, 114.3, 129.2, 129.4, 130.2, 159.2, 172.3. 
 
 
 
 
(R)-3-(4-Methoxy-benzyloxy)-2-methyl-propan-1-ol (4.25) 
A solution of PMB ether 4.24 (4.95 g, 20.8 mmol, 1 eq) in THF (44 mL) was cooled to 0 °C and 
added to a solution of LiAlH4 (0.87 g, 22.9 mmol, 1.1 eq) in THF (6.3 mL) over 30 min, warmed 
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gradually to R.T., and stirred for 2 h. The reaction mixture was then cooled to 0 °C and quenched 
via dropwise addition of H2O (0.96 mL), 15% NaOH (0.96 mL), H2O (2.4 mL). The mixture was 
stirred for 30 min and then treated with Na2SO4, filtered (3.5 mL Et2O rinse), and concentrated 
under reduced pressure, furnishing an orange oil. Purification by flash chromatography (60:40 
hexane/EtOAc) afforded the corresponding alcohol 4.25 (3.8 g, 87% yield) as a pale yellow oil. 
Rf 0.42 (60:40 hexane/EtOAc);1H NMR (400 MHz, CDCl3): δ = 0.89 (d, J = 7.2 Hz, 3H), 2.06 (br 
s, 1H), 2.08 (s, 1H), 3.39-3.43 (m, 2H), 3.52-3.64 (m, 2H), 3.83 (s, 3H), 4.47 (s, 2H), 6.91 (d, J = 
8.7 Hz, 2H), 7.28 (d, J = 8.7 Hz, 2H); 13C NMR (100 MHz, CDCl3): δ = 13.5, 35.6, 55.3, 67.9, 
73.1, 75.1, 113.9, 130.0, 129.2, 159.3. 
 
 
 
 
(S)-1-((3-iodo-2-methylpropoxy)methyl)-4-methoxybenzene (4.26) 
Imidazole and triphenylphosphine were crystallized from EtOH prior to use. Imidazole (769 mg, 
11.3 mmol, 2.5 eq), triphenylphosphine (2.96 g, 11.3 mmol, 2.5 eq) and iodine (2.29 g, 9.04 mmol, 
2 eq) were added sequentially to a solution of the alcohol 4.25 (950 mg, 4.52 mmol, 1 eq) in a 
Et2O/acetonitrile 2:1 mixture  (90 mL). The reaction mixture was stirred for 1.5 h at R.T. and then 
quenched with a saturated aqueous solution of sodium thiosulfate. The organic phase was 
separated and the aqueous layer extracted with Et2O (2 x 30 mL). The combined organic phases 
were washed with brine, dried over Na2SO4, and concentrated under reduced pressure. Purification 
of the crude product by flash chromatography (98:2 hexane/Et2O) afforded the iodide 4.26 (1.37 g, 
95% yield) as a colorless liquid. 
Rf 0.45 (90:10 hexane/EtOAc); [α]27D = + 9.7 (c = 0.53, CHCl3); 1H NMR (400 MHz, CDCl3): δ = 
1.00 (d, J = 6.7 Hz, 3H), 1.74-1.82 (m, 1H), 3.26-3.41 (m, 4H), 3.83 (s, 3H), 4.47 (s, 2H), 6.90 (d, 
J = 8.6 Hz, 2H), 7.28 (d, J = 8.6 Hz, 2H); 13C NMR (100 MHz, CDCl3): δ = 14.9, 18.4, 35.8, 56.0, 
73.6, 74.5, 114.5, 130.0, 131.1, 159.9; IR (film): ν = 808, 1088, 1243, 1505, 1608, 2855; HRMS 
(FAB+) calcd. for C12H17O2I: 320.0273 [M]+; found 320.0272; HRMS (ESI): calcd. for 
C12H17O2INa: 343.01654 [M+Na]+; found: 343.01625. 
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(2S,4R)-N-((1R,2R)-1-hydroxy-1-phenylpropan-2-yl)-5-((4-methoxybenzyl)oxy)-N,2,4-
trimethylpentanamide (4.28) 
A solution of nBuLi in hexane (1.6 M, 7.5 mL, 12 mmol, 4.0 eq) was slowly added to a suspension 
of LiCl (1.6 g, 38.1 mmol, 12.7 eq, flame-dried under vacuum) and DIPA (1.8 mL, 12.9 mmol, 4.3 
eq) in THF (16 mL) at 0 °C. After 30 min at 0 °C, the suspension was cooled to -78 °C. An ice-
cooled solution of the Myers amide 4.27 (1.39 g, 6.3 mmol, 2.1 eq) in THF (12 mL, followed by a 
2 mL rinse) was added. The mixture was stirred at -78 °C for 1 h, at 0 °C for 15 min, and at 23 °C 
for 5 min. The mixture was re-cooled to 0 °C, and the iodide 4.26 (0.96 g, 3 mmol, 1 eq) was 
added to the solution. After 5 minutes, the ice bath was removed and the suspension stirred for 20 
h at R.T. The reaction mixture was then treated with half-saturated aq. NH4Cl solution (20 mL), 
and the resulting mixture was extracted with EtOAc (4 x 15 mL). The combined organic extracts 
were dried and concentrated under reduced pressure. Purification of the residue by flash 
chromatography (65:35 hexane/EtOAc) afforded the amide 4.28 as a highly viscous, yellow oil 
containing mixture of rotamers (1.14 g, 92% yield, minor resonances are denoted by an asterisk). 
Rf 0.15 (60:40 hexane/EtOAc); [α]20D= –43.0 (c = 1.0, CHCl3); 1H NMR (400 MHz, CDCl3): δ = 
0.89 (d, J = 6.8 Hz, 2.7H), 0.95* (d, J = 6.8 Hz, 0.3H), 0.99* (d, J = 6.8 Hz, 0.3H), 1.10 (d, J = 6.8 
Hz, 2.7H), 1.13 (d, J = 6.8 Hz, 3H), 1.71-1.83 (m, 2H), 2.63-2.69* (m, 0.3H), 2.74-2.79 (m, 0.7H), 
2.84 (s, 2.7H), 2.89* (s, 0.3H), 3.21-3.6 (m, 2H), 3.81* (s, 0.3H), 3.83 (s, 2.7H), 4.43 (s, 3H), 4.47-
4.50 (m, 1H), 4.62 (t, J = 7.2 Hz, 1H), 6.85-7.37 (m, 9H); 13C NMR (100 MHz, CDCl3): δ = 15.1, 
16.2, 18.3, 18.4, 19.0, 19.7, 27.6, 31.8, 32.6*, 34.7, 34.9*, 38.8, 39.7*,56.0, 58.8*, 73.3, 75.9*, 
76.2, 76.8*, 77.2, 114.4, 127.0, 127.7*, 128.2, 129.0, 129.4*, 129.8, 130.0*, 131.4, 141.8*, 143.2, 
159.7, 179.8; IR (neat): ν = 1041, 1084, 1248, 1464, 1513, 1612, 1628, 1742, 2847, 2934, 3299, 
3413; HRMS (ESI): calcd. for C25H35NaNO4: 436.24583 [M+Na]+; found: 436.24541.  
 
 
 
 
(2S,4R)-5-((4-methoxybenzyl)oxy)-2,4-dimethylpentan-1-ol (4.29) 
A solution of nBuLi in hexane (1.6 M, 6.6 mL, 10.6 mmol, 3.9 eq) was added to a solution of 
DIPA (1.6 mL, 11.4 mmol, 4.2 eq) in THF (11 mL) at 0 °C. After 30 min at 0 °C, borane-ammonia 
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complex (90%, 336 mg, 10.9 mmol, 4.0 eq) was added in one portion. The suspension was stirred 
at 0 °C for 15 min and then warmed up to 23 °C. After 15 min, the suspension was re-cooled to 0 
°C and a solution of the amide 4.28 (1.13 g, 2.72 mmol, 1 eq) in THF (5 mL, followed by a 2 mL 
rinse) was added over 5 min. The reaction mixture was warmed to 23 °C, kept at that temperature 
for 2 h, and then cooled to 0 °C. The excess hydride was quenched by careful addition of 3 N aq. 
HCl (25 mL). The mixture was stirred for 30 min at 0 °C and then extracted with four 60 mL 
portions of Et2O. The combined organic extracts were washed sequentially with 3 N aq. HCl (30 
mL), 2 N aq. NaOH (20 mL), and brine (20 mL). The ether extracts were dried and concentrated 
under reduced pressure. Purification of the residue by flash chromatography (60:40 
hexane/EtOAc) afforded the alcohol 4.29 as a colorless oil (652 mg, 95% yield). 
Rf 0.52 (60:40 hexane/EtOAc); [α]20D = –5.43 (c = 1.0, CHCl3); 1H NMR (400 MHz, CDCl3): δ = 
0.95 (d, J = 5.2 Hz, 3H), 0.96 (d, J = 5.2 Hz, 3H), 0.89-0.99 (m, 1H), 1.45-1.52 (m, 1H), 1.67-1.75 
(m, 1H), 1.82-1.89 (m, 1H), 1.90 (br s, 1H), 3.21-3.32 (m, 2H), 3.39-3.50 (m, 2H), 3.82 (s, 3H), 
4.45 (s, 2H), 6.90 (d, J = 8.5 Hz, 2H), 7.28 (d, J = 8.5 Hz, 2H); 13C NMR (100 MHz, CDCl3): δ = 
18.3, 18.8, 31.7, 33.9, 38.3, 55.9, 68.5, 73.4, 76.3, 114.4, 129.8, 131.3, 159.7; IR (neat): ν = HRMS 
1040, 1098, 1301, 1462, 1513, 1613, 2872, 2954, 3466, 3640; HRMS (ESI): calcd. for 
C15H24NaO3: 275.16177 [M+Na]+; found: 275.16153. 
 
 
 
 
1-((((2R,4S)-5-(benzyloxy)-2,4-dimethylpentyl)oxy)methyl)-4-methoxybenzene (4.30) 
A solution of the alcohol 4.29 (563 mg, 2.23 mmol, 1 eq) in THF (2 mL) was added to a 
suspension of NaH (60% in mineral oil, 178.4 mg, 4.46 mmol, 2 eq) in THF (12 mL) at 0 °C. The 
reaction mixture was stirred at 25 °C for 1.5 h, and then re-cooled to 0 °C before adding BnBr (397 
μL, 3.34 mmol, 1.5 equiv) and nBu4NI (24.7 mg, 0.067 mmol, 0.03 eq). The reaction mixture was 
allowed to warm to 25 °C and stirred for 11 h. After quenching the excess NaH by the addition of 
MeOH (1 mL), the reaction mixture was diluted with Et2O (20 mL), washed with a sat. aq. NH4Cl 
solution (2 x 20 mL), dried and concentrated under reduced pressure. The residue was purified by 
flash chromatography (10:1 hexane/EtOAc) to afford the benzyl ether 4.30 (633.9 mg, 83% yield). 
Rf 0.40 (9:1 hexane/EtOAc); [α]20D = –0.49 (c = 1.0, CHCl3); 1H NMR (400 MHz, CDCl3): δ = 
0.99 (d, J = 6.6 Hz, 3H), 1.01 (d, J = 6.6 Hz, 3H), 1.48-1.55 (m, 1H), 1.91 (septet, J = 6.6 Hz, 2H), 
3.20-3.27 (m, 2H), 3.34-3.41 (m, 2H), 3.84 (s, 3H), 4.46 (d, J = 2.2 Hz, 2H), 4.53 (d, J = 2.2 Hz, 
2H), 6.91 (d, J = 8.6 Hz, 2H), 7.26-7.40 (m, 7H); 13C NMR (100 MHz, CDCl3): δ = 18.8, 31.7, 
38.9, 56.0, 73.3, 73.7, 76.3, 76.6, 114.4, 128.1, 128.2, 129.0, 129.7, 131.6, 139.5, 159.7; IR (neat): 
ν = 1041, 1095, 1245, 1455, 1513, 1613, 2790, 2853, 3032, 3066; HRMS (ESI): calcd. for 
C22H30NaO3: 365.20872 [M+Na]+; found: 365.20817. 
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(2R,4S)-5-(benzyloxy)-2,4-dimethylpentan-1-ol (4.31) 
CAN (2.66 g, 4.86 mmol, 3 eq) was added at 0 °C, in four portions, to a solution of the PMB ether 
4.30 (555 mg, 1.62 mmol, 1 eq) in CH3CN/water 4:1 (95 mL). The temperature was maintained at 
0 °C for 15 min, then the reaction mixture was warmed to R.T. After 2 h, the reaction mixture was 
diluted with DCM (100 mL), washed with brine (100 mL) and water (100 mL). After drying, 
filtering and concentrating under reduced pressure, flash chromatography (85:15 hexane/EtOAc) 
gave the product 4.31 as a colourless oil (334.9 mg, 93% yield). 
Rf 0.30 (85:15 hexane/EtOAc); [α]20D = +6.85 (c = 1.0, CHCl3); 1H NMR (400 MHz, CDCl3): δ = 
0.96 (d, J= 6.8 Hz, 3H), 0.99 (d, J=6.8 Hz, 3H), 1.47-1.54 (m, 2H), 1.54 (br s, 1H), 1.68-1.78 (m, 
1H), 1.83-1.93 (m, 1H), 3.25-3.37 (m, 2H), 3.42-3.54 (m, 2H), 4.52 (d, J= 2 Hz, 2H), 7.27-7.39 
(m, 5H); 13C NMR (100 MHz, CDCl3): δ =17.7, 18.3, 31.7, 34.0, 38.3, 68.7, 73.7, 76.5, 128.1, 
128.2, 129.0, 139.3; IR (neat): ν = 1028, 1097, 1362, 1455, 1496, 2872, 2926, 2957, 3488, 3640; 
HRMS (ESI): calcd. for C14H22NaO2: 245.15120 [M+Na]+; found: 245.15070. 
 
 
 
 
(2R,4S)-5-(benzyloxy)-2,4-dimethylpentanal (4.20) 
Pyridine (270 μL, 3.34 mmol, 2.5 eq) and DMP (681 mg, 1.6 mmol, 1.2 eq) were added to a 0 °C 
solution of the alcohol 4.31 (298 mg, 1.34 mmol) in DCM (7.5 mL). The reaction mixture was 
warmed to R.T. and stirred for 1 h. The reaction was monitored by TLC and, on disappearance of 
the alcohol, the reaction mixture was quenched by the addition of sat. aq. NaHCO3 solution and 
Na2S2O3 (2.4 g, 9.76 mmol, 7.3 eq). After stirring for 30 min, the phases were separated, and the 
aqueous phase was extracted with Et2O (3 x 30 mL). The combined organic extracts were washed 
with brine, dried over Na2SO4 and concentrated under reduced pressure. The crude aldehyde 4.32 
was used without further purification. 
Rf 0.89 (60:40 hexane/EtOAc); 1H NMR (400 MHz, CDCl3): δ = 0.94 (d, J = 6.6 Hz, 3H), 1.08 (d, 
J = 6.9 Hz, 3H), 1.16-1.25 (m, 1H), 1.83-1.95 (m, 2H), 2.44-2.51 (m, 1H), 3.32 (d, J= 6.0 Hz, 2H), 
4.51 (s, 2H), 7.28-7.38 (m, 5H), 9.59 (d, J= 2.4 Hz, 1H). 
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((((2S,4R)-2,4-dimethylhex-5-yn-1-yl)oxy)methyl)benzene (4.19) 
 
SHIOIRI ALKYNYLATION 
A solution of nBuLi in hexane (1.6 M, 1.17 mL, 1.87 mmol, 1.4 eq) was added to a solution of 
DIPA (262 μL, 1.87 mmol, 1.4 eq) in THF (10 mL) at 0 °C. After 30 min at 0°C, the mixture was 
cooled to -78 °C, and trimethylsilyldiazomethane in Et2O (2.0 M, 935 μL, 1.87 mmol, 1.4 eq) was 
added. After 30 min, a solution of aldehyde 4.32 (295 mg, 1.34 mmol, 1 eq) in THF (3.5 mL) was 
slowly added. After 1 h at -78 °C, the temperature was raised to 23 °C, and stirring was maintained 
overnight. The mixture was then poured into ice-cooled water, and extracted with Et2O. The 
combined organic extracts were dried and concentrated under reduced pressure. The residue was 
purified by flash chromatography (10:1 hexane/EtOAc) to afford the alkyne 4.19 as a yellow oil 
(176.9 mg, 61%). 
 
BESTMANN-OHIRA ALKYNYLATION 
A solution of NaOMe (1,05 g, 19,4 mmol, 4 eq) in THF (37 mL) was cooled to -78 °C and 
dimethyl (1-diazo-2-oxopropyl)phosphonate 4.33 (3.73 g, 19.4 mmol, 4 eq) in THF (84 mL) was 
added via cannula. After 15 min a solution of crude aldehyde 4.32 (1,07 g, 4.85 mmol, 1 eq) in 
THF (25 mL) was added. The reaction mixture was stirred at -78 °C over 30 min, then the solution 
was slowly allowed to R.T. over 2 h. The mixture was quenched with sat. aq. NH4Cl solution (15 
mL), diluted with water and extracted with Et2O. The organic phase was washed with brine and, 
after drying, filtering and concentrating under reduced pressure, flash chromatography (10:1 
hexane/EtOAc) gave the alkyne 4.19 as a colorless oil (955 mg, 91% yield). 
Rf 0.87 (10:1 hexane/EtOAc); 1H NMR (400 MHz, CDCl3): δ = 0.98 (d, J = 6.8 Hz, 3H), 1.17-1.22 
(m, 1H), 1.23 (d, J = 6.8 Hz, 3H), 1.58-1.68 (m, 1H), 2.05 (d, J = 2.4 Hz, 1H), 2.08-2.20 (m, 1H), 
2.50-2.62 (m, 1H), 3.30-3.39 (m, 2H), 4.54 (s, 2H), 7.26-7.37 (m, 5H); 13C NMR (100 MHz, 
CDCl3): δ = 16.9, 22.0, 23.8, 32.0, 41.2, 68.8, 73.3, 76.5, 89.4, 127.8, 127.9, 128.7, 139.2; HRMS 
(ESI): calcd. for C15H20NaO: 239.14064 [M+Na]+; found: 239.14059. 
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6.5 Synthesis of Aldehyde C19-C233 
 
 
 
 
(S)-3-((4-methoxybenzyl)oxy)-2-methylpropanal (4.34) 
A solution of DMSO (4.24 mL, 59.7 mmol, 3.3 eq) in DCM (86.5 mL) was cooled to -78 °C and 
oxalyl chloride (3.92 mL, 29 mmol, 1.6 eq) was added over 30 min (internal temp <-65 °C). After 
additional 30 min, a solution of alcohol 4.25 (3.8 g, 18.1 mmol, 1 eq) in DCM (55.3 mL) was 
added dropwise over 45 min. The resulting mixture was stirred for additional 30 min at -78 °C, 
then DIPEA (19.1 mL, 117.6 mmol, 6.5 eq) was added over 10 min. The mixture was stirred for 30 
min at -78 °C, then slowly warmed to 0 °C via removal of the external cooling bath. The reaction 
was quenched by addition to a vigorously stirred 1 M aq. KHSO4 solution (115 mL). The layers 
were separated and the aqueous phase was extracted with Et2O (3 x 50 mL). The combined organic 
layers were dried over Na2SO4, filtered and concentrated under reduced pressure to give the 
corresponding aldehyde 4.34 (3.9 g) as a pale yellow oil, which was used without further 
purification.  
Rf 0.63 (60:40 hexane/EtOAc); 1H NMR (400 MHz, CDCl3): δ = 1.16 (d, J = 7.1 Hz, 3H), 2.63-
2.74 (m, 1H), 3.64-3.74 (m, 2H), 4.55 (s, 2H), 7.24-7.41 (m, 5H), 9.75 (d, J = 1.5 Hz, 1H). 
 
 
 
 
(R)-4-benzyl-3-((2R,3S,4S)-3-hydroxy-5-((4-methoxybenzyl)oxy)-2,4-
dimethylpentanoyl)oxazolidin-2-one (4.36) 
A solution of oxazolidinone 4.35 (4.85 g, 20.8 mmol, 1.15 eq) in DCM (55 mL) was cooled to 0 
°C and nBu2BOTf in DCM (1 M, 21.7 mL 21.7 mmol, 1.2 eq) was introduced over 30 min, 
followed by addition of TEA (3.28 mL, 25.5 mmol, 1.3 eq) over 10 min. The mixture was stirred 
at 0 °C for 30 min and cooled to -78 °C. A -78 °C pre-cooled solution of aldehyde 4.34 (18.1 
mmol, 1 eq) in DCM (11 mL) was added via syringe over 30 min. After 2 h at -78°C and 2 h at 
0°C, the solution was quenched with pH 7 potassium phosphate monobasic sodium hydroxide 
buffer (0.05M, 22 mL). A solution of 30% H2O2 in MeOH (1:2, 56 mL) was added to the 
vigorously stirred reaction mixture at such a rate as to maintain temperature at 0 °C. The reaction 
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was stirred for 10 h at room temperature and the residue was extracted with Et2O/DCM (10:1). The 
combined organic extracts were washed with sat. aq. NaHCO3, water and brine, then dried with 
NaSO4 and concentrated under reduced pressure. Purification of the residue by flash 
chromatography (70:30 hexane/EtOAc) afforded the product 4.36 as a white solid (6.0 mg, 75% 
yield). 
Rf 0.50 (60:40 hexane/EtOAc); 1H NMR (400 MHz, CDCl3): δ = 0.96 (d, J = 7.0 Hz, 3H), 1.27 (d, 
J = 6.9 Hz, 3H), 1.59 (br s, 1H), 1.96-2.02 (m, 1H), 2.78 (dd, J = 13.3 Hz, 12.2 Hz, 1H), 3.35 (dd, 
J = 13.3 Hz, 3.0 Hz, 1H), 3.52-3.61 (m, 2H), 3.82 (s, 3H), 3.87-3.90 (m, 1H), 3.92-3.93 (m, 1H), 
4.17-4.20 (m, 2H), 4.46 (s, 2H), 4.65-4.72 (m, 2H) 6.88 (d, J = 8.6 Hz, 2H), 7.22-7.37 (m, 7H); 13C 
NMR (100 MHz, CDCl3): δ = 9.7, 13.6, 36.0, 40.7, 55.3, 55.7, 73.2, 74.7, 75.5, 113.8, 127.3, 
128.6, 128.8, 129.5, 129.9, 135.4, 153.2, 159.3, 176.2. 
 
 
 
(2R,3S,4S)-3-hydroxy-N-methoxy-5-((4-methoxybenzyl)oxy)-N,2,4-trimethylpentanamide 
(4.37) 
A suspension of N,O-dimethylhydroxylamine hydrochloride (3.98 g, 40.8 mmol, 3 eq) in THF (30 
mL) was cautiously treated with an AlMe3 hexane solution (2.0 M, 20.4 mL, 40.8 mmol, 3 eq) at 0 
°C over 30 min (venting bubbler is absolutely required). The resultant solution was stirred over 30 
min at 0 °C and 90 min at R.T., and then cooled to -20 °C. A solution of 4.36 (6.0 g, 13.6 mmol, 1 
eq) in THF (30 mL) was introduced over 10 min. After additional 2 h at -20 °C, the solution was 
poured slowly into a solution of 1 N aq. HCl (79 mL) and DCM (79 mL) and stirred vigorously at 
0 °C for 2 h. The aqueous phase was extracted with DCM and the combined organic layers were 
washed with water and saturated brine, dried over Na2SO4, filtered and concentrated under reduced 
pressure. Purification of the residue by flash chromatography (80:20 hexane/EtOAc) afforded the 
Weinreb amide 4.37 as a white solid (3.30 mg, 75% yield). 
Rf 0.23 (70:30 hexane/EtOAc);1H NMR (400 MHz, CDCl3): δ = 1.00 (d, J = 7.2 Hz, 3H), 1.19 (d, J 
= 6.8 Hz, 3H), 1.85-1.93 (m, 1H), 3.06 (br s, 1H), 3.21 (s, 3H), 3.54-3.56 (dd, J = 8.8 Hz, 6Hz, 
1H), 3.63-3.65 (dd, J = 8.8 Hz, 4 Hz, 1H), 3.71-3.73 (dd, J = 8.4 Hz, 3.6 Hz, 1H), 3.81 (s, 3H), 
4.47 (AB system, νA= 4.49, νB= 4.45, JAB = 11.6 Hz, 2H), 4.47 (s, 2H) 6.89 (d, J = 8.8 Hz, 2H), 
7.26 (d, J = 8.8 Hz, 2H); 13C NMR (100 MHz, CDCl3): δ = 10.8, 14.7, 32.4, 36.4, 36.9, 55.7, 61.9, 
73.2, 73.4, 74.3, 114.1, 114.1, 129.6, 131.0, 159.5. 
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(R)-N-methoxy-2-((2S,4S,5S)-2-(4-methoxyphenyl)-5-methyl-1,3-dioxan-4-yl)-N-
methylpropanamide (4.38) 
A vigorously stirred suspension of Weinreb amide 4.37 (3.30 g, 10.2 mmol, 1 eq) and powdered 4 
Å molecular sieves (4 g) in DCM (76 mL) was treated with DDQ (4.48 g, 12.2 mmol, 1.2 eq) at -
10°C. The resultant mixture was warmed to 0 °C over 90 min and filtered through a pad of celite. 
The solution was diluted with hexane, washed with 1 N aq. NaOH and brine, dried over Na2SO4, 
filtered and concentrated under reduced pressure. Purification of the residue by flash 
chromatography (70:30 hexane/EtOAc) afforded the PMP acetal 4.38 as a white solid (1.98 mg, 
60% yield). 
Rf 0.22 (60:40 hexane/EtOAc); 1H NMR (400 MHz, CDCl3): δ = 0.75 (d, J = 6.8 Hz, 3H), 1.26 (d, 
J = 7.0 Hz, 3H), 1.89-2.00 (m, 1H), 3.18 (s, 3H), 3.14-3.21 (m, 1H), 3.51 (t, J = 11.2 Hz, 1H), 3.69 
(s, 3H), 3.78 (s, 3H), 3.82 (dd, J = 9.8 Hz, 6.4 Hz, 1H), 4.03 (dd, J = 11.3 Hz, 4.7 Hz, 1H), 5.46 (s, 
1H), 6.86 (d, J= 8.8 Hz, 2H), 7.40 (d, J= 8.8 Hz, 2H); 13C NMR (100 MHz, CDCl3): δ = 12.4, 
13.0, 32.6, 33.7, 38.9, 55.2, 61.3, 72.8, 82.8, 100.7, 113.5, 127.2, 131.2, 159.7, 175.8. 
 
 
 
 
(R)-2-((2S,4S,5S)-2-(4-methoxyphenyl)-5-methyl-1,3-dioxan-4-yl)propanal (4.20) 
A solution of amide 4.38 (110 mg, 0.34 mmol, 1 eq) in THF (0.68 mL) was added over 15 min to a 
-60 °C suspension of LiAlH4 (20.6 mg, 0.54 mmol, 1.6 eq) in THF (2.72 mL). The resultant 
solution was stirred for 2 h at -60 °C, warmed to 0 °C, stirred for 1 h, and quenched via dropwise 
addition of glacial acetic acid (0.14 mL, 1.7 mmol, 5 eq) over 45 min. A sat. aq. sodium potassium 
tartrate solution (8.5 mL) was added, and the resultant solution was vigorously stirred at R.T. After 
1 h, the reaction mixture was diluted with hexane (8.5 mL), and the layers was separated. The 
aqueous layer was extracted with DCM, and combined organic layers were washed with water, 
brine and sat. aq. NaHCO3 solution. The organic phase was dried, filtered and concentrated under 
reduced pressure to give 4.20 as a pale yellow oil (90 mg, 100%), that was used without further 
purification. 
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Rf 0.20 (80:20 hexane/EtOAc); 1H NMR (400 MHz, CDCl3): δ = 0.84 (d, J = 6.8 Hz, 3H), 1.27 (d, 
J = 7.2 Hz, 3H), 2.10-2.14 (m, 1H), 2.58-2.62 (m, 1H), 3.61 (t, J = 11.2 Hz, 1H,), 3.81 (s, 3H), 
4.09 (dd, J = 10.0 Hz, 2.4 Hz, 1H,), 4.17 (dd, J = 11.2 Hz, 4. 8 Hz, 1H), 5.51 (s, 1H), 6.88 (d, J = 
8.6 Hz, 2H), 7.36 (d, J = 8.6 Hz, 2H), 9.79 (s, 1H). 
 
 
 
6.6 Synthesis of Alkyne C10-C23 
 
 
 
 
(2S,3S/R,6R,8S)-9-(benzyloxy)-2-((4S,5S)-2-(4-methoxyphenyl)-5-methyl-1,3-dioxan-4-yl)-6,8-
dimethylnon-4-yn-3-ol (4.39 and 4.40) 
nBuLi in hexane (1.6 M, 940 μL, 0.15 mmol, 1.5 eq) was added slowly to a stirred solution of 
alkyne 4.19 (25.9 mg, 0.12 mmol, 1.2 eq) in THF (2.0 mL) at -78 °C. The yellowish solution was 
stirred for 90 min at -78 °C. A solution of aldehyde 4.20 (26.4 mg, 0.10 mmol, 1 eq) in THF (0.35 
mL) was added dropwise and the solution became colorless. The reaction was stirred overnight at -
78 °C for one night. A sat. aq. NH4Cl solution was then added, the layers were separated and the 
aqueous phase extracted with Et2O (3 x 4 mL). The combined organic extracts were dried over 
Na2SO4, filtered and concentrated under reduced pressure. Purification of the crude product by 
flash chromatography (90:10 hexane/EtOAc) afforded a mixture of diastereomeric propargylic 
alcohols 4.39 and 4.40 in a 7:3 dr (29.3 mg, 61%) as a colorless oil. The diastereomeric ratio was 
determined by NMR. 
 
 
 
 
(2S,3S,6R,8S)-9-(benzyloxy)-2-((4S,5S)-2-(4-methoxyphenyl)-5-methyl-1,3-dioxan-4-yl)-6,8-
dimethylnon-4-yn-3-ol (4.39) 
 
 
Chapter 6 
 90 
 
CARREIRA ASYMMETRIC ALKYNYLATION 
Zinc triflate (474 mg, 1.3 mmol, 4.3 eq) was flame-dried under vacuum; (-)-N-methylephedrine 
(179.3 mg, 1 mmol, 3.3 eq) was added, and the flask was purged with nitrogen for 15 min. Toluene 
(6.6 mL) was added, followed by TEA (140 μl, 1 mmol, 3.3 eq). After 2 h, a solution of the alkyne 
4.19 (220 mg, 1 mmol, 3.3 eq) in toluene (0.4 mL) was added. After 30 min, a solution of the 
aldehyde 4.20 (79.3 mg, 0.3 mmol, 1 equiv) in toluene (1 mL) was slowly added through a syringe 
pomp over 6 h. The reaction mixture was left under stirring overnight. The reaction was monitored 
by TLC (95:5 benzene/Et2O). On disappearance of the aldehyde, the reaction mixture was 
quenched with a sat. aq. NH4Cl solution (12 mL), and extracted with Et2O (3 x 15 mL). The 
combined organic extracts were dried and concentrated under reduced pressure. Purification of the 
crude product by flash chromatography (80:20 hexane/EtOAc) afforded diastereoisomerically pure 
propargylic alcohol 4.39 (96.6 mg, 67%) as a colorless oil. 
 
HYDRYDE REDUCTION 
Li(t-BuO)3AlH in THF (1M, 0,24 mL, 0.23 mmol, 3 eq), was added to a solution of 4.41 (37.2 mg, 
0.078 mmol, 1 eq) in THF (0.8 mL). After 3 min of stirring at R.T. the reaction was quenched with 
sat. aq. NH4Cl solution (0.11 mL) and stirred for 1 h; then it was dried, filtered and concentrated 
under reduced pressure. Purification of the crude product by flash chromatography (80:20 
hexane/EtOAc) afforded a mixture of distereomeric propargylic alcohols 4.39 and 4.40 in a 75:25 
dr (36 mg, 96%) as a colorless oil. The diastereomeric ratio was determined by NMR. 
 
NOYORI TRANSFER HYDROGENATION 
(S,S) Noyori Catalyst (183 mg, 0.29 mmol, 0.2 eq) was added to a solution of 4.41 (690 mg, 1.44 
mmol, 1 eq) in iPrOH (15 mL). The reaction mixture was stirred at R.T. for 12 h. The solvent was 
removed under reduced pressure and the crude residue was purified by flash chromatography 
(80:20 hexane/EtOAc) affording diastereoisomerically pure propargylic alcohol 4.39 (678 mg, 
98%) as a colorless oil. 
Rf 0.42 (85:15 hexane/EtOAc); [α]20D = + 35.89 (c = 1.03, CHCl3); 1H NMR (400 MHz,C6D6): δ = 
0.45 (d, J = 6.8 Hz, 3H), 1.07 (d, J = 6.8 Hz, 3H), 1.12-1.22 (m, 1H), 1.25 (d, J = 6.8 Hz, 3H), 1.38 
(d, J = 6.8 Hz, 3H), 1.77-1.84 (m, 1H), 1.97-2.05 (m, 2H), 2.25 (br s, 1H,), 2.38-2.43 (m, 1H), 
2.62-2.69 (m, 1H), 3.16-3.31 (m, 2H), 3.34 (s, 3H), 3.34-3.43 (m, 1H), 3.87 (dd, J = 10.0 Hz, 2.0 
Hz, 1H), 4.02 (dd, J = 11.2 Hz, 4.8 Hz1 H), 4.46 (s, 2H), 4.75 (d, J = 5.6 Hz, 1H), 5.61 (s, 1H), 
6.89 (d, J = 8.6 Hz, 2H), 7.18-7.43 (m, 5H), 7.68 (d, J = 8.6 Hz, 2H); 13C NMR (100 MHz, C6D6): 
δ = 9.2, 12.1, 17.1, 22.6, 24.5, 31.2, 32.8, 41.7, 41.8, 55.2, 67.0, 73.6, 76.7, 82.7, 85.8, 89.7, 102.0, 
114.3, 129.0, 132.4, 136.7, 161.2; IR (CHCl3): ν = 1462, 1518, 1615, 1732, 2851, 2874, 2933, 
2969, 3024, 3040, 3501; HRMS (ESI): calcd. for: 503.27680 [M+Na]+; found: 503.27575. 
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(2S,3S,6R,8S)-9-(benzyloxy)-2-((4S,5S)-2-(4-methoxyphenyl)-5-methyl-1,3-dioxan-4-yl)-6,8-
dimethylnon-4-yn-3-ol (4.40) 
Zinc triflate (474 mg, 1.3 mmol, 4.3 eq) was flame-dried under vacuum; (+)-N-methylephedrine 
(179.3 mg, 1 mmol, 3.3 eq) was added, and the flask was purged with nitrogen for 15 min. Toluene 
(6.6 mL) was added, followed by TEA (140 μl, 1 mmol, 3.3 eq). After 2 h, a solution of the alkyne 
4.19 (220 mg, 1 mmol, 3.3 eq) in toluene (0.4 mL) was added. After 30 min, a solution of the 
aldehyde 4.38 (79.3 mg, 0.3 mmol, 1 eq) in toluene (1 mL) was slowly added. The reaction 
mixture was stirred overnight and monitored by TLC (95:5 benzene/Et2O). On disappearance of 
the aldehyde, the reaction mixture was quenched with a sat. aq. NH4Cl solution (12 mL), and 
extracted with Et2O (3 x 15 mL). The combined organic extracts were dried and concentrated 
under reduced pressure. Purification of the crude product by flash chromatography (80:20 
hexane/EtOAc) afforded a mixture of diastereomeric propargylic alcohols 4.39 and 4.40 in 7:93 
ratio (7.2 mg, 5%) as a colorless oil. The diastereomeric ratio was determined by NMR. 
 
 
 
 
(2R,6R,8S)-9-(benzyloxy)-2-((4S,5S)-2-(4-methoxyphenyl)-5-methyl-1,3-dioxan-4-yl)-6,8-
dimethylnon-4-yn-3-one (4.41) 
Alkyne 4.19 (969,1 mg, 4.48 mmol, 1 eq) was dissolved in THF (45.2 mL) and cooled to -78 °C, 
then nBuLi in hexane (1.6 M, 45.2 mL, 1 eq) was added slowly. After 5 min, the mixture was 
warmed to 0 °C and stirred for 30 min. The solution was then cooled to -78 °C and Weinreb amide 
4.38 (1.64 g, 5.06 mmol) in THF (2.8 mL) was added slowly. After 5 min the solution was warmed 
to 0 °C and stirred for 1 h. The reaction was quenched with a sat. aq. NH4Cl solution (2.8 mL). The 
aqueous phase was extracted with Et2O and the combined organic extracts were washed with brine 
and dried over Na2SO4. Filtration and concentration under reduced pressure, followed by flash 
chromatography (90:10 hexane/EtOAc) afforded the ynone 4.41 (1.5 g, 70% yield) as a pale 
yellow oil: 
Rf 0.53 (80:20 hexane/EtOAc); [α]22D= + 46.44 (c = 1.00, CHCl3); 1H NMR (400 MHz, CDCl3): δ 
= 0.81 (d, J = 6.7 Hz, 3H), 0.97 (d, J = 6.7 Hz, 3H), 1.27 (d, J = 6.6 Hz, 3H), 1.27 (d, J = 7.2 Hz, 
3H), 1.74 (ddd, J = 14.4 Hz, 10.5 Hz, 4.2 Hz, 1H), 2.00-2.11 (m, 2H), 2.76 (m, 2H), 3.31 (d, J = 
Chapter 6 
 92 
6.2 Hz, 2H) 3.55 (t, J = 11.1 Hz, 1H), 3.80 (s, 3H), 4.15 (dd, J = 13.3 Hz, 6.4 Hz, 1H), 4.23 (dd, J 
= 10.1 Hz, 2.8 Hz, 1H), 4.50 (s, 2H), 5.48 (s, 1H), 6.86 (d, J = 8.7 Hz, 2H), 7.33 (m, 7H); 13C 
NMR (100 MHz, CDCl3): δ = 8.3, 11.8, 16.5, 20.8, 24.0, 30.9, 32.0, 40.2, 49.4, 55.1, 72.8, 72.9, 
75.8, 80.4, 82.8, 98.1, 100.9, 113.3, 127.3, 127.4, 128.3, 131.2, 138.8, 159.8, 188.7; IR (neat): ν = 
699, 737, 829, 1034, 1078, 1127, 1249, 1303, 1372, 1392, 1456, 1518, 1615, 1678, 1737, 2207, 
2850, 2874, 2933, 2968; HRMS (ESI): calcd. for C30H38O5Na: 501.26115 [M+Na]+; found: 
501,26102. 
 
 
 
 
(2S,3S,4S,5S,8R,10S)-11-(benzyloxy)-3-((4-methoxybenzyl)oxy)-2,4,8,10-tetramethylundec-6-
yne-1,5-diol (4.42) 
A solution of PMP acetal 4.39 (96.6 mg, 0.2 mmol, 1 eq) in DCM (20 ml) was cooled to -20 °C; 
DIBAL-H in hexane (1.0 M, 2.0 mL, 2 mmol, 10 eq) was added over 10 min. After 30 min, the 
temperature was raised to 0°C, and the reaction mixture was stirred for additional 2 h. On 
completion of the reaction (75:25 hexane/EtOAc) the mixture was quenched with a sat. aq. 
solution of Rochelle’s salt (2.5 ml). After 1 h under vigorous stirring, the reaction mixture was 
diluted with Et2O (190 mL), washed with a sat. aq. solution of Rochelle’s salt and brine, dried and 
concentrated under reduced pressure. The residue was purified by flash chromatography (85:15 
hexane/EtOAc) to afford the product 4.42 as a pale yellow oil (72.4 mg, 75% yield).  
Rf 0.13 (70:30 hexane/EtOAc); [α]28D= + 12.55 (c = 1.04, CHCl3); 1H NMR (400 MHz, C6D6): δ = 
0.97 (d, J = 7.2 Hz, 3H), 1.06 (d, J = 6.8 Hz, 3H), 1.10-1.18 (m, 1H), 1.24 (d, J = 6.8 Hz, 3H), 1.34 
(d, J = 6.8 Hz, 3H), 1.74-1.81 (m, 1H), 2.04-2.10 (m, 2H), 2.34-2.42 (m + br s, 2H), 2.60-2.66 (m, 
1H), 3.22-3.31 (m, 2H), 3.41 (s, 3H), 3.69 (dd, J = 10.8 Hz, 5.6 Hz, 1H), 3.81 (dd, J = 10.8 Hz, 4.0 
Hz, 1H), 3.97-4.03 (m, 1H), 4.45 (s, 2H), 4.52 (dd, J = 7.2 Hz, 2.0 Hz, 2H), 4.74 (AB system, νA= 
4.77, νB= 4.71, JAB = 10.8 Hz, 2H), 6.90 (d, J = 8.8 Hz, 2H), 7.19-7.43 (m, 7H); 13C NMR (100 
MHz, C6D6): δ = 10.9, 15.1, 17.1, 22.5, 24.5, 32.8, 39.2, 41.8, 43.8, 55.2, 66.0, 66.6, 73.7, 75.0, 
76.8, 82.9, 83.9, 90.6, 114.6, 129.0, 130.0, 131.9, 139.7, 160.1; IR (neat): ν = 1263, 1455, 1514, 
1613, 1730, 2874, 2932, 2963, 3024, 3048; HRMS (ESI): calcd. for C30H42O5Na: 505.29245 
[M+Na]+; found: 505.29115. 
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(2S,3S,4S,5R,8S,10S)-11-(benzyloxy)-3-((4-methoxybenzyl)oxy)-2,4,8,10-
tetramethylundecane-1,5-diol (4.43) 
Wilkinson’s catalyst [Rh(PPh3)3Cl] (13.9 mg, 0.015 mmol, 0.1 eq) was added to a degassed 
solution of alkyne 4.42 (72.4 mg, 0.15 mmol, 1 eq) in benzene (6 mL) in an autoclave. The 
reaction mixture was purged with hydrogen, and stirred overnight under 60 psi (approximately 4 
bar) of H2 pressure. Silica gel was added to the reaction mixture and the solvent was evaporated 
under reduced pressure. Purification of the crude product by flash chromatography (70:30 
hexane/EtOAc) afforded diol 4.43 (51.1 mg, 70% yield) as a yellowish oil. 
Rf 0.13 (70:30 hexane/EtOAc); [α]28D= + 14.50 (c = 1.00, CHCl3); 1H NMR (400 MHz, C6D6): δ = 
1.01 (d, J = 7.0 Hz, 3H), 1.04 (d, J = 6.4 Hz, 3H), 1.12 (d, J = 6.7 Hz, 3H), 1.16 (d, J = 7.0 Hz, 
3H), 1.02-1.24 (m, 1H), 1.56-1.86 (m, 7H), 2.00-2.14 (m, 2H), 3.26 (dd, J = 8.8 Hz, 6.4 Hz, 1H), 
3.35 (dd, J = 8.8 Hz, 5.6 Hz, 1H), 3.40 (s, 3H), 3.63-3.69 (m, 2H), 3.78-3.82 (m, 2H), 4.47 (d, J = 
3.0 Hz, 2H), 4.65 (AB system, νA= 4.65, νB= 4.59, JAB = 10.6 Hz, 2H), 6.88 (d, J = 8.6 Hz, 2H), 
7.19-7.44 (m, 7H); 13C NMR (100 MHz, C6D6): δ = 8.6, 15.2, 18.7, 21.1, 31.1, 31.9, 33.3, 34.1, 
38.6, 40.4, 42.4, 55.2, 65.6, 73.6, 74.7, 75.5, 76.5, 86.2, 114.7, 128.0, 128.1, 129.0, 130.2, 131.4, 
140.0, 160.3; IR (film): ν = 1247, 1301, 1374, 1455, 1514, 1613, 1738, 2871, 2928, 2955, 3442; 
HRMS (ESI): calcd. for C30H46O5Na: 509.32375 [M+Na]+; found: 509.32290. 
 
 
 
 
(5R,6R,7S,8S)-5-((3S,5S)-6-(benzyloxy)-3,5-dimethylhexyl)-7-((4-methoxybenzyl)oxy)-
2,2,3,3,6,8,11,11,12,12-decamethyl-4,10-dioxa-3,11-disilatridecane (4.44) 
Freshly distilled 2,6-lutidine (93 μl, 0.8 mmol, 8 eq) and TBSOTf (69 μl, 0.3 mmol, 3 eq) were 
added to a stirred solution of diol 4.43 (48.6 mg, 0.1 mmol, 1 eq) in DCM (2.5 mL) at -20 °C. The 
reaction was monitored by TLC (80:20 hexane/EtOAc). On completion of the reaction 
(approximately 1.5 hours), the mixture was quenched with a sat. aq. NH4Cl solution. The organic 
phase was separated and the aqueous layer extracted with DCM. The combined organic extracts 
were washed with brine, dried over Na2SO4 and evaporated under reduced pressure. Purification of 
the crude product by flash chromatography (80:20 hexane/EtOAc) afforded the product 4.44 (69.4 
mg, 97% yield) as a colorless oil. 
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Rf 0.67 (80:20 hexane/EtOAc); [α]26D= + 1.23 (c = 1.05, CHCl3); 1H NMR (400 MHz, C6D6): δ = 
0.19 (s, 3H), 0.26 (s, 6H), 0.40 (s, 3H), 1.07 (d, J = 6.8 Hz, 3H), 1.12 (s, 9H), 1.15 (d, J = 6.8 Hz, 
3H), 1.18 (s, 9H), 1.21 (d, J = 6.8 Hz, 3H), 1.34 (d, J = 6.8 Hz, 3H), 1.29-1.35 (m, 1H), 1.59-1.90 
(m, 6H), 2.05-2.14 (m, 3H), 3.28 (dd, J = 8.8 Hz, 6.4 Hz, 1H), 3.37 (dd, J = 8.8 Hz, 5.6 Hz, 1H), 
3.42 (s, 3H), 3.77-3.85 (m, 2H), 3.93-3.99 (m, 2H), 4.48 (d, J = 2.8 Hz, 2H), 4.78 (AB system, νA= 
4.82, νB = 4.75, JAB = 10.8 Hz, 2H), 6.95 (d, J = 8.4 Hz, 2H), 7.19-7.48 (m, 7H); 13C NMR (100 
MHz, C6D6): δ = -4.7, -3.6, -3.4, 1.8, 11.0, 16.0, 18.7, 18.9, 21.2, 26.3, 26.7, 26.8, 31.3, 32.0, 32.2, 
32.8, 39.8, 40.6, 42.3, 55.2, 65.5, 73.6, 74.7, 75.4, 76.5, 81.5, 114.5, 129.0, 129.4, 132.6, 140.0, 
160.0; IR (film): ν = 1251, 1360, 1462, 1514, 1586, 1613, 2856, 2928, 2955; HRMS (ESI): calcd. 
for C42H74O5Si2Na: 737.49670 [M+Na]+; found: 737.49705. 
 
 
 
 
(2S,4S,7R,8R,9S,10S)-7,11-bis-(tert-butyl-dimethyl-silanyloxy)-9-(4-methoxy-benzyloxy)-
2,4,8,10-tetramethyl-undecan-1-ol (4.45) 
Raney-Nickel was washed with water until the washings were pH neutral, and then rinsed five 
times with absolute EtOH. A solution of substrate 4.44 (69.4 mg, 0.097 mmol, 1 eq) in absolute 
EtOH (6.5 mL) was added. The mixture was accurately degassed and then purged three times with 
hydrogen. After stirring for 24 h, the Raney-Nickel was removed by filtration and the filtrate, after 
concentration under reduced pressure, was purified by flash chromatography (90:10 
hexane/EtOAc) to afford alcohol 4.45 (49.1 mg, 81% yield) as a colorless oil. 
Rf 0.34 (80:20 hexane/EtOAc); [α]18D= - 4.72 (c = 1.10, CHCl3); 1H NMR (400 MHz, C6D6): δ = 
0.19 (s, 6H), 0.25 (s, 6H), 0.93-1.04 (m, 1H), 1.01 (d, J = 6.8 Hz, 3H), 1.04 (d, J = 6.0 Hz, 3H), 
1.12 (s, 9H), 1.17 (s, 9H), 1.10-1.20 (m, 2H), 1.20 (d, J = 7.2 Hz, 3H), 1.29 (d, J = 7.2 Hz, 3H), 
1.42-1.90 (m, 5H), 2.09-2.15 (m, 2H), 3.27-3.32 (m, 1H), 3.39-3.43 (m, 1H), 3.44 (s, 3H), 3.76-
3.84 (m, 2H), 3.91-4.00 (m, 2H), 4.77 (AB system, νA = 4.81, νB = 4.73, JAB = 11.2 Hz, 2H), 6.95 
(d, J = 8.4 Hz, 2H), 7.46 (d, J = 8.4 Hz, 2H); 13C NMR (100 MHz, C6D6): δ = -4.7, -3.6, -3.4, 11.0, 
16.0, 18.0, 18.9, 19.0, 21.2, 26.7, 31.3, 32.1, 32.7, 33.9, 39.8, 40.6, 41.8, 55.2, 65.5, 68.5, 74.7, 
75.3, 81.4, 114.5, 129.5, 132.6, 160.0; IR (film): ν = 1250, 1301, 1360, 1387, 1463, 1471, 1515, 
1587, 1614, 2857, 2928, 2954, 3377; HRMS (ESI): calcd. for C35H69O5Si2: 625.46780 [M+H]+; 
found: 625.46921. 
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(2S,4S,7R,8R,9S,10S)-7,11-bis-(tert-butyl-dimethyl-silanyloxy)-9-(4-methoxy-benzyloxy)-
2,4,8,10-tetramethyl-undecanal (4.46).  
Solid TPAP (2.4 mg, 0.0068 mmol, 0.05 eq) was added to a stirred solution of alcohol 4.45 (84.4 
mg, 0.135 mmol, 1 eq) and NMO (23.7 mg, 0.202 mmol, 1.5 eq) in DCM (0.3 mL), in presence of 
4 Å molecular sieves (500 mg/mmol) at R.T. On completion of the reaction, the mixture was 
filtered through a pad of celite (rinsed with EtOAc). The solvent was removed under reduced 
pressure, and the crude aldehyde 4.46, obtained quantitatively, was used without further 
purification. 
Rf 0.55 (80:20 hexane/EtOAc); 1H NMR (400 MHz, C6D6): δ = 0.18 (s, 6H), 0.38 (s, 6H), 0.98 (d, 
J = 7.2 Hz, 3H), 0.90-1.04 (m, 1H), 1.10 (d, J = 6.4 Hz, 3H), 1.11 (s, 9H), 1.15 (s, 9H), 1.17 (d, J = 
7.2 Hz, 3H), 1.10-1.20 (m, 2H), 1.24 (d, J = 7.2 Hz, 3H), 1.21-2.12 (m, 7H), 3.46 (s, 3H), 3.75-
4.04 (m, 4H), 4.76 (AB system, νA = 4.81, νB = 4.72, JAB = 11.2 Hz, 2H), 6.95 (d, J = 8.4 Hz, 2H), 
7.44 (d, J = 8.4 Hz, 2H), 9.44 (d, J = 2.0 Hz, 1H). 
 
 
 
 
(3S,4R,5S,7S,10R,11R,12S,13S)-10,14-bis-(tert-butyl-dimethyl-silanyloxy)-12-(4-methoxy-
benzyloxy)-3,5,7,11,13-pentamethyl-tetradec-1-yn-4-ol (4.47) 
Triphenylphosphine (re-crystallized from ethanol prior to use, 1.2 mg, 0.0045 mmol, 0.05 eq), the 
crude aldehyde 4.47 (56.0 mg, 0.09 mmol, 1 eq) and (R)-mesyl-butynol 4.21 (20.0 mg, 0.135 
mmol, 1.5 eq) were sequentially added to a cooled (-78 °C) solution of Pd(OAc)2 (1.0 mg, 0.0045 
mmol, 0.05 eq) in THF (0.9 ml). Diethylzinc in hexane (1.0 M, 270 μl, 0.27 mmol, 3 eq) was 
added over 15 min. After 10 min., the temperature was raised to -20 °C, and the reaction mixture 
was stirred overnight at -20 °C. The mixture was quenched with NH4Cl/Et2O 1:1. The Et2O layer 
was washed with brine, dried and concentrated under reduced pressure. The residue was purified 
by flash chromatography (95:5 hexane/EtOAc) to afford the product 4.47 as a yellow oil (50.2 mg, 
82% yield over two steps) with very high diastereoselectivity (dr > 98:2). 
Rf 0.49 (80:20 hexane/EtOAc); [α]22D= - 4.51 (c = 0.61, CHCl3); 1H NMR (400 MHz, C6D6): δ = 
0.20 (s, 6H), 0.27 (s, 6H), 1.04 (d, J = 6.8 Hz, 3H), 1.06 (d, J = 6.8 Hz, 3H), 1.13 (s, 9H), 1.17 (d, J 
= 6.8 Hz, 3H), 1.18 (s, 9H), 1.22 (d, J = 6.9 Hz, 3H), 1.31 (d, J = 6.9 Hz, 3H), 1.62-1.95 (m, 9H), 
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2.11-2.19 (m, 2H), 2.62-2.67 (m, 1H), 3.28 (dd, J = 10.8 Hz, 6.0 Hz, 1H), 3.43 (s, 3H), 3.80-3.87 
(m, 2H), 3.92-4.00 (m, 2H), 4.80 (AB system, νA= 4.83, νB= 4.77, JAB = 10.8 Hz, 2H), 6.97 (d, J = 
8.8 Hz, 2H), 7.49 (d, J = 8.4 Hz, 2H); 13C NMR (100 MHz, C6D6): δ = -4.7, -3.6, -3.4, 11.1, 14.5, 
16.0, 18.0, 18.9, 21.2, 26.7, 26.8, 31.0, 31.7, 32.1, 32.7, 33.6, 39.9, 40.7, 42.1, 55.2, 65.5, 71.7, 
74.6, 75.5, 77.5, 81.4, 86.6, 114.5, 129.5, 132.6, 160.0; IR (CHCl3): ν = 1255, 1301, 1386, 1462, 
1470, 1514, 1613, 1727, 2655, 2663, 2857, 2882, 2930, 2956, 3306; HRMS (ESI): calcd. for 
C39H72O5Si2Na: 699.48105 [M+Na]+; found: 699.48154. 
 
 
 
 
(5R,6S,8S,11R,12R,13S,14S)-5-((S)-but-3-yn-2-yl)-11-((tert-butyldimethylsilyl)oxy)-13-((4-
methoxybenzyl)oxy)-2,2,3,3,6,8,12,14,17,17,18,18-dodecamethyl-4,16-dioxa-3,17-
disilanonadecane (4.3) 
Freshly distilled 2,6-lutidine (9.3 μl, 0.08 mmol, 4 eq) and TBSOTf (6.9 μl, 0.03 mmol, 1.5 eq) 
were added to a stirred solution of compound 4.47 (13.5 mg, 0.02 mmol, 1 eq) in DCM (0.5 mL) at 
-20 °C. On completion of the reaction (approximately 2 hours), the mixture was quenched with a 
sat. aq. NH4Cl solution. The organic phase was separated and the aqueous layer extracted with 
DCM. The combined organic extracts were washed with brine, dried over Na2SO4 and evaporated 
under reduced pressure. Purification of the crude product by flash chromatography (70:30 
hexane/EtOAc) afforded compound 4.3 (15.8 mg, 100% yield) as a colorless oil.  
Rf 0.80 (80:20 hexane/EtOAc); [α]22D= - 3.10 (c = 0.51, CHCl3); 1H NMR (400 MHz, C6D6): δ = 
0.21 (s, 6H), 0.25 (s, 3H), 0.26 (s, 3H), 0.27 (s, 3H), 0.28 (s, 3H), 1.10 (d, J = 7.2 Hz, 3H), 1.12 (d, 
J = 6.8 Hz, 3H), 1.13 (s, 9H), 1.16 (s, 9H), 1.19 (s, 9H), 1.23 (d, J = 7.2 Hz, 3H), 1.30 (d, J = 6.8 
Hz, 3H), 1.31 (d, J = 6.4 Hz, 3H), 1.13-1.32 (m, 2H), 1.64-1.81 (m, 4H), 1.96-2.01 (m, 1H), 2.02 
(d, J = 2.4 Hz, 1H), 2.13-2.17 (m, 3H), 2.71-2.79 (m, 1H), 3.43 (s, 3H), 3.69-4.01 (m, 5H), 4.80 
(AB system, νA= 4.83, νB= 4.77, JAB = 10.8 Hz, 2H), 6.97 (d, J = 8.4 Hz, 2H), 7.49 (d, J = 8.4 Hz, 
2H); 13C NMR (100 MHz, C6D6): δ = -4.7, -3.6, -3.3, -3.2, -3.1, 11.0, 15.9, 16.0, 18.0, 20.9, 26.6, 
26.7, 26.8, 31.4, 32.4, 32.7, 32.9, 34.1, 39.9, 40.7, 43.7, 55.2, 65.6, 71.2, 74.7, 75.4, 78.5, 81.5, 
87.9, 114.5, 129.5, 132.6, 160.0; IR (film): ν = 1256, 1471, 1514, 1587, 1614, 2856, 2884, 2904, 
2929, 2957, 3312; HRMS (ESI): calcd. for C45H86O5Si3Na: 813.56753 [M+Na]+; found: 
813.56718. 
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6.7 Synthesis of (Z)-Vinyl Iodide C10-C26 
 
 
 
 
(5R,6S,8S,11R,12R,13S,14S)-11-(tert-butyldimethylsilyloxy)-5-((S)-4-iodobut-3-yn-2-yl)-13-(4-
methoxybenzyloxy)-2,2,3,3,6,8,12,14,17,17,18,18-dodecamethyl-4,16-dioxa-3,17-
disilanonadecane (4.55) 
A 1.6 M solution of nBuLi in hexane (0.22 mL, 0.35 mmol, 1.2 eq) was added dropwise over 5 
min to a solution of alkyne 4.3 (229 mg, 0.29 mmol, 1 eq) in THF (1.5 mL) at -50 °C. After 1 h, a 
solution of iodine (125 mg, 0.50 mmol, 1.7 eq) in THF (0.10 mL) was added. The mixture was 
stirred at -50 °C for 30 min, then warmed to a R.T. over 30 min. After quenching by the addition 
of sat. aq. Na2S2O3 solution (0.8 mL) and brine (0.8 mL), the mixture was extracted with EtOAc (3 
x 3 mL) and the combined organic layers were washed with brine (2 x 4 mL). The organic phase 
was dried over Na2SO4 and concentrated under reduced pressure. The crude product was purified 
by flash chromatography (9.5:0.5 hexane/EtOAc) to give the desired product 4.55 (266 mg, 100% 
yield) as a colorless oil.  
Rf 0.40 (9.5:0.5 hexane/EtOAc); [α]19D = -24 (c = 0.4, CHCl3); 1H NMR (400 MHz, CDCl3): δ = 
0.07 (s, 9H), 0.10 (s, 6H), 0.11 (s, 3H), 0.85 (d, J = 6.7 Hz, 3H), 0.88 (d, J = 6.5 Hz, 3H), 0.93 (s, 
9H), 0.93 (s, 9H), 0.94 (s, 9H), 0.94 (d, J = 6.7 Hz, 3H), 1.00 (d, J = 6.8 Hz, 3H), 0.98-1.05 (m, 
2H), 1.18 (d, J = 7.1 Hz, 3H), 1.27-1.50 (m, 4H), 1.63 (m, 1H), 1.81 (m, 2H), 1.91 (m, 1H), 2.76 
(m, 1H), 3.48 (dd, J = 4.3 Hz, 6.7 Hz, 1H), 3.52 (dd, J = 2.5 Hz, 5.7 Hz, 1H), 3.69 (m, 3H), 3.83 
(s, 3H), 4.50 (d, JAB = 10.9 Hz, 1H, upfield part of an AB system), 4.57 (d, JAB = 10.9 Hz, 1H, 
downfield part of an AB system), 6.89 (d, J = 8.6 Hz, 2H), 7.27 (d, J = 8.6 Hz, 2H); 13C NMR (100 
MHz, CDCl3): δ = -3.7 (CH3), -3.6 (CH3), -3.3 (CH3), -3.2 (CH3), -3.1 (CH3), 10,8 (CH3), 15.4 
(CH3), 16.0 (CH3), 18.0 (CH3), 18.9 (C0), 19.0 (C0), 19.6 (C0), 20.7 (CH3), 26.7 (CH3), 26.8 (CH3), 
30.4 (CH2), 31.1 (CH), 32.3 (CH2), 32.5 (CH2), 33.7 (CH), 35.1 (CH), 39.5 (CH), 40.3 (CH), 43.5 
(CH2), 56.0 (CH3), 65.3 (CH2), 74.7 (CH2), 74.9 (CH), 78.3 (CH), 81.7 (CH), 114.4 (CH), 129.6 
(CH), 132.4 (C0), 159.6 (C0); IR (neat): ν = 670, 773, 835, 939, 1078, 1171, 1250, 1301, 1361, 
1387, 1462, 1514, 1613, 2856, 2928. HRMS (ESI): calcd. for C45H85IO5Si3Na: 939.46417 [M + 
Na]+; found: 939.46033. 
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(5R,6S,8S,11R,12R,13S,14S)-11-(tert-butyldimethylsilyloxy)-5-((S,Z)-4-iodobut-3-en-2-yl)-13-
(4-methoxybenzyloxy)-2,2,3,3,6,8,12,14,17,17,18,18-dodecamethyl-4,16-dioxa-3,17-
disilanonadecane (4.56) 
A solution of iodoalkyne 4.55 (266 mg, 0.29 mmol, 1 eq) in THF (0.7 mL) and iPrOH (0.7 mL) at 
R.T. was treated with TEA (53 μL, 0.377 mmol, 1.3 eq) and NBSH (74.0 mg, 0.34 mmol, 1.1 eq). 
After 12 h, additional TEA (24 μL, 0.174 mmol, 0.6 eq) and NBSH (33.0 mg, 0.15 mmol, 0.5 eq) 
were added, and the mixture was stirred for 12 h. The reaction was quenched by adding water (1.7 
mL) and the mixture was extracted with EtOAc (3 x 3 mL). The combined organic layers were 
washed with brine (2 x 3 mL), dried over Na2SO4 and concentrated under reduced pressure. The 
crude product was purified by flash chromatography (9.5:0.5 hexane/EtOAc) to give the desired 
product 4.56 (245 mg, 92% yield) as a colorless oil. 
Rf 0.85 (8:2 hexane/EtOAc); [α]23D = +2.9 (c = 0.5, CHCl3); 1H NMR (400 MHz, CDCl3): δ = 0.07 
(s, 6H), 0.08 (s, 3H), 0.09 (s, 3H), 0.10 (s, 6H), 0.86 (d, J = 7.2 Hz, 3H), 0.90 (d, J = 8.0 Hz, 3H), 
0.93 (s, 30H), 0.99 (d, J = 6.8 Hz, 3H), 1.00 (d, J = 7.0 Hz, 3H), 1.28-1.47 (m, 6H), 1.60-1.71 (m, 
2H), 1.80 (m, 1H), 1.90 (m, 1H), 2.71 (m, 1H), 3.48 (m, 2H), 3.68 (m, 3H), 3.82 (s, 3H), 4.49 (d, 
JAB = 10.9 Hz, 1H, upfield part of an AB system), 4.57 (d, JAB = 10.9 Hz, 1H, downfield part of an 
AB system), 6.14 (d, J = 7.3 Hz, 1H), 6.29 (dd, J = 8.8 Hz, 7.3 Hz, 1H), 6.89 (d, J = 8.7 Hz, 2H), 
7.28 (d, J = 8.7 Hz, 2H); 13C NMR (100 MHz, CDCl3): δ = -5.3 (CH3), -5.2 (CH3), -4.3 (CH3), -4.0 
(CH3), -3.7 (CH3), -3.6 (CH3), 10.1 (CH3), 15.2 (CH3), 15.8 (CH3), 17.7 (CH3), 18.1 (C0), 18.3 
(C0), 18.4 (C0), 20.5 (CH3), 26.0 (CH3), 26.1 (CH3), 26.2 (CH3), 29.7 (CH2), 30.8 (CH), 31.1 
(CH2), 31.6 (CH2), 35.3 (CH), 38.9 (CH), 39.6 (CH), 41.5 (CH2), 43.5 (CH), 55.2 (CH3), 64.6 
(CH2), 74.0 (CH2), 74.2 (CH), 79.1 (CH), 81.1 (CH), 81.2 (CH), 113.7 (CH), 128.9 (CH), 131.6 
(C0), 144.2 (CH), 158.9 (C0); IR (neat): ν = 773, 805, 835, 1079, 1256, 1377, 1462, 1514, 1611, 
2855, 2927, 2956; HRMS (ESI): calcd. for C45H87IO5Si3Na: 941.47982 [M + Na]+; found: 
941.47749. 
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(2S,3S,4R,5R,8S,10S,11R,12S,Z)-5,11-bis(tert-butyldimethylsilyloxy)-14-iodo-3-(4-
methoxybenzyloxy)-2,4,8,10,12-pentamethyltetradec-13-en-1-ol (4.57) 
A solution of compound 4.56 (680 mg, 0.74 mmol, 1 eq) in THF (3.8 mL) at 0 °C was treated with 
a solution of HF·Py in THF/pyridine [16.5 mL, prepared by slow addition of commercially 
available 70% HF in pyridine (1.3 mL) to a mixture of pyridine (5.0 mL) and THF (10.2 mL)]. The 
reaction mixture was warmed to R.T. and stirred for 3 h. After quenching the reaction by addition 
of sat. aq. NaHCO3 solution (30 mL), the mixture was extracted with EtOAc (4 x 20 mL). The 
combined organic extracts were washed with sat. aq. CuSO4 solution (3 x 15 mL) and brine (2 x 40 
mL), dried over Na2SO4 and concentrated under reduced pressure. The crude product was purified 
by flash chromatography (90:10 hexane/EtOAc) to give the desired product 4.57 (477 mg, 80% 
yield) as a colorless oil. 
Rf 0.29 (08:20 hexane/EtOAc); [α]16D = +9.6 (c = 0.9, CHCl3); 1H NMR (400 MHz, CDCl3): δ = 
0.07 (s, 3H), 0.08 (s, 3H), 0.09 (s, 3H), 0.10 (s, 3H), 0.88 (d, J = 6.5 Hz, 3H), 0.89 (d, J = 6.8 Hz, 
3H), 0.86-0.91 (m, 2H), 0.94 (s, 18H), 1.01 (d, J = 7.0 Hz, 3H), 1.02 (d, J = 6.8 Hz, 3H), 1.13 (d, J 
= 7.1 Hz, 3H), 1.28-1.47 (m, 4H), 1.60-1.71 (m, 2H), 1.90 (m, 1H), 1.96 (m, 1H), 2.71 (m, 1H), 
2.87 (br s, 1H), 3.48 (m, 2H), 3.61 (m, 2H), 3.83 (s, 3H), 3.84 (m, 1H), 4.55 (s, 2H), 6.13 (d, J = 
7.3 Hz, 1H), 6.30 (t, J = 7.3 Hz, 1H), 6.89 (d, J = 8.6 Hz, 2H), 7.28 (d, J = 8.6 Hz, 2H); 13C NMR 
(100 MHz, CDCl3): δ = -3.7 (CH3), -3.1 (CH3), -2.9 (CH3), 10.7 (CH3), 16.5 (CH3), 16.7 (CH3), 
18.5 (CH3), 18.8 (C0), 19.1 (C0), 21.2 (CH3), 26.7 (CH3), 26.9 (CH3), 31.5 (CH), 32.3 (CH2), 32.8 
(CH2), 36.2 (CH), 37.6 (CH), 41.2 (CH), 42.1 (CH2), 44.0 (CH), 56.0 (CH3), 65.9 (CH2), 74.3 
(CH), 76.0 (CH2), 79.8 (CH), 81.9 (CH), 86.7 (CH), 114.6 (CH), 130.0 (CH), 131.2 (C0), 144.8 
(CH), 159.9 (C0); IR (neat): ν = 773, 805, 1028, 1255, 1377, 1461, 1514, 1614, 2067, 2959, 3448; 
HRMS (ESI+): calcd. for C39H73IO5Si2Na [M + Na]+: 827.39334; found: 827.39126. 
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(2R,3R,4R,5R,8S,10S,11R,12S,Z)-5,11-bis(tert-butyldimethylsilyloxy)-14-iodo-3-(4-
methoxybenzyloxy)-2,4,8,10,12-pentamethyltetradec-13-enal (4.58) 
A solution of alcohol 4.57 (394 mg, 0.49 mmol 1 eq) in DCM (3.1 mL) at 0 °C was treated with 
pyridine (0.10 mL, 1.2 mmol, 2.5 eq) and DMP (250 mg, 0.59 mmol, 1.2 eq). The reaction mixture 
was warmed to R.T. and stirred for 1 h. After completion of the reaction, sat. aq. NaHCO3 solution 
(8.0 mL) and Na2S2O3 (888 mg, 3.6 mmol) were added. The resulting mixture was stirred for 30 
min, then the phases were separated and the aqueous phase was extracted with Et2O (3 x 5 mL). 
The combined organic extracts were washed with brine (2 x 10 mL), dried and evaporated under 
reduced pressure, providing the crude aldehyde 4.58, which was used without further purification. 
Rf 0.60 (80:20 hexane/EtOAc); 1H NMR (400 MHz, CDCl3): δ = 0.07 (s, 3H), 0.08 (s, 3H), 0.09 (s, 
3H), 0.10 (s, 3H), 0.84-0.94 (m, 2H), 0.88 (d, J = 6.3 Hz, 3H), 0.89 (d, J = 6.7 Hz, 3H), 0.93 (s, 
9H), 0.94 (s, 9H), 1.01 (d, J = 6.4 Hz, 3H), 1.02 (d, J = 6.6 Hz, 3H), 1.17 (d, J = 6.9 Hz, 3H), 1.28-
1.49 (m, 4H), 1.58-1.73 (m, 2H), 1.90 (m, 1H), 2.71 (m, 1H), 2.80 (m, 1H), 3.49 (dd, J = 3.7 Hz, 
1H), 3.68 (m, 2H), 3.83 (s, 3H), 4.52 (s, 2H), 6.13 (d, J = 7.3 Hz, 1H), 6.30 (t, J = 7.3 Hz, 1H), 
6.89 (d, J = 8.6 Hz, 2H), 7.27 (d, J = 8.6 Hz, 2H), 9.83 (d, J = 2.2 Hz, 1H). 
 
 
 
 
(5R,6S,8S,11R)-5-((S,Z)-4-iodobut-3-en-2-yl)-11-((2R,3S,4S,Z)-3-(4-methoxybenzyloxy)-4-
methylocta-5,7-dien-2-yl)-2,2,3,3,6,8,13,13,14,14-decamethyl-4,12-dioxa-3,13-
disilapentadecane (4.54) 
To a slurry of CrCl2 (301 mg, 2.45 mmol, 5 eq) in THF (4.9 mL), obtained by sonication and 
cooled to 0°C, freshly-prepared aldehyde 4.58 (394 mg, 0.49 mmol, 1 eq) in THF (1.7 mL) and (1-
bromoallyl)trimethylsilane 4.59 (530 mg, 2.74 mmol, 5.6 eq) were added. The resulting mixture 
was stirred for 3h at R.T. before being re-cooled to 0°C and quenched by the addition of MeOH 
(2.1 mL) and 6 N aq. KOH (4.2 mL). After stirring for 20 h at R.T., the phases were separated and 
the aqueous layer was extracted with DCM (4 x 5 mL). The combined organic extracts were 
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washed with brine (2 x 15 mL), dried over Na2SO4 and concentrated under reduced pressure. The 
crude product was purified by flash chromatography (100:0.5 hexane/EtOAc) to give the desired 
product 4.54 (308 mg, 76% yield over two steps) as a colorless oil. 
Rf 0.45 (10:0.5 hexane/EtOAc); [α]22D = +22.4 (c = 0.2, CHCl3); 1H NMR (400 MHz, CDCl3): δ = 
0.04-0.11 (m, 12H), 0.77-1.01 (m, 14 H), 0.94 (s, 9H), 0.95 (s, 9H), 1.12 (d, J = 6.9 Hz, 3H), 1.25-
1.38 (m, 4H), 1.59-1.70 (m, 3H), 2.70 (m, 1H), 3.00 (m, 1H), 3.35 (dd, J = 2.9 Hz, 7.9 Hz, 1H), 
3.47 (m, 1H), 3.63 (m, 1H), 3.83 (s, 3H), 4.56 (d, JAB = 10.6 Hz, 1H, upfield part of an AB 
system), 4.52 (d, JAB = 10.5 Hz, 1H, downfield part of an AB system), 5.12 (d, J = 10.1 Hz, 1H), 
5.20 (d, J = 16.8 Hz, 1H), 5.60 (t, J = 10.6 Hz, 1H), 6.03 (t, J = 11.1 Hz, 1H), 6.13 (d, J = 7.3 Hz, 
1H), 6.28 (t, J = 7.4 Hz, 1H), 6.60 (ddd, J = 10.7 Hz, 10.7 Hz, J = 16.9 Hz, 1H), 6.89 (d, J = 8.4 
Hz, 2H), 7.31 (d, J = 8.4 Hz, 2H); 13C NMR (100 MHz, CDCl3): δ = -3.8 (CH3), -3.2 (CH3), -3.0 
(CH3), -2.9 (CH3), 9.9 (CH3), 16.5 (CH3), 18.4 (CH3), 18.9 (C0), 19.1 (C0), 19.5 (CH3), 21.1 (CH3), 
26.7 (CH3), 26.9 (CH3), 31.3 (CH), 31.9 (CH2), 33.1 (CH2), 35.9 (CH), 36.0 (CH), 41.2 (CH), 42.1 
(CH2), 44.0 (CH), 56.0 (CH3), 73.4 (CH), 75.8 (CH2), 79.9 (CH), 81.9 (CH), 85.2 (CH), 114.4 
(CH), 117.9 (CH2), 129.6 (CH), 129.8 (CH), 132.1 (C0), 133.0 (CH), 135.3 (CH), 144.9 (CH), 
159.7 (C0); IR (neat): ν = 772, 835, 1039, 1172, 1251, 1376, 1462, 1514, 1613, 1735, 2855, 2927; 
HRMS (ESI): calcd. for C42H75IO4Si2Na: 849.41408 [M + Na]+; found: 849.41248. 
 
 
 
6.8 Completion of the Synthesis of (+)-9-epi-Dictyostatin 
 
 
 
 
(2Z,4E,6R,7S,9R,10Z,12S,13R,14S,16S,19R,20R,21S,22S,23Z)-methyl-7,13,19-tris(tert-
butyldimethylsilyloxy)-9-hydroxy-21-(4-methoxybenzyloxy)-6,12,14,16,20,22-
hexamethylhexacosa-2,4,10,23,25-pentaenoate (4.60) 
To a solution of tBuLi (1.7 M in pentane, 0.17 mL, 0.29 mmol, 2.2 eq ) in Et2O (0.2 mL) kept at -
78 °C under argon atmosphere, a solution of vinyl iodide 4.54 (110 mg, 0.13 mmol, 1 eq) in Et2O 
(0.4 mL) was added. After stirring for 30 min, a dimethylzinc toluene solution (2.0 M, 0.11 mL, 
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0.21 mmol, 1.6 eq) was added dropwise and the reaction mixture was further stirred at -78 oC for 
15 min. A solution of aldehyde 4.2 (64 mg, 0.20 mmol, 1.5 eq), azeotropically dried with toluene, 
in Et2O (0.6 mL) was added dropwise, and the mixture was stirred for 1 h at -78 oC. The reaction 
was quenched with water (2.2 mL), warmed to R.T. and diluted with Et2O (3.6 mL). Phases were 
separated and the aqueous layer was extracted with Et2O (3 x 5 mL). The combined organic 
extracts were washed with brine (2 x 5 mL), dried over Na2SO4 and concentrated under reduced 
pressure. The crude product was purified by flash chromatography (10:0.5 hexane/EtOAc) to give 
the desired (Z)-allylic alcohol 4.60 (53 mg, 40% yield) as a light yellow oil. Unreacted aldehyde 
4.2 (32 mg) was recovered. 
Rf 0.55 (80:20 hexane/EtOAc); [α]19D = +2.6 (c = 1.4, CHCl3); 1H NMR (400 MHz, CDCl3): δ = 
0.05 (s, 3H), 0.06 (s, 3H), 0.10 (s, 3H), 0.11 (s, 9H), 0.80-0.82 (m, 1H), 0.83 (d, J = 6.5 Hz, 3H), 
0.87 (d, J = 6.8 Hz, 3H), 0.90 (d, J = 7.0 Hz, 3H), 0.92 (s, 9H), 0.93 (s, 9H), 0.95 (s, 9H), 0.97 (d, J 
= 6.8 Hz, 3H), 1.06-1.07 (m, 1H), 1.12 (d, J = 6.8 Hz, 6H), 1.17-1.42 (m, 4H), 1.44-1.62 (m, 2H), 
1.65-1.79 (m, 3H), 2.38 (br s, 1H), 2.63 (m, 1H), 2.71 (m, 1H), 3.01 (m, 1H), 3.34 (m, 2H), 3.64 
(m, 1H), 3.74 (s, 3H), 3.82 (s, 3H), 3.88 (m, 1H), 4.49 (m, 1H), 4.51 (d, JAB = 10.6 Hz, 1H, upfield 
part of an AB system), 4.58 (d, JAB = 10.6 Hz, 1H, downfield part of an AB system), 5.12 (d, J = 
10.2 Hz, 1H), 5.20 (dd, J = 1.8 Hz, 16.8 Hz, 1H), 5.40 (m, 2H), 5.61 (t, J = 11.4 Hz, 1H), 5.62 (d, J 
= 11.4 Hz, 1H), 6.00-6.09 (m, 2H), 6.58 (t, J = 11.3 Hz, 1H), 6.62 (t, J = 10.7 Hz, 1H), 6.89 (d, J = 
8.6 Hz, 2H), 7.30 (d, J = 8.6 Hz, 2H), 7.41 (dd, J = 11.3 Hz, 15.4 Hz, 1H); 13C NMR (100 MHz, 
CDCl3): δ = -4.4 (CH3), -4.4 (CH3), -4.3 (CH3), -3.8 (CH3), -3.5 (CH3), -2.7 (CH3), 9.2 (CH3), 14.7 
(CH3), 15.4 (CH3), 18.1 (C0), 18.2 (C0), 18.6 (C0), 18.8 (CH3), 19.0 (CH3), 20.2 (CH3), 25.9 (CH3), 
26.0 (CH3), 26.4 (CH3), 30.3 (CH), 31.5 (CH2), 32.4 (CH2), 34.0 (CH), 35.2 (CH), 36.8 (CH), 40.5 
(CH), 41.4 (CH2), 42.4 (CH2), 42.5 (CH), 51.1 (CH3), 55.3 (CH3), 65.3 (CH), 72.8 (CH), 73.6 
(CH), 75.1 (CH2), 79.6 (CH), 84.4 (CH), 113.7 (CH), 115.6 (CH), 117.2 (CH2), 127.1 (CH), 128.9 
(CH), 129.1 (CH), 131.4 (C0), 132.4 (CH), 132.6 (CH), 134.6 (CH), 136.2 (CH), 145.5 (CH), 
147.0 (CH), 159.0 (C0), 166.8 (C0); IR (neat): ν = 773, 836, 1075, 1174, 1251, 1377, 1462, 1514, 
1613, 1637, 1720, 2855, 2926, 3503; HRMS (ESI): calcd. for C59H106O8Si3Na: 1049.70877 [M + 
Na]+; found: 1049.70940. 
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(2Z,4E,6R,7S,9R,10Z,12S,13R,14S,16S,19R,20R,21S,22S,23Z)-methyl-7,9,13,19-tetrakis(tert-
butyldimethylsilyloxy)-21-(4-methoxybenzyloxy)-6,12,14,16,20,22-hexamethylhexacosa-
2,4,10,23,25-pentaenoate (4.61) 
2,6-lutidine (18 μL, 0.156 mmol, 4 eq) and TBSOTf (18 μL, 0.078 mmol, 2 eq) were added 
dropwise to a stirred solution of 4.60 (40 mg, 0.039 mmol, 1 eq) in DCM (0.3 mL) cooled at -78 
oC. After stirring at -78 °C for 1 h, the reaction was quenched by adding dropwise sat. aq. NaHCO3 
solution (1.7 mL), then it was warmed to R.T.. The mixture was diluted with DCM (11 mL), layers 
were separated and the aqueous phase was extracted with DCM (3 x 10 mL). The combined 
organic extracts were washed with brine (2 x 5 mL), dried over Na2SO4 and evaporated under 
reduced pressure. The crude product was purified by flash chromatography (10:0.5 hexane/EtOAc) 
to give the desired product 4.61 (45 mg, 100% yield) as a pale yellow oil. 
Rf 0.80 (80:20 hexane/EtOAc); [α]24D = +7.3 (c = 0.4, CHCl3); 1H NMR (400 MHz, CDCl3): δ = 
0.05 (s, 3H), 0.06 (s, 3H), 0.06 (s, 3H), 0.08 (s, 3H), 0.10 (s, 9H), 0.10 (s, 3H), 0.80-0.82 (m, 1H), 
0.82 (d, J = 6.1 Hz, 3H), 0.83 (d, J = 6.9 Hz, 3H), 0.86 (d, J = 6.8 Hz, 3H), 0.91 (s, 9H), 0.92 (s, 
9H), 0.92 (s, 9H), 0.94 (s, 9H), 0.97 (d, J = 6.8 Hz, 3H), 1.01 (m, 1H), 1.12 (d, J = 6.8 Hz, 3H), 
1.12 (d, J = 6.8 Hz, 3H), 1.27-1.42 (m, 4H), 1.46 (m, 1H), 1.62-1.72 (m, 4H), 2.49 (m, 1H), 2.59 
(m, 1H), 3.00 (m, 1H), 3.34 (dd, J = 8.0 Hz, 3.1 Hz, 1H), 3.41 (m, 1H), 3.64 (m, 1H), 3.72 (s, 3H), 
3.82 (s, 3H), 3.93 (m, 1H), 4.43 (br t, J = 8.4 Hz, 1H), 4.52 (d, JAB = 10.6 Hz, 1H, upfield part of 
an AB system), 4.57 (d, JAB = 10.6 Hz, 1H, downfield part of an AB system), 5.11 (d, J = 10.2 Hz, 
1H), 5.20 (dd, J = 1.7 Hz, 16.9 Hz, 1H), 5.25 (dd, J = 11.4 Hz, 8.2 Hz, 1H), 5.47 (t, J = 10.5 Hz, 
1H), 5.58-5.63 (m, 2H), 6.02 (t, J = 11.0 Hz, 1H), 6.20 (dd, J = 15.5 Hz, 8.9 Hz, 1H), 6.55-6.65 
(m, 2H), 6.89 (d, J = 8.7 Hz, 2H), 7.30 (d, J = 8.7 Hz, 2H), 7.43 (dd, J = 15.5 Hz, 11.2 Hz, 1H); 
13C NMR (100 MHz, CDCl3): δ = -4.8 (CH3), -4.7 (CH3), -4.3 (CH3), -4.5 (CH3), -4.1 (CH3), -3.8 
(CH3), -3.5 (CH3), 9.1 (CH3), 14.1 (CH3), 15.6 (CH3), 18.0 (C0), 18.1 (C0), 18.2 (C0), 18.5 (CH3), 
18.9 (CH3), 20.5 (CH3), 25.8 (CH3), 26.0 (CH3), 26.0 (CH3), 26.2 (CH3), 30.5 (CH), 31.7 (CH2), 
32.6 (CH2), 35.1 (CH), 35.2 (CH), 36.5 (CH), 40.4 (CH), 40.9 (CH), 41.5 (CH2), 44.8 (CH2), 50.9 
(CH3), 55.3 (CH3), 66.4 (CH), 72.4 (CH), 72.6 (CH), 75.1 (CH2), 79.1 (CH), 84.5 (CH), 113.7 
(CH), 115.0 (CH), 117.2 (CH2), 127.4 (CH), 128.9 (CH), 129.1 (CH), 131.4 (C0), 131.6 (CH), 
132.4 (CH), 132.6 (CH), 134.6 (CH), 146.0 (CH), 147.2 (CH), 159.0 (C0), 166.8 (C0); IR (neat): ν 
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= 669, 802, 865, 1078, 1257, 1361, 1412, 1461, 1514, 1637, 719, 2856, 2928, 2961; HRMS (ESI): 
calcd. for C65H120O8Si4Na: 1163.79525 [M + Na]+; found: 1163.79601. 
 
 
 
 
(2Z,4E,6R,7S,9R,10Z,12S,13R,14S,16S,19R,20R,21S,22S,23Z)-methyl-7,9,13,19-tetrakis(tert-
butyldimethylsilyloxy)-21-hydroxy-6,12,14,16,20,22-hexamethylhexacosa-2,4,10,23,25-
pentaenoate (4.62) 
DDQ (11.6 mg, 0.051 mmol, 1.3 eq) was added to a solution of the PMB ether 4.61 (44.0 mg, 
0.039 mmol, 1 eq) in DCM (1.2 mL) stirred at 0 °C in the presence of of a KH2PO4/K2HPO4 buffer 
solution at pH 7 (0.12 mL). The reaction was stirred at 0 oC for 1 h before being quenched by 
dropwise addition of sat. aq. NaHCO3 solution (19 mL). After diluting with DCM (37 mL), layers 
were separated and the aqueous phase was extracted with DCM (3 x 30 mL). The combined 
organic extracts were washed with brine (2 x 30 mL), dried over Na2SO4 and concentrated under 
reduced pressure. The crude product was purified by flash chromatography (95:5 hexane/EtOAc) 
to give the desired product 4.62 (35.9 mg, 90% yield) as a colorless oil. 
Rf 0.35 (90:10 hexane/EtOAc); [α]18D = -4.1 (c = 0.2, CHCl3); 1H NMR (400 MHz, CDCl3): δ = 
0.07 (s, 3H), 0.07 (s, 3H), 0.08 (s, 3H), 0.10 (s, 12H), 0.11 (s, 3H), 0.85 (d, J = 6.9 Hz, 3H), 0.89-
0.90 (m, 6H), 0.90 (m, 1H), 0.92-0.95 (m, 39H), 0.99 (d, J = 6.9 Hz, 3H), 1.01-1.08 (m, 1H), 1.13 
(d, J = 6.8 Hz, 3H), 1.18-1.50 (m, 5H), 1.58-1.79 (m, 4H), 2.51 (m, 1H), 2.59 (m, 1H), 2.83 (m, 
1H), 3.44 (m, 1H), 3.50 (dd, J = 7.3 Hz, 2.1 Hz, 1H), 3.73 (s, 3H), 3.78 (m, 1H), 3.95 (m, 1H), 
4.45 (t, J = 8.4 Hz, 1H), 5.14 (d, J = 10.3 Hz, 1H), 5.21-5.29 (m, 2H), 5.48 (m, 2H), 5.60 (d, J = 
11.3 Hz, 1H);  6.12 (t, J = 11.0 Hz, 1H); 6.20 (dd, J = 8.9 Hz, 15.5 Hz, 1H), 6.60 (t, J = 11.3 Hz, 
1H), 6.62-6.71 (m, 1H), 7.43 (dd, J = 11.3 Hz, 15.5 Hz, 1H); 13C NMR (100 MHz, CDCl3): δ = -
4.8 (CH3), -4.7 (CH3), -4.4 (CH3), -4.1 (CH3), -3.9 (CH3), -3.8 (CH3), -3.7 (CH3), -3.5 (CH3), 6.8 
(CH3), 15.7 (CH3), 17.8 (CH3), 18.0 (C0), 18.1 (C0), 18.1 (C0), 18.5 (CH3), 20.2 (CH3), 20.6 (CH3), 
25.8 (CH3), 25.9 (CH3), 25.9 (CH3), 26.2 (CH3), 30.7 (CH), 31.7 (CH2), 32.4 (CH2), 35.5 (CH), 
36.1 (CH), 36.5 (CH), 37.7 (CH), 40.9 (CH), 41.6 (CH2), 44.8 (CH2), 50.9 (CH3), 66.5 (CH), 72.4 
(CH), 76.8 (CH), 77.8 (CH), 79.2 (CH), 115.0 (CH), 117.2 (CH2), 127.3 (CH), 129.9 (CH), 131.4 
(CH), 132.3 (CH), 132.7 (CH), 135.4 (CH), 145.9 (CH), 147.1 (CH), 166.6 (C0); IR (neat): ν = 
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799, 1020, 1093, 1260, 1412, 1461, 1601, 1637, 1720, 2855, 2927, 2961, 3447; HRMS (ESI): 
calcd. for C57H112O7Si4Na: 1043.73773 [M + Na]+; found: 1043.73670. 
 
 
 
 
(2Z,4E,6R,7S,9R,10Z,12S,13R,14S,16S,19R,20R,21S,22S,23Z)-7,9,13,19-tetrakis(tert-
butyldimethylsilyloxy)-21-hydroxy-6,12,14,16,20,22-hexamethylhexacosa-2,4,10,23,25-
pentaenoic acid (4.63) 
To a stirred solution of the ester 4.62 (35.0 mg, 0.034 mmol, 1 eq) in THF (1.8 mL) and EtOH (4.1 
mL), 1 N aq. KOH (0.33 mL) was added, and the reaction was refluxed (bath temperature: 52 oC) 
for 5 h. The solvent was removed under reduced pressure. The residue was diluted with Et2O (26 
mL) and sat. aq. NH4Cl solution (8 mL); layers were separated and the aqueous layer was 
extracted with Et2O (3 x 15 mL). The combined organic extracts were dried over Na2SO4 and 
evaporated under reduced pressure. The product was purified by flash chromatography (90:10 
hexane/EtOAc) to afford the seco acid 4.63 (34.3 mg, 100% yield) as a colorless oil. 
Rf 0.26 (80:20 hexane/EtOAc); [α]32D = +3.4 (c = 0.2, CHCl3); 1H NMR (400 MHz, CDCl3): δ = 
0.03 (s, 6H), 0.04 (s, 3H), 0.05 (s, 3H), 0.06 (s, 3H), 0.07 (s, 6H), 0.08 (s, 3H), 0.82 (d, J = 7.0 Hz, 
3H), 0.85 (d, J = 6.9 Hz, 3H), 0.86 (d, J = 6.2 Hz, 3H), 0.88 (s, 9H), 0.89 (s, 9H), 0.89-0.92 (m, 
1H), 0.90 (s, 18H), 0.92 (d, J = 7.1 Hz, 3H), 0.96 (d, J = 6.8 Hz, 3H), 0.99-1.05 (m, 1H), 1.09 (d, J 
= 6.7 Hz, 3H), 1.22-1.46 (m, 5H), 1.60-1.66 (m, 3H), 1.73-1.76 (m, 1H), 2.43 (m, 1H), 2.56 (m, 
1H), 2.78 (m, 1H), 3.41 (m, 1H), 3.53 (dd, J = 2.7 Hz, 7.6 Hz, 1H), 3.75 (m, 1H), 3.91 (m, 1H), 
4.40 (br t, J = 8.6 Hz, 1H), 5.11 (d, J = 10.2 Hz, 1H), 5.19-5.27 (m, 2H), 5.38-5.48 (m, 2H), 5.57 
(d, J = 11.4 Hz, 1H), 6.10 (t, J = 11.0 Hz, 1H), 6.22 (dd, J = 9.0 Hz, 15.5 Hz, 1H), 6.58-6.67 (m, 
2H), 7.36 (dd, J = 11.4 Hz, 15.5 Hz, 1H); 13C NMR (100 MHz, CDCl3): δ = -4.8 (CH3), -4.7 
(CH3), -4.4 (CH3), -4.1 (CH3), -3.8 (CH3), -3.7 (CH3), -3.5 (CH3), 7.4 (CH3), 15.6 (CH3), 17.7 
(CH3), 18.0 (C0), 18.1 (C0), 18.5 (C0), 18.7 (CH3), 20.3 (CH3), 20.5 (CH3), 25.8 (CH3), 25.9 (CH3), 
26.0 (CH3), 26.2 (CH3), 30.7 (CH), 31.9 (CH2), 32.0 (CH2), 35.5 (CH), 36.2 (CH), 37.1 (CH), 38.1 
(CH), 41.0 (CH), 42.3 (CH2), 45.0 (CH2), 66.5 (CH), 72.4 (CH), 76.5 (CH), 77.3 (CH), 79.3 (CH), 
114.6 (CH), 117.8 (CH2), 127.4 (CH), 130.1 (CH), 131.5 (CH), 132.2 (CH), 132.7 (CH), 135.1 
(CH), 147.3 (CH), 147.9 (CH), 169.2 (C0); IR (neat): ν = 774, 836, 1005, 1027, 1081, 1255, 1377, 
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1461, 1600, 1636, 1686, 2855, 2927, 2955, 3417; HRMS (ESI): calcd. for C56H109O7Si4: 
1005.72559 [M – H]–; found: 1005.72635. 
 
 
 
 
(3Z,5E,7R,8S,10R,11Z,13S,14R,15S,17S,20R,21R,22S)-8,10,14,20-tetrakis(tert-
butyldimethylsilyloxy)-22-((S,Z)-hexa-3,5-dien-2-yl)-7,13,15,17,21-
pentamethyloxacyclodocosa-3,5,11-trien-2-one (4.64) 
To a solution of the seco acid 4.63 (18.0 mg, 0.018 mmol, 1 eq) in THF (2.2 mL) cooled to 0 °C, 
TEA (15 μL, 0.108 mmol, 6 eq) and 2,4,6-trichlorobenzoyl chloride (14 μL, 0.09 mmol, 5 eq) were 
added. The reaction was stirred at 0 oC for 1 h and monitored by TLC (90:10 hexane/EtOAc; Rf 
anhydride: 0.4) before being added to a 4-DMAP (22.0 mg, 0.18 mmol, 10 eq) solution in toluene 
(8.9 mL) at R.T.. The mixture was stirred at R.T. for 24 h (TLC: 97:3 hexane/EtOAc; Rf 
macrolactone: 0.31) and the solvent was removed under reduced pressure. The residue was diluted 
with Et2O (22 mL) and water (16 mL), layers were separated and the aqueous layer was extracted 
with Et2O (3 x 15 mL). The combined organic extracts were washed with brine (2 x 15 mL), dried 
over Na2SO4 and evaporated under reduced pressure. The crude product was purified by flash 
chromatography (90:10 hexane/DCM; Rf macrolactone: 0.13) to give macrolactone 4.64 (14.0 mg, 
80% yield) as a pale yellow oil. 
Rf 0.31 (97:3 hexane/EtOAc); [α]21D = -19.6 (c = 0.1, CHCl3); 1H NMR (400 MHz, CDCl3): δ = 
0.04 (s, 6H), 0.05 (s, 3H), 0.06 (s, 9H), 0.07 (s, 6H), 0.84-0.85 (m, 6H), 0.86-0.89 (m, 6H), 0.89-
0.90 (br s, 27H), 0.92 (s, 9H), 1.01 (d, J = 6.8 Hz, 3H), 1.10 (d, J = 7.0 Hz, 3H), 1.11 (m, 2H), 
1.15-1.32 (m, 4H), 1.38-1.55 (m, 3H), 1.62 (m, 1H), 1.78-1.86 (m, 1H), 2.41-2.47 (m, 1H), 2.47-
2.54 (m, 1H), 3.05 (m, 1H), 3.41 (d, J = 2.8 Hz, 1H), 3.56 (m, 1H), 3.94 (m, 1H), 4.41 (t, J = 8.8 
Hz, 1H), 5.12-5.28 (m, 4H), 5.43 (t, J = 10.4 Hz, 1H), 5.50-5.54 (m, 2H), 6.05 (t, J = 11.0 Hz, 1H), 
6.16 (dd, J = 9.1 Hz, 15.5 Hz, 1H), 6.53 (t, J = 11.5 Hz, 1H), 6.61 (dt, J = 10.6 Hz, 16.8 Hz, 1H), 
7.17 (dd, J = 11.2 Hz, 15.5 Hz, 1H); 13C NMR (100 MHz, CDCl3): δ = -5.0 (CH3), -4.8 (CH3), -4.4 
(CH3), -4.1 (CH3), -3.8 (CH3), -3.7 (CH3), -3.3 (CH3), 10.7 (CH3), 14.1 (CH3), 14.3 (CH3), 18.0 
(C0), 18.1 (CH3), 18.1 (C0), 18.7 (C0), 18.7 (CH3), 21.2 (CH3), 25.8 (CH3), 25.9 (CH3), 26.3 (CH3), 
29.5 (CH2), 29.7 (CH2), 30.2 (CH), 34.5 (CH), 37.9 (CH), 39.3 (CH), 40.0 (CH), 41.1 (CH), 43.8 
(CH2), 44.8 (CH2), 66.5 (CH), 72.4 (CH), 73.1 (CH), 77.3 (CH), 81.8 (CH), 116.7 (CH), 118.1 
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(CH2), 127.6 (CH), 130.0 (CH), 131.5 (CH), 132.1 (CH), 132.4 (CH), 133.4 (CH), 143.7 (CH), 
146.2 (CH), 166.4 (C0); IR (neat): ν = 662, 743, 799, 1020, 1260, 1413, 1462, 1637, 1709, 2854, 
2927, 2961; HRMS (ESI): calcd. for C56H108O6Si4Na: 1011.71152 [M + Na]+; found: 1011.71340. 
 
 
 
 
(+)-9-epi-Dictyostatin (4.65) 
To a solution of macrolactone 4.64 (10.0 mg, 10.2 mol, 1 eq) in THF (1.34 mL) kept at 0 °C in a 
plastic vial, HF-Py (0.34 mL) was added dropwise over 2 min, and the solution was allowed to 
slowly warm to R.T.. The reaction was stirred for 20 h, then it was cooled to 0 °C, diluted with 
EtOAc (7.0 mL) and quenched with a sat. aq. NaHCO3 solution (7.0 mL). The layers were 
separated and the aqueous layer was extracted with EtOAc (3 x 10 mL). The combined organic 
extracts were dried over Na2SO4 and evaporated under reduced pressure. The crude product was 
purified by flash chromatography (30:70 hexane/EtOAc) to give (+)-9-epi-dictyostatin 4.65 (3.8 
mg, 70% yield) as a white powder. 
Rf 0.54 (100% EtOAc); [α]31D = +43.4 (c = 0.17, CHCl3); 1H NMR (400 MHz, C6D6): 0.85 (d, J = 
6.7 Hz, 3H), 0.92 (d, J = 6.5 Hz, 3H), 0.93 (d, J = 6.5 Hz, 3H), 0.99 (d, J = 6.6 Hz, 6H), 1.03 (d, J 
= 7.0 Hz, 3H), 1.24-1.58 (m, 7H), 1.69-1.84 (m, 3H), 1.83-1.94 (m, 2H), 2.19-2.28 (m, 1H), 2.81-
2.96 (m, 2H), 3.18-3.22 (m, 1H), 3.26-3.35 (m, 1H), 3.41-3.53 (m, 2H), 3.90-3.96 (m, 1H), 4.21 
(br s, 1H), 4.60 (br s, 1H), 4.98-5.02 (m, 2H), 5.09 (t, J = 16.7 Hz, 1H), 5.27-5.38 (m, 2H), 5.44 
(dd, J = 11.6 Hz, 4.4 Hz, 1H), 5.56 (d, J = 11.3 Hz, 1H), 5.74 (dd, J = 15.8 Hz, 6.2 Hz, 1H), 5.98 
(t, J = 11.0 Hz, 1H), 6.25 (t, J = 11.3 Hz, 1H), 6.58 (dt, J = 16.7 Hz, 10.6 Hz, 1H), 7.89 (dd, J = 
15.7 Hz, 11.3 Hz, 1H); 13C NMR (100 MHz, C6D6): δ = 9.4 (CH3), 14.9 (CH3), 16.7 (CH3), 17.6 
(CH3), 18.5 (CH3), 21.9 (CH3), 30.3 (CH), 32.9 (CH2), 33.5 (CH2), 33.6 (CH), 35.1 (CH), 35.9 
(CH), 40.7 (CH), 41.6 (CH2), 41.7 (CH2), 42.2 (CH), 71.1 (CH), 73.8 (CH), 74.2 (CH), 76.6 (CH), 
77.7 (CH), 116.3 (CH), 118.0 (CH2), 127.5 (CH), 130.5 (CH), 132.5 (CH), 133.1 (CH), 133.8 
(CH), 133.9 (CH), 146.2 (CH), 146.9 (CH), 167.2 (C0); IR (neat): ν = 665, 740, 804, 1019, 1380, 
1415, 1460, 1602, 1637, 1685, 1709, 2927, 2961, 3380; HRMS (ESI): calcd. for C32H52O6Na: 
555.36561 [M + Na]+; found: 555.36537. 
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6.9 Synthesis of (Z)-Vinyl Iodide 12,13-bis-epi-C10-C26 
 
 
 
 
(3R,4S,5S,7S,10R,11R,12S,13S)-10,14-Bis-(tert-butyl-dimethyl-silanyloxy)-12-(4-methoxy-
benzyloxy)-3,5,7,11,13-pentamethyl-tetradec-1-yn-4-ol (5.4)  
Triphenylphosphine (re-crystallized from ethanol prior to use, 0.6 mg, 0.00225 mmol, 0.05 eq), the 
crude aldehyde 4.46 (28.0 mg, 0.045 mmol, 1 eq) and (S)-mesyl-butynol 5.3 (10.0 mg, 0.0675 
mmol, 1.5 eq) were sequentially added to a cooled (-78 °C) solution of Pd(OAc)2 (0.5 mg, 0.00225 
mmol, 0.05 eq) in THF (0.45 ml). Diethylzinc (1.0 M in hexane, 135 μl, 0.135 mmol, 3 eq) was 
added over 15 min. After 10 min, the temperature was raised to -20 °C, and the reaction mixture 
was stirred overnight at -20°C. The mixture was then quenched with NH4Cl/Et2O 1:1. The Et2O 
layer was washed with brine, dried and concentrated under reduced pressure. The residue was 
purified by flash chromatography (95:5 hexane/EtOAc) to afford the product 5.4 as a yellow oil 
(25.6 mg, 84% over two steps), with high diastereoselectivity (dr >95:5). 
Rf 0.39 (80:20 hexane/EtOAc); [α]23D= - 4.61 (c = 0.505, CHCl3); 1H NMR (400 MHz, C6D6): δ = 
0.20 (s, 6H), 0.26 (s, 6H), 1.00 (d, J = 6.4 Hz, 3H), 1.10 (d, J = 6.8 Hz, 3H), 1.15-1.03 (m, 1H), 
1.13 (s, 9H), 1.18 (s, 9H), 1.22 (d, J = 6.8 Hz, 3H), 1.26 (d, J = 6.8 Hz, 3H), 1.30 (d, J = 7.2 Hz, 
3H), 1.46-1.95 (m, 11H), 2.06-2.20 (m, 3H), 2.61-2.74 (m, 1H), 2.94-3.15 (m, 1H), 3.43 (s, 3H), 
3.79-4.00 (m, 4H), 4.79 (AB system, νA = 4.82, νB = 4.76, JAB = 11.2 Hz, 2H), 6.96 (d, J = 8.4 Hz, 
2H), 7.48 (d, J = 8.4 Hz, 2H); 13C NMR (100 MHz, C6D6): δ = -4.7, -3.6, -3.4, 11.1, 16.0, 17.3, 
18.8, 18.9, 21.9, 31.0, 31.5, 32.0, 32.1, 35.7, 39.9, 40.6, 40.8, 55.2, 65.6, 71.8, 74.6, 75.6, 79.6, 
81.4, 114.5, 129.5, 132.6, 160.0; IR (film): ν = 1255, 1301, 1360, 1386, 1462, 1470, 1514, 1613, 
1727, 2655, 2663, 2850, 2933, 2960, 3309; HRMS (ESI): calcd. for C39H72O5Si2Na: 699.48105 
[M+Na]+; found: 699.47937. 
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(5S,6S,8S,11R,12R,13S,14S)-5-((R)-but-3-yn-2-yl)-11-((tert-butyldimethylsilyl)oxy)-13-((4-
methoxybenzyl)oxy)-2,2,3,3,6,8,12,14,17,17,18,18-dodecamethyl-4,16-dioxa-3,17-
disilanonadecane (5.5) 
2,6-Lutidine (0.22 mL, 1.85 mmol, 5 eq) and TBSOTf (0.26 mL, 1.11 mmol, 3 eq) were added 
dropwise to a stirred solution of 5.4 (252 mg, 0.37 mmol, 1 eq) in DCM (9.3 mL) cooled at 0 oC. 
After stirring at 0 °C for 1.5 h, the reaction was quenched by adding sat. aq. NH4Cl solution (3.5 
mL) dropwise, then it was warmed to R.T.. Layers were separated and the aqueous phase was 
extracted with DCM (3 x 15 mL). The combined organic extracts were washed with brine (10 mL), 
dried over Na2SO4 and evaporated under reduced pressure. The crude product was purified by 
flash chromatography (98:2 hexane/EtOAc) to give the desired product 5.5 (231 mg, 79% yield) as 
a colorless oil. 
Rf 0.62 (85:15 hexane/EtOAc); [α]22D = -4.8 (c = 0.3, CHCl3); 1H NMR (400 MHz, C6D6): δ = 0.09 
(s, 6H), 0.11 (s, 3H), 0.12 (s, 3H), 0.14 (s, 3H), 0.15 (s, 3H),0.99 (d, J = 6.1 Hz, 3H), 1.01 (s, 9H), 
1.05 (s, 9H), 1.06 (s, 9H), 1.11 (d, J = 7.1 Hz, 3H), 1.13 (d, J = 7.1 Hz, 3H), 1.19 (d, J = 6.9 Hz, 
3H), 1.23 (d, J = 7.1 Hz, 3H), 1.28-1.35 (m, 2H), 1.50-1.58 (m, 2H), 1.59-1.70 (m, 2H), 1.79-1.86 
(m, 1H), 1.90 (d, J = 2.5 Hz, 1H), 2.02 (m, 3H), 2.65 (m, 1H), 3.31 (s, 3H), 3.42 (dd, J = 3.9 Hz, 
4.9 Hz, 1H), 3.69 (dd, J = 3.9 Hz, 6.9 Hz, 1H), 3.73 (dd, J = 3.4 Hz, 9.7 Hz, 1H), 3.81 (m, 1H), 
3.87 (m, 1H), 4.64 (d, JAB = 11.1 Hz, 1H, upfield part of an AB system), 4.71 (d, JAB = 11.1 Hz, 
1H, downfield part of an AB system), 6.84 (d, J = 8.6 Hz, 2H), 7.36 (d, J = 8.6 Hz, 2H); 13C NMR 
(100 MHz, CDCl3): δ = -5.3 (CH3), -5.2 (CH3), -4.3 (CH3), -4.1 (CH3), -4.0 (CH3), -3.9 (CH3), 
10.1 (CH3), 15.3 (CH3), 16.7 (CH3), 18.1 (C0), 18.2 (CH3), 18.3 (C0), 18.4 (C0), 20.9 (CH3), 25.9 
(CH3), 26.0 (CH3), 26.1 (CH3), 30.2 (CH), 30.5 (CH), 31.0 (CH2), 31.4 (CH2), 35.1 (CH), 38.8 
(CH), 39.7 (CH), 40.3 (CH2), 55.3 (CH3), 64.6 (CH2), 69.9 (CH), 73.9 (CH2), 74.3 (CH), 78.8 
(CH), 80.9 (CH), 87.3 (C0), 113.7 (CH), 128.9 (CH), 131.6 (C0), 158.9 (C0); IR (neat): ν = 625, 
669, 774, 836, 939, 1040, 1079, 1172, 1251, 1302, 1361, 1387, 1463, 1514, 1614, 2856, 2929; 
HRMS (ESI): calcd. for C45H86O5Si3Na: 813.56753 [M + Na]+; found: 813.56975. 
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(5S,6S,8S,11R,12R,13S,14S)-11-((tert-butyldimethylsilyl)oxy)-5-((R)-4-iodobut-3-yn-2-yl)-13-
((4-methoxybenzyl)oxy)-2,2,3,3,6,8,12,14,17,17,18,18-dodecamethyl-4,16-dioxa-3,17-
disilanonadecane (5.6) 
A solution of nBuLi in hexane (1.6 M, 0.22 mL, 0.35 mmol, 1.2 eq) was added dropwise over 5 
min to a solution of alkyne 5.5 (231 mg, 0.29 mmol, 1 eq) in THF (1.5 mL) at -50 °C. After 1 h, a 
solution of iodine (125 mg, 0.50 mmol, 1.7 eq) in THF (0.1 mL) was added. The mixture was 
stirred at -50 °C for 30 min, then warmed to R.T. over 30 min. After quenching by the addition of 
a sat. aq. Na2S2O3 solution (0.8 mL) and brine (0.8 mL), the mixture was extracted with EtOAc (3 
x 3 mL) and the combined organic layers were washed with brine (2 x 4 mL). The organic phase 
was dried over Na2SO4 and concentrated under reduced pressure. The crude product was purified 
by flash chromatography (95:5 hexane/EtOAc) to give the desired product 5.6 (268 mg, 100% 
yield) as a colorless oil.  
Rf 0.41 (95:5 hexane/EtOAc); [α]28D = -0.9 (c = 0.3, CHCl3); 1H NMR (400 MHz, CDCl3): δ = 
0.05 (s, 9H), 0.06 (s, 3H), 0.07 (s, 3H), 0.09 (s, 3H), 0.89 (d, J = 7.0 Hz, 3H), 0.92 (s, 9H), 0.92 (s, 
9H), 0.93 (s, 9H), 0.94 (d, J = 7.0 Hz, 3H), 0.95 (d, J = 7.0 Hz, 3H), 0.98 (d, J = 6.9 Hz, 3H), 1.17 
(d, J = 7.1 Hz, 3H), 1.28-1.33 (m, 3H), 1.35-1.44 (m, 3H), 1.58-1.62 (m, 1H), 1.73-1.82 (m, 2H), 
1.89 (m, 1H), 2.76 (m, 1H), 3.40 (t, J = 4.4 Hz, 1H), 3.48 (dd, J = 4.2 Hz, 6.9 Hz, 1H), 3.61-3.70 
(m, 3H), 3.80 (s, 3H), 4.48 (d, JAB = 10.9 Hz, 1H, upfield part of an AB system), 4.56 (d, JAB = 
10.9 Hz, 1H, downfield part of an AB system), 6.87 (d, J = 8.7 Hz, 2H), 7.26 (d, J = 8.6 Hz, 2H); 
13C NMR (100 MHz, CDCl3): δ = -5.4 (CH3), -5.3 (C0), -5.2 (CH3), -4.2 (CH3), -4.1 (CH3), -4.0 
(CH3), -3.9 (CH3), 10.1 (CH3), 15.3 (CH3), 16.7 (CH3), 18.1 (C0), 18.2 (CH3), 18.3 (C0), 18.3 (C0), 
20.8 (CH3), 25.9 (CH3), 26.0 (CH3), 26.1 (CH3), 30.5 (CH), 31.1 (CH2), 31.4 (CH2), 32.5 (CH), 
35.0 (CH), 38.9 (CH), 39.7 (CH), 39.9 (CH2), 55.3 (CH3), 64.7 (CH2), 73.9 (CH2), 74.4 (CH), 79.0 
(CH), 80.9 (CH), 97.6 (C0), 113.7 (CH), 128.9 (CH), 131.7 (C0), 158.9 (C0); IR (neat): ν = 670, 
773, 836, 1038, 1078, 1172, 1250, 1302, 1361, 1387, 1462, 1514, 1614, 1677, 2208, 2855, 2928, 
2954; HRMS (ESI+): calcd. for C45H85IO5Si3Na: 939.46417 [M + Na]+; found: 939.46313. 
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(5S,6S,8S,11R,12R,13S,14S)-11-((tert-butyldimethylsilyl)oxy)-5-((R,Z)-4-iodobut-3-en-2-yl)-
13-((4-methoxybenzyl)oxy)-2,2,3,3,6,8,12,14,17,17,18,18-dodecamethyl-4,16-dioxa-3,17-
disilanonadecane (5.7) 
A solution of iodoalkyne 5.6 (147 mg, 0.16 mmol, 1 eq) in THF (0.4 mL) and iPrOH (0.4 mL) at 
R.T. was treated with TEA (30 μL, 0.21 mmol, 1.3 eq) and NBSH (38.0 mg, 0.18 mmol, 1.1 eq). 
After 12 h, additional TEA (10 μL, 0.10 mmol, 0.6 eq) and NBSH (17.0 mg, 0.08 mmol, 0.5 eq) 
were added, and the mixture was stirred for 12 hours. The reaction was quenched by adding water 
(1.0 mL), and the mixture was extracted with EtOAc (3 x 3 mL). The combined organic layers 
were washed with brine (2 x 3 mL), dried over Na2SO4 and concentrated under reduced pressure. 
The crude product was purified by flash chromatography (95:5 hexane/EtOAc) to give the desired 
product 5.7 (147 mg, 100% yield) as a colorless oil. 
Rf 0.85 (80:20 hexane/EtOAc); [α]24D = -14.3 (c = 0.2, CHCl3); 1H NMR (400 MHz, CDCl3): δ = 
0.04 (s, 6H), 0.05 (s, 3H), 0.06 (s, 3H), 0.07 (s, 3H), 0.08 (s, 3H), 0.81 (d, J = 6.9 Hz, 3H), 0.90 (d, 
J = 7.1 Hz, 3H), 0.91 (s, 12H), 0.92 (s, 9H), 0.93 (s, 9H), 0.97 (d, J = 6.8 Hz, 3H), 0.98 (d, J = 6.8 
Hz, 3H), 0.99-1.02 (m, 1H), 1.22-1.32 (m, 2H), 1.36-1.49 (m, 3H), 1.58-1.62 (m, 1H), 1.66-1.73 
(m, 1H), 1.78 (m, 1H), 1.88 (m, 1H), 2.68 (m, 1H), 3.46 (dd, J = 4.1 Hz, 6.9 Hz, 1H), 3.49 (dd, J = 
1.8 Hz, 5.1 Hz, 1H), 3.62-3.69 (m, 3H), 3.80 (s, 3H), 4.47 (d, JAB = 10.9 Hz, 1H, upfield part of an 
AB system), 4.55 (d, JAB = 10.9 Hz, 1H, downfield part of an AB system), 6.06 (d, J = 7.3 Hz, 
1H), 6.38 (dd, J = 7.3 Hz, 8.8 Hz, 1H), 6.86 (d, J = 8.7 Hz, 2H), 7.25 (d, J = 8.6 Hz, 2H); 13C NMR 
(100 MHz, CDCl3): δ = -5.3 (CH3), -5.2 (CH3), -4.2 (CH3), -3.9 (CH3), -3.7 (CH3), 10.2 (CH3), 
15.3 (CH3), 15.5 (CH3), 18.2 (C0), 18.3 (C0), 18.8 (CH3), 20.6 (CH3), 26.8 (CH3), 29.7 (CH2), 30.5 
(CH), 31.5 (CH2), 36.5 (CH), 39.0 (CH), 39.8 (CH), 41.2 (CH2), 41.6 (CH), 55.3 (CH3), 64.7 
(CH2), 74.0 (CH2), 74.3 (CH), 79.0 (CH), 80.4 (CH), 81.0 (CH), 113.7 (CH), 128.9 (CH), 131.7 
(C0), 144.2 (CH), 159.0 (C0); IR (neat): ν = 773, 836, 1038, 1078, 1171, 1249, 1301, 1360, 1387, 
1461, 1514, 1614, 1677, 2855, 2928, 2954; HRMS (ESI): calcd. for C45H87IO5Si3Na: 941.47982 
[M + Na]+; found: 941.47890. 
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(2S,3S,4R,5R,8S,10S,11S,12R,Z)-5,11-bis((tert-butyldimethylsilyl)oxy)-14-iodo-3-((4-
methoxybenzyl)oxy)-2,4,8,10,12-pentamethyltetradec-13-en-1-ol (5.8) 
A solution of compound 5.7 (147 mg, 0.16 mmol, 1 eq) in THF (0.8 mL) at 0 °C was treated with a 
solution of HF-Py in THF/pyridine [3.6 mL, prepared by slow addition of commercially available 
70% HF in pyridine (0.31 mL) to a mixture of pyridine (1.1 mL) and THF (2.2 mL)]. The reaction 
mixture was warmed to R.T. and stirred for 4 hours. After quenching the reaction by the addition 
of sat. aq. NaHCO3 solution (6 mL), the mixture was extracted with EtOAc (4 x 10 mL). The 
combined organic extracts were washed with sat. aq. CuSO4 solution (3 x 10 mL) and brine (2 x 10 
mL), dried over Na2SO4 and concentrated under reduced pressure. The crude product was purified 
by flash chromatography (90:10 hexane/EtOAc) to give the desired product 5.8 (102 mg, 80% 
yield) as a colorless oil. 
Rf 0.29 (80:20 hexane/EtOAc); [α]25D = -9.0 (c = 0.2, CHCl3); 1H NMR (400 MHz, CDCl3): δ = 
0.05 (s, 3H), 0.06 (s, 3H), 0.07 (s, 3H), 0.08 (s, 3H), 0.82 (d, J = 6.9 Hz, 3H), 0.89 (d, J = 6.8 Hz, 
3H), 0.91 (s, 9H), 0.92 (s, 9H), 0.98 (d, J = 7.1 Hz, 3H), 1.01 (d, J = 6.9 Hz, 3H), 1.11 (d, J = 7.0 
Hz, 3H), 1.20-1.70 (m, 8H), 1.88 (m, 1H), 1.95 (m, 1H), 2.68 (m, 1H), 3.44-3.49 (m, 2H), 3.56-
3.64 (m, 2H), 3.78-3.82 (m, 1H), 3.80 (s, 3H), 4.53 (s, 2H), 6.06 (d, J = 7.3 Hz, 1H), 6.38 (dd, J = 
7.4 Hz, 8.8 Hz, 1H), 6.87 (d, J = 8.6 Hz, 2H), 7.26 (d, J = 8.6 Hz, 2H); 13C NMR (100 MHz, 
CDCl3): δ = -4.4 (CH3), -4.2 (CH3), -3.8 (CH3), -3.7 (CH3), 10.1 (CH3), 15.5 (CH3), 15.8 (CH3), 
18.2 (C0), 18.3 (C0), 18.8 (CH3), 20.5 (CH3), 26.0 (CH3), 26.1 (CH3), 30.5 (CH), 31.8 (CH2), 31.9 
(CH2), 36.6 (CH), 37.0 (CH), 40.7 (CH), 41.1 (CH2), 41.6 (CH), 55.3 (CH3), 65.2 (CH2), 73.8 
(CH), 75.2 (CH2), 79.0 (CH), 80.4 (CH), 85.9 (CH), 113.9 (CH), 129.3 (CH), 130.6 (C0), 144.2 
(CH), 159.3 (C0); IR (neat): ν = 772, 806, 835, 1037, 1077, 1251, 1302, 1378, 1462, 1514, 1612, 
2852, 2925, 2955, 3447; HRMS (ESI): calcd. for C39H73IO5Si2Na [M + Na]+: 827.39334; found: 
827.39306. 
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(2R,3R,4R,5R,8S,10S,11S,12R,Z)-5,11-bis((tert-butyldimethylsilyl)oxy)-14-iodo-3-((4-
methoxybenzyl)oxy)-2,4,8,10,12-pentamethyltetradec-13-enal (5.9) 
A solution of alcohol 5.8 (91 mg, 0.11 mmol 1 eq) in DCM (0.6 mL) was treated at 0 °C with 
pyridine (23 μL, 0.28 mmol, 2.5 eq) and DMP (58 mg, 0.14 mmol, 1.2 eq). The reaction mixture 
was warmed to R.T. and stirred for 1 h. After completion of the reaction, sat. aq. NaHCO3 solution 
(2.0 mL) and Na2S2O3 (205 mg, 0.82 mmol) were added. The obtained mixture was stirred for 30 
min, then the phases were separated and the aqueous phase was extracted with Et2O (3 x 4 mL). 
The combined organic extracts were washed with brine (2 x 5 mL), dried (Na2SO4) and evaporated 
under reduced pressure, providing the crude aldehyde 5.9, which was used without further 
purification. 
Rf 0.60 (80:20 hexane/EtOAc); 1H NMR (400 MHz, CDCl3): δ = 0.04 (s, 3H), 0.05 (s, 3H), 0.06 (s, 
3H), 0.07 (s, 3H), 0.82 (d, J = 6.9 Hz, 3H), 0.88 (d, J = 6.4 Hz, 3H), 0.90 (s, 9H), 0.92 (s, 9H), 
0.98 (d, J = 7.0 Hz, 3H), 1.00 (d, J = 6.9 Hz, 3H), 1.15 (d, J = 7.0 Hz, 3H), 1.27-1.36 (m, 3H), 
1.38-1.43 (m, 2H), 1.53-1.69 (m, 3H), 1.87 (m, 1H), 2.67 (m, 1H), 2.78 (m, 1H), 3.48 (dd, J = 1.9 
Hz, J = 5.1 Hz 1H), 3.67 (m, 2H), 3.80 (s, 3H), 4.49 (s, 2H), 6.06 (d, J = 7.3 Hz, 1H), 6.37 (dd, J = 
7.3 Hz, 8.8 Hz, 1H), 6.86 (d, J = 8.7 Hz, 2H), 7.23 (d, J = 8.6 Hz, 2H), 9.80 (d, J = 2.3 Hz, 1H). 
 
 
 
 
(5S,6S,8S,11R)-5-((R,Z)-4-iodobut-3-en-2-yl)-11-((2R,3S,4S,Z)-3-((4-methoxybenzyl)oxy)-4-
methylocta-5,7-dien-2-yl)-2,2,3,3,6,8,13,13,14,14-decamethyl-4,12-dioxa-3,13-
disilapentadecane (5.2) 
To a slurry of CrCl2 (69 mg, 0.57 mmol, 5 eq) in THF (1.1 mL), obtained by sonication and cooled 
to 0°C, freshly-prepared aldehyde 5.9 (0.11 mmol, 1 eq) in THF (0.4 mL) and (1-
bromoallyl)trimethylsilane 4.58 (122 mg, 0.63 mmol, 5.6 eq) were added. The resulting mixture 
was stirred for 3 h at R.T. before being re-cooled to 0°C and quenched by the addition of MeOH 
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(0.5 mL) and 6 N aq. KOH (1.0 mL). After stirring for 20 h at R.T., the phases were separated and 
the aqueous layer was extracted with DCM (4 x 5 mL). The combined organic extracts were 
washed with brine (2 x 10 mL), dried over Na2SO4 and concentrated under reduced pressure. The 
crude product was purified by flash chromatography (100:0.5 hexane/EtOAc) to give the desired 
product 5.2 (86 mg, 92% yield over two steps) as a colorless oil. 
Rf 0.50 (95:5 hexane/EtOAc); [α]22D = -0.6 (c = 0.3, CHCl3); 1H NMR (400 MHz, CDCl3): δ = 
0.05 (s, 3H), 0.06 (s, 3H), 0.07 (s, 3H), 0.08 (s, 3H), 0.79 (d, J = 6.9 Hz, 3H), 0.84 (d, J = 6.3 Hz, 
3H), 0.85-0.97 (m, 2H), 0.92 (s, 9H), 0.93 (s, 9H), 0.95 (d, J = 7.4 Hz, 3H), 0.97 (d, J = 7.3 Hz, 
3H), 1.10 (d, J = 6.9 Hz, 3H), 1.18-1.37 (m, 4H), 1.48-1.54 (m, 1H), 1.57-1.67 (m, 2H), 2.67 (m, 
1H), 2.98 (m, 1H), 3.33 (dd, J = 3.3 Hz, 7.8 Hz, 1H), 3.46 (dd, J = 1.9 Hz, 5.1 Hz, 1H), 3.61 (m, 
1H), 3.80 (s, 3H), 4.49 (d, JAB = 10.6 Hz, 1H, upfield part of an AB system), 4.56 (d, JAB = 10.6 
Hz, 1H, downfield part of an AB system), 5.10 (d, J = 10.1 Hz, 1H), 5.18 (dd, J = 1.8 Hz, 16.8 Hz, 
1H), 5.58 (t, J = 10.6 Hz, 1H), 6.01 (t, J = 11.1 Hz, 1H), 6.06 (d, J = 7.3 Hz, 1H), 6.37 (dd, J = 7.3 
Hz, 8.8 Hz, 1H), 6.58 (td, J = 10.7 Hz, 16.8 Hz, 1H), 6.87 (d, J = 8.7 Hz, 2H), 7.28 (d, J = 8.7 Hz, 
2H); 13C NMR (100 MHz, CDCl3): δ = -4.4 (CH3), -4.2 (CH3), -3.7 (CH3), -3.5 (CH3), 9.3 (CH3), 
15.5 (CH3), 18.2 (C0), 18.3 (C0), 18.7 (CH3), 18.8 (CH3), 20.5 (CH3), 26.0 (CH3), 26.1 (CH3), 30.2 
(CH), 31.6 (CH2), 32.2 (CH2), 35.3 (CH), 36.4 (CH), 40.6 (CH), 41.1 (CH2), 41.6 (CH), 55.3 
(CH3), 72.8 (CH), 75.0 (CH2), 79.1 (CH), 80.4 (CH), 84.4 (CH), 113.7 (CH), 117.2 (CH2), 128.9 
(CH), 129.1 (CH), 131.4 (C0), 132.4 (CH), 134.6 (CH), 144.2 (CH), 159.0 (C0); IR (neat): ν = 772, 
804, 835, 868, 1039, 1179, 1257, 1361, 1377, 1462, 1514, 1613, 2854, 2925, 2956; HRMS (ESI): 
calcd. for C42H75IO4Si2Na: 849.41408 [M + Na]+; found: 849.41270. 
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6.10 Synthesis of 12,13-bis-epi-Dictyostatin Precursors 
 
 
 
 
(2Z,4E,6R,7S,9R,10Z,12R,13S,14S,16S,19R,20R,21S,22S,23Z)-methyl 7,13,19-tris((tert-
butyldimethylsilyl)oxy)-9-hydroxy-21-((4-methoxybenzyl)oxy)-6,12,14,16,20,22-
hexamethylhexacosa-2,4,10,23,25-pentaenoate (5.10) 
To a solution of tBuLi in pentane (1.7 M, 0.15 mL, 0.23 mmol, 2.2 eq) in Et2O (0.2 mL) kept at -
78 °C under argon atmosphere, a solution of vinyl iodide 5.2 (86 mg, 0.104 mmol, 1 eq) in Et2O 
(0.4 mL) was added. After stirring for 30 min, dimethylzinc in toluene (2.0 M, 0.08 mL, 0.17 
mmol, 1.6 eq) was added dropwise and the reaction mixture was further stirred at -78 oC for 15 
min. A solution of aldehyde 4.2 (51 mg, 0.16 mmol, 1.5 eq), azeotropically dried with toluene, in 
Et2O (0.5 mL) was added dropwise, and the mixture was stirred for 1 h at -78 oC. The reaction was 
quenched with water (2.0 mL), warmed to R.T. and diluted with Et2O (3.0 mL). Phases were 
separated and the aqueous layer was extracted with Et2O (3 x 5 mL). The combined organic 
extracts were washed with brine (2 x 5 mL), dried over Na2SO4 and concentrated under reduced 
pressere. The crude product was purified by flash chromatography (10:0.3 hexane/EtOAc) to give 
the desired (Z)-allylic alcohol 5.10 (42 mg, 40% yield) as a light yellow oil. 
Rf 0.41 (8:2 hexane/EtOAc); [α]29D = -10.6 (c = 0.2, CHCl3); 1H NMR (400 MHz, CDCl3): δ = 0.04 
(s, 6H), 0.07 (s, 3H), 0.08 (s, 6H), 0.13 (s, 3H), 0.72-0.78 (m, 1H), 0.83 (d, J = 6.4 Hz, 3H), 0.84 
(d, J = 6.9 Hz, 3H), 0.88-0.91 (m, 5H), 0.90 (s, 9H), 0.91 (s, 9H), 0.92 (s, 9H), 0.95 (d, J = 6.8 Hz, 
3H), 1.07 (d, J = 6.9 Hz, 3H), 1.10 (d, J = 6.9 Hz, 3H), 1.17-1.41 (m, 6H), 1.45-1.55 (m, 1H), 
1.61-1.68 (m, 1H), 2.01 (br s, 1H), 2.55 (m, 1H), 2.69 (m, 1H), 2.98 (m, 1H), 3.30-3.34 (m, 2H), 
3.61 (m, 1H), 3.72 (s, 3H), 3.80 (s, 3H), 3.95 (m, 1H), 4.49 (d, JAB = 10.6 Hz, 1H, upfield part of 
an AB system), 4.54-4.59 (m, 1H), 4.55 (d, JAB = 10.8 Hz, 1H, downfield part of an AB system), 
5.09 (d, J = 10.1 Hz, 1H), 5.17 (dd, J = 1.7 Hz, 16.8 Hz, 1H), 5.33 (dd, J = 8.8 Hz, 10.8 Hz, 1H), 
5.51-5.58 (m, 2H), 5.59 (d, J = 11.5 Hz, 1H), 5.96-6.06 (m, 2H), 6.53-6.62 (m, 2H), 6.86 (d, J = 
8.7 Hz, 2H), 7.28 (d, J = 8.8 Hz, 2H), 7.37 (dd, J = 11.3 Hz, 15.4 Hz, 1H); 13C NMR (100 MHz, 
CDCl3): δ = -4.5 (CH3), -4.4 (CH3), -4.3 (CH3), -3.7 (CH3), -3.6 (CH3), -3.5 (CH3), 9.3 (CH3), 14.5 
(CH3), 16.0 (CH3), 18.1 (C0), 18.2 (C0), 18.4 (C0), 18.8 (CH3), 20.1 (CH3), 20.8 (CH3), 25.9 (CH3), 
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26.0 (CH3), 26.2 (CH3), 30.3 (CH), 31.0 (CH2), 32.2 (CH2), 35.0 (CH), 35.2 (CH), 35.7 (CH), 40.4 
(CH2), 40.6 (CH), 41.0 (CH2), 43.1 (CH), 51.0 (CH3), 55.3 (CH3), 64.2 (CH), 72.3 (CH), 72.8 
(CH), 75.0 (CH2), 80.5 (CH), 84.4 (CH), 113.7 (CH), 115.6 (CH), 117.2 (CH2), 126.8 (CH), 128.9 
(CH), 129.1 (CH), 131.4 (CH), 131.4 (C0), 132.4 (CH), 134.6 (CH), 135.0 (CH), 145.5 (CH), 
147.2 (CH), 159.0 (C0), 166.9 (C0); IR (neat): ν = 773, 806, 836, 1039, 1080, 1174, 1252, 1377, 
1462, 1514, 1602, 1638, 1721, 2855, 2926, 2955, 3427; HRMS (ESI): calcd. for C59H106O8Si3Na: 
1049.70877 [M + Na]+; found: 1049.70714. 
 
 
 
 
(2Z,4E,6R,7S,9R,10Z,12R,13S,14S,16S,19R,20R,21S,22S,23Z)-methyl 7,9,13,19-tetrakis((tert-
butyldimethylsilyl)oxy)-21-((4-methoxybenzyl)oxy)-6,12,14,16,20,22-hexamethylhexacosa-
2,4,10,23,25-pentaenoate (5.11) 
2,6-Lutidine (3 μL, 28 μmol, 4 eq) and TBSOTf (3 μL, 14 μmol, 2 eq) were added dropwise to a 
stirred solution of 5.10 (7.2 mg, 7 μmol, 1 eq) in DCM (0.2 mL) cooled at -78 oC. After stirring at -
78 °C for 1 h, the reaction was quenched by adding sat. aq. NaHCO3 solution (1.0 mL) dropwise, 
then it was warmed to R.T.. The mixture was diluted with DCM (5 mL), layers were separated and 
the aqueous phase was extracted with DCM (3 x 5 mL). The combined organic extracts were 
washed with brine (2 x 5 mL), dried over Na2SO4 and evaporated under reduced pressure. The 
crude product was purified by flash chromatography (95:5 hexane/EtOAc) to give the desired 
product 5.11 (8.0 mg, 100% yield) as a pale yellow oil. 
Rf 0.80 (80:20 hexane/EtOAc); [α]29D = -14.7 (c = 0.4, CHCl3); 1H NMR (400 MHz, CDCl3): δ = 
0.02 (s, 3H), 0.04 (s, 6H), 0.07 (s, 6H), 0.08 (s, 6H), 0.10 (s, 3H), 0.83 (d, J = 6.8 Hz, 6H), 0.82-
0.95 (m, 8H), 0.84 (s, 9H), 0.90 (s, 9H), 0.91 (s, 9H), 0.92 (s, 9H), 1.04 (d, J = 6.8 Hz, 3H), 1.10 
(d, J = 6.9 Hz, 3H), 1.20-1.39 (m, 5H), 1.47-1.55 (m, 2H), 1.59-1.67 (m, 2H), 2.53 (m, 1H), 2.62 
(m, 1H), 2.97 (m, 1H), 3.31-3.35 (m, 2H), 3.61 (m, 1H), 3.72 (s, 3H), 3.80 (s, 3H), 3.92 (m, 1H), 
4.49-4.57 (m, 1H), 4.50 (d, JAB = 10.6 Hz, 1H, upfield part of an AB system), 4.54 (d, JAB = 10.6 
Hz, 1H, downfield part of an AB system), 5.09 (d, J = 10.6 Hz, 1H), 5.17 (d, J = 16.8 Hz, 1H), 
5.26 (dd, J = 9.3 Hz, 10.9 Hz, 1H), 5.55-5.62 (m, 2H), 5.59 (d, J = 11.1 Hz, 1H), 5.97-6.02 (m, 
2H), 6.52-6.62 (m, 2H), 6.86 (d, J = 8.6 Hz, 2H), 7.27 (d, J = 8.8 Hz, 2H), 7.36 (dd, J = 11.3 Hz, 
15.5 Hz, 1H); 13C NMR (100 MHz, CDCl3): δ = -4.5 (CH3), -4.3 (CH3), -4.2 (CH3), -4.1 (CH3), -
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4.0 (CH3), -3.7 (CH3), -3.5 (CH3), -2.9 (CH3), 9.2 (CH3), 13.5 (CH3), 16.7 (CH3), 18.1 (C0), 18.2 
(C0), 18.4 (C0), 18.9 (CH3), 20.9 (CH3), 20.6 (CH3), 25.8 (CH3), 25.9 (CH3), 26.0 (CH3), 26.2 
(CH3), 29.7 (CH2), 30.1 (CH), 31.6 (CH2), 34.3 (CH), 35.1 (CH), 36.1 (CH), 40.5 (CH), 41.0 
(CH2), 43.4 (CH2), 43.5 (CH), 51.0 (CH3), 55.3 (CH3), 66.7 (CH), 72.2 (CH), 72.7 (CH), 75.1 
(CH2), 80.3 (CH), 84.4 (CH), 113.6 (CH), 115.4 (CH), 117.2 (CH2), 126.8 (CH), 128.9 (CH), 
129.0 (CH), 131.3 (CH), 131.4 (C0), 132.3 (CH), 132.4 (CH), 134.5 (CH), 145.6 (CH), 147.3 
(CH), 158.9 (C0), 166.9 (C0); IR (neat): ν = 773, 802, 836, 1005, 1040, 1082, 1174, 1251, 1462, 
1514, 1602, 1638, 1721, 2855, 2927, 2955; HRMS (ESI): calcd. for C65H120O8Si4Na: 1163.79525 
[M + Na]+; found: 1163.79475. 
 
 
 
 
(2Z,4E,6R,7S,9R,10Z,12R,13S,14S,16S,19R,20R,21S,22S,23Z)-methyl 7,9,13,19-tetrakis((tert-
butyldimethylsilyl)oxy)-21-hydroxy-6,12,14,16,20,22-hexamethylhexacosa-2,4,10,23,25-
pentaenoate (5.12) 
DDQ (2.1 mg, 9 μmol, 1.3 eq) was added to a solution of the PMB ether 5.11 (8.0 mg, 7 μmol, 1 
eq) in DCM (0.3 mL) stirred at 0 °C in the presence of a KH2PO4/K2HPO4 buffer solution at pH 7 
(25 μL) The reaction was stirred at 0 oC for 1 h before being quenched by dropwise addition of sat. 
aq. NaHCO3 solution (3 mL). After diluting with DCM (7 mL), layers were separated and the 
aqueous phase was extracted with DCM (3 x 10 mL). The combined organic extracts were washed 
with brine (2 x 10 mL), dried over Na2SO4 and concentrated under reduced pressure. The crude 
product was purified by flash chromatography (60:40 hexane/DCM) to give the desired product 
5.12 (6.1 mg, 85% yield) as a colorless oil. 
Rf  0.30 (95:5 hexane/EtOAc); 1H NMR (400 MHz, CDCl3): δ = 0.02 (s, 3H), 0.05 (s, 9H), 0.07 (s, 
3H), 0.09 (s, 6H), 0.11 (s, 3H), 0.87-0.94 (m, 11H), 0.89 (s, 9H), 0.90 (s, 9H), 0.91 (s, 9H), 0.92 (s, 
9H), 0.95 (d, J = 6.7 Hz, 6H), 1.04 (d, J = 6.8 Hz, 3H), 1.25-1.34 (m, 3H), 1.38-1.44 (m, 2H), 
1.50-1.71 (m, 4H), 2.35 (br s, 1H), 2.53 (m, 1H), 2.63 (m, 1H), 2.80 (m, 1H), 3.35 (m, 1H), 3.48 
(dd, J = 2.2 Hz, 7.6 Hz, 1H), 3.73 (s, 3H), 3.74-3.78 (m, 1H), 3.93 (m, 1H), 4.54 (t, J = 8.8 Hz, 
1H), 5.12 (d, J = 10.3 Hz, 1H), 5.21 (d, J = 16.9 Hz, 1H), 5.22-5.28 (m, 1H), 5.42 (t, J = 10.5 Hz, 
1H), 5.56-5.63 (m, 1H), 5.59 (d, J = 11.0 Hz, 1H), 5.99 (dd, J = 7.1 Hz, 15.5 Hz, 1H), 6.09 (t, J = 
11.1 Hz, 1H), 6.55 (t, J = 11.4 Hz, 1H), 6.63 (td, J = 10.8 Hz, 17.1 Hz, 1H), 7.36 (dd, J = 11.3 Hz, 
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15.4 Hz, 1H); 13C NMR (100 MHz, CDCl3): δ = -4.4 (CH3), -4.2 (CH3), -4.1 (CH3), -4.0 (CH3), -
3.8 (CH3), -3.6 (CH3), -2.9 (CH3), 6.7 (CH3), 14.1 (CH3), 15.6 (CH3), 17.7 (CH3), 18.0 (C0), 18.1 
(C0), 18.3 (C0), 20.7 (CH3), 20.9 (CH3), 25.8 (CH3), 25.9 (CH3), 26.0 (CH3), 26.1 (CH3), 30.2 
(CH), 30.9 (CH2), 31.6 (CH2), 34.2 (CH), 36.0 (CH), 36.2 (CH), 37.5 (CH), 41.1 (CH2), 43.4 
(CH2), 43.5 (CH), 51.0 (CH3), 66.7 (CH), 72.2 (CH), 77.3 (CH), 77.9 (CH), 80.2 (CH), 115.4 
(CH), 117.7 (CH2), 126.8 (CH), 129.8 (CH), 131.2 (CH), 132.3 (CH), 132.5 (CH), 135.4 (CH), 
145.6 (CH), 147.3 (CH), 166.9 (C0); HRMS (ESI): calcd. for C57H112O7Si4Na: 1043.73773 [M + 
Na]+; found: 1043.73677. 
 
 
 
 
(2Z,4E,6R,7S,9R,10Z,12R,13S,14S,16S,19R,20R,21S,22S,23Z)-7,9,13,19-tetrakis((tert-
butyldimethylsilyl)oxy)-21-hydroxy-6,12,14,16,20,22-hexamethylhexacosa-2,4,10,23,25-
pentaenoic acid (5.13) 
To a stirred solution of the ester 5.12 (6.1 mg, 9 μmol, 1 eq) in THF (0.2 mL) and EtOH (0.5 mL), 
1 N aq. KOH (40 μL) was added, and the reaction was refluxed for 6 h (bath temperature: 52 °C). 
The solvent was removed under reduced pressure. The residue was diluted with Et2O (2 mL) and 
sat. aq. NH4Cl solution  (1 mL); layers were separated and the aqueous layer was extracted with 
Et2O (3 x 5 mL). The combined organic extracts were dried over Na2SO4 and evaporated under 
reduced pressure. The product was purified by flash chromatography (90:10 hexane/EtOAc) to 
afford the seco acid 5.13 (6.0 mg, 100% yield) as a colorless oil. 
Rf 0.27 (80:20 hexane/EtOAc); 1H NMR (400 MHz, CDCl3): δ = 0.02 (s, 3H), 0.05 (s, 6H), 0.07 (s, 
6H), 0.08 (s, 6H), 0.11 (s, 3H), 0.85 (s, 9H), 0.86-0.92 (m, 14H), 0.88 (s, 9H), 0.91 (s, 9H), 0.92 (s, 
9H), 0.95 (d, J = 6.8 Hz, 3H), 1.04 (d, J = 6.8 Hz, 3H), 1.23-1.34 (m, 5H), 1.40-1.43 (m, 1H), 
1.50-1.73 (m, 3H), 2.52 (m, 1H), 2.62 (m, 1H), 2.80 (m, 1H), 3.35 (m, 1H), 3.48 (m, 1H), 3.76 (m, 
1H), 3.90 (m, 1H), 4.52 (t, J = 8.8 Hz, 1H), 5.12 (d, J = 10.3 Hz, 1H), 5.19-5.28 (m, 2H), 5.42 (t, J 
= 10.3 Hz, 1H), 5.60 (m, 2H), 6.02-6.12 (m, 2H), 6.59-6.68 (m, 2H), 7.33 (dd, J = 11.5 Hz, 15.4 
Hz, 1H). 
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Appendix B 
 
 
 
Compound Numbering 
 
For the most part, accepted naming and numbering priorities (IUPAC) are used throughout this 
dissertation. The numbering system used for dictyostatin by Pettit and co-workers1 has been 
adopted for dictyostatin and respective analog/hybrids of the same compound. 
 
 
 
 
Nomenclature 
 
The syn and anti convention introduced by Masamune,2 for assigning the relative 
stereochemistry of vicinal stereocenters is used in this dissertation. A syn relationship refers to the 
two substituents both pointing into or out of a plane defined by the main chain drawn in a zig-zag 
conformation. Conversely, an anti relationship refers to the two substituent on opposite sides of the 
plane. The two diastereoisomers A and B are thus referred to as syn and anti respectively. 
 
 
 
The Cahn-Ingold-Prelog priority rules, CIP system or CIP conventions3 for assigning the 
configuration of each stereocenter (R or S descriptor) and each double bond (E or Z descriptor) are 
used in this dissertation.  
 
                                                 
 
1 Pettit, G. R.; Cichacz, Z. A.; Gao, F.; Boyd, M. R.; Schmidt, J. M. J. Chem. Soc. Chem. Commun. 1994, 1111. 
2 Masamune, S.; Ali, S.; Snitman, D. L.; Garvey, D. S.; Angew. Chem. Int. Ed. 1980, 19, 557. 
3 Chan, R. S.; Ingold, C. K.; Prelog, V. Angew. Chem. Int. Ed. 1966, 5, 385. 
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Appendix C 
 
 
List of Abbreviations 
 
 
1A9 Ovarian cancer cell line 
1A9/Ptx10 Ovarian cancer Taxol®-resistant cell line 
1A9/Ptx22 Ovarian cancer Taxol®-resistant cell line 
2,6-lut 2,6-Lutidine 
Ac Acetyl 
ACS American Cancer Society 
aq. Aqueous 
AsPC-1 Pancreatic cancer cell line 
Bn Benzyl 
Bu Butyl 
CAN Ceric ammonium nitrate 
CBS Corey-Bakshi-Shibata oxazaborolidine 
CCNS Cellular Cycle Nonspecific  
CCS Cellular Cycle Specific  
CM Cross-metathesis 
CSA Camphorsulfonic acid 
Cy Cyclohexyl 
DBU 1,8-diazabicyclo[5.4.0]undec-7-ene 
DCM Dichloromethane 
DDQ 2,3-Dichloro-5,6-dicyano-p-benzoquinone 
DIBAL-H Diisobutylaluminum hydride 
DIPA Diisopropylamine 
DIPEA Diisopropylethylamine 
DLD-1 Colon cancer cell line 
DMAP 4-Dimethylamino pyridine 
DMP Dess Martin Periodinane 
DMPU 1,3-Dimethyltetrahydropyrimidin-2(1H)-one 
DMSO Dimethylsulfoxide 
dr Diastereoisomeric ratio 
EDC 1-(3-dimethylaminopropyl)-3-ethyl carbodiimide hydrochloride 
Epo Epothilone 
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ESI Electrospray ionization 
Et Ethyl 
FDA Food and Drug Administration (US) 
GTP Guanosine 5’-triphosphate 
h hour 
HMRS  High resolution mass spectrometry 
HPLC High Performance Liquid Chromatography 
HT29 Colon cancer cell line 
HWE Horner-Wadsworth-Emmons 
IC50 Mean inhibitory concentration 
Imid Imidazole 
iPr Isopropyl 
IR Infra-red 
KHMDS Potassium hexamethyldisilazide 
LDA Lithium diisopropylamide 
MAP Microtubule Associated Protein 
MDR Multiple Drug Resistance 
Me Methyl 
Mes Mesityl 
min Minutes 
M Micromolar 
Ms Methanesulfonyl 
m.s. Molecular Sieves 
MSA Microtubule Stabilizing Agent 
MTOCs Microtubule Organising Centres 
NBSH 2-Nitrobenzenesulfonylhydrazide 
NCI National Cancer Institute (US) 
NCI/ADR Taxol®-resistant Cancer cell line 
NMO N-methylmorpholine oxide 
o.n. Over Night 
OTf Trifluoromethanesulfonate 
PANC-1 Pancreatic cancer cell line 
PgP Phospho-glycoprotein 
Ph Phenyl 
PMB p-Methoxybenzyl 
PMP p-Methoxyphenyl 
PPTS Pyridinium p-toluenesulfonate 
Pr Propyl 
p-TSA p-Toluenesulfonic acid 
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Py Pyridine 
r.t. and R.T. Room temperature 
Rf Retention factor 
SAR Structure Activity Relationship 
sat. Saturated  
TBS tert-Butyldimethylsilyl 
TBSOTf tert-Butyldimethylsilyl-trifluoromethanesulfonate 
TEA Triethylamine 
TES Triethylsilyl 
Tf Trifluoromethanesulfonyl 
THF Tetrahydrofuran 
TIPS Triisopropylsilyl 
TLC Thin Layer Chromatography 
TMS Trimethylsilyl 
TPAP Tetrapropylammonium perruthenate 
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Completion of the Synthesis of (+)-9-epi-Dictyostatin 
NMR Spectra 
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Solvent: CD3OD 
(+)-9-epi-dictyostatin (4.65) 
 Solvent: CD3OD 
(-)-dictyostatin 
 
Sample kindly provided by 
Prof. Ian Paterson (Cambridge) 
 Solvent: C6D6 
(+)-9-epi-dictyostatin (4.65) 
 
 
Solvent: C6D6 
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As reported by I. Paterson et al. in Bioorg. 
Med. Chem. Lett. 2007,17, 2443-2447. 
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30700 scans 
D1 1.5 sec  
(+)-9-epi-dictyostatin (4.65) 
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54500 scans 
D1 3 sec 
 
(+)-9-epi-dictyostatin (4.65) 
 
 
Solvent: C6D6 
(+)-9-epi-dictyostatin 
 
As reported by I. Paterson et al. in Bioorg. 
Med. Chem. Lett. 2007,17, 2443-2447. 
  
 
 
 
 
Synthesis of (Z)-Vinyl Iodide 12,13-bis-epi-C10-C26 
NMR Spectra 
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Synthesis of 12,13-bis-epi-Dictyostatin Precursors 
NMR Spectra 
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